[{"text": "Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? Usman Kabir Thu, Jan 23, 2025, 9:37 AM 4 min read In This Article: EWTX +0.64% We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks . In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen's other long-term stock picks. Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global , one of the most successful equity-focused hedge funds in the world. Known for his disciplined investment approach and ability to identify long-term opportunities, Halvorsen has built a reputation as a leader in the financial industry. Halvorsen was born in 1961 in Norway. He attended the Norwegian Naval Academy, where he developed a strong work ethic, leadership skills, and a disciplined mindset. After completing his military service, Halvorsen decided to pursue a career in finance. He enrolled at Williams College, a prestigious liberal arts institution in the United States, and graduated with a degree in economics. Halvorsen later attended the Stanford Graduate School of Business, earning his MBA in 1990. Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs . After graduating from Stanford, Halvorsen began his career at Morgan Stanley, where he worked in the investment banking division. He later joined Tiger Management, the legendary hedge fund founded by Julian Robertson. Halvorsen became one of Robertson's top prot\u00e9g\u00e9s, earning the title of a Tiger Cub. At Tiger Management, Halvorsen gained valuable experience analyzing global markets, identifying undervalued equities, and managing risk. This experience laid the foundation for his future success. In 1999, Halvorsen co-founded Viking Global Investors alongside two other Tiger alumni, David Ott and Brian Olson. The firm, based in Greenwich, Connecticut, focuses on long/short equity strategies, aiming to generate returns through a combination of long-term investments in undervalued companies and short positions in overvalued ones. Viking Global quickly gained a reputation for its rigorous research, disciplined investment process, and focus on high-quality companies. Halvorsen\u2019s leadership has been instrumental in the firm's success. Viking Global manages approximately $27 billion in 13F securities as of the end of the third quarter of 2023. It has delivered annualized returns exceeding 10% since its inception, consistently outperforming benchmarks. Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities . Story Continues For this article, we selected stocks by combing through the 13F portfolio of Viking Global at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) Number of Hedge Fund Holders: 41 Viking Global's Stake: $39.5 million Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is a significant unmet medical need. These factors underscore why the company is a solid investment opportunity. Firstly, as per the report of the third quarter of 2024, Edgewise Therapeutics has demonstrated a robust strategy by securing substantial capital to support its ongoing programs. The $232 million raised in early 2024 provides a solid foundation for advancing muscular dystrophy and cardiovascular initiatives. However, the company's reliance on the success of its key drug candidates, sevasemten and EDG-7500, underscores the importance of continued positive trial outcomes to maintain investor confidence and drive future revenue streams. Secondly, the company has highlighted progress in its drug pipeline, especially the positive Phase 2 trial results for sevasemten in Becker muscular dystrophy and initial positive results from EDG-7500 in patients with obstructive hypertrophic cardiomyopathy. Overall EWTX ranks 14th on our list of Billionaire Andreas Halvorsen's top long-term stock picks. While we acknowledge the potential of EWTX as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a stock that is more promising than EWTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-23T06:37:22+00:00", "sentiment": {"score": 0.14300712384283543, "confidence": 0.15645986795425415, "probabilities": {"positive": 0.15645986795425415, "negative": 0.013452744111418724, "neutral": 0.8300873637199402}}, "embedding": [-0.012238586321473122, -0.045268334448337555, -0.040551356971263885, -0.011634665541350842, -0.0191887766122818, -0.08673162758350372, 0.008604689501225948, 0.1413731873035431, 0.06119760125875473, 0.04251055419445038, -0.036413706839084625, 0.059388644993305206, 0.07500932365655899, -0.004804573953151703, -0.11577188968658447, 0.01750767230987549, -0.03832363337278366, 0.03955960273742676, -0.1099824383854866, 0.08050495386123657, -0.088486447930336, -0.19590598344802856, -0.004854947328567505, -0.16665884852409363, 0.09334824234247208, 0.07969996333122253, 0.022729948163032532, 0.01128876768052578, -0.10225028544664383, -0.05008025839924812, 0.17310041189193726, 0.04075928404927254, 0.040014177560806274, 0.029813412576913834, -0.05630749464035034, 0.10691695660352707, 0.023921839892864227, 0.08064156770706177, -0.030952660366892815, 0.03206273913383484, -0.023699237033724785, -0.01974601298570633, -0.03743205592036247, -0.0762513279914856, -0.006571794860064983, -0.16935473680496216, -0.044090740382671356, -0.09730011224746704, 0.006869064643979073, 0.11633046716451645, -0.13991022109985352, -0.11011211574077606, 0.07450293749570847, -0.1653595268726349, 0.04518752545118332, 0.06146204099059105, -0.08985137939453125, 0.07718528062105179, 0.026575438678264618, -0.08149056136608124, 0.13770470023155212, -0.11021986603736877, 0.04464871063828468, -0.040031492710113525, 0.005040120333433151, -0.03705940768122673, -0.01092342659831047, 0.16939811408519745, -0.050959281623363495, -0.007926087826490402, 0.19433094561100006, -0.15044501423835754, -0.2321208268404007, 0.028526637703180313, 0.021663686260581017, 0.030105967074632645, 0.13991373777389526, 0.11225181818008423, 0.02394041046500206, -0.08192769438028336, 0.11017996072769165, 0.09763708710670471, 0.013872360810637474, -0.003825550898909569, -0.09121090918779373, 0.06326597929000854, 0.03873785585165024, -0.0072088222950696945, 0.07984928786754608, 0.05054768919944763, 0.10573472082614899, -0.12050890922546387, -0.048311665654182434, -0.0661364197731018, 0.1473495364189148, -0.040333546698093414, 0.0136121716350317, 0.11190900951623917, -0.11303181946277618, 0.05967022478580475, 0.06217323616147041, -0.01910008303821087, -0.09671410173177719, -0.03325885906815529, -0.02802703157067299, -0.057107724249362946, 0.09944124519824982, 0.12269270420074463, 0.06334448605775833, -0.09979157894849777, -0.1158410906791687, 0.026286188513040543, -0.13928991556167603, -0.014400551095604897, -0.011073953472077847, 0.041469916701316833, -0.07633204758167267, -0.03651154041290283, 0.12245045602321625, 0.03029729053378105, 0.10682546347379684, 0.16479656100273132, -0.05976754054427147, 0.05877680331468582, -0.09948401153087616, 0.07809010148048401, -0.05619075894355774, 1.0179456347806595e-32, -0.15730951726436615, 0.05685616284608841, -0.06761831790208817, 0.011292672716081142, -0.08555245399475098, 0.045539554208517075, 0.0232185497879982, -0.027591003105044365, -0.15461793541908264, -0.08770723640918732, -0.07800184190273285, 0.18848156929016113, -0.05736353248357773, -0.007441455498337746, -0.08775316923856735, -0.039411112666130066, -0.027408935129642487, -0.01126046385616064, 0.05079994350671768, -0.04156889766454697, 0.1605730950832367, 0.0104772187769413, 0.0278570968657732, -0.040628254413604736, 0.012108717113733292, -0.1263943761587143, 0.02123860828578472, -0.118133045732975, 0.1570681482553482, 0.070369653403759, -0.13106951117515564, -0.024045534431934357, -0.07147728651762009, -0.013944681733846664, 0.09324967861175537, 0.11704431474208832, -0.09160389006137848, -0.10718661546707153, -0.016675032675266266, -0.06127896159887314, -0.07843192666769028, 0.0743819922208786, -0.0957128033041954, -0.03972364217042923, -0.08424655348062515, 0.06343305110931396, 0.040553979575634, 0.022510237991809845, 0.05549333244562149, -0.1112227588891983, -0.14139851927757263, 0.05696786940097809, 0.07777345180511475, -0.11635453999042511, -0.05390849709510803, 0.053867828100919724, 0.029627004638314247, 0.005484381224960089, -0.07914745807647705, -0.01917981170117855, -0.027143064886331558, 0.05829388648271561, -0.09190209954977036, 0.1111205518245697, -0.08704885840415955, 0.08040694892406464, 8.991453796625137e-06, 0.13001859188079834, -0.06600615382194519, 0.07847318053245544, 0.01813695952296257, 0.002828128170222044, 0.057205043733119965, -0.08806063234806061, -0.03341387212276459, -0.039232149720191956, -0.10684791207313538, 0.13879737257957458, -0.12712478637695312, 0.070074662566185, 0.01554066501557827, 0.05169198289513588, 0.01778903231024742, -0.0369873046875, -0.026776887476444244, 0.10782939195632935, 0.05567621439695358, -0.03450179100036621, 0.04528806358575821, 0.05509336292743683, 0.03522464632987976, -0.10672982037067413, 0.07940171658992767, -0.025745805352926254, -0.10713517665863037, -1.1095137059738387e-32, -0.11280419677495956, -0.07054628431797028, 0.12658827006816864, 0.03813278675079346, 0.09016675502061844, 0.12149001657962799, -0.05575216934084892, -0.02512398734688759, -0.1763976812362671, -0.07141079753637314, 0.13688525557518005, 0.01959357038140297, -0.061842307448387146, -0.008850270882248878, -0.045586638152599335, -0.041773200035095215, 0.03361237049102783, -0.04532232880592346, -0.08549949526786804, -0.15505951642990112, 0.24325859546661377, 0.0040562935173511505, -0.10774387419223785, 0.15151189267635345, -0.043142203241586685, 0.03775552287697792, 0.09036058187484741, 0.0525457002222538, -0.016975967213511467, 0.05465397238731384, 0.00036111101508140564, 0.11915548145771027, -0.0930127426981926, 0.02304406277835369, -0.04119246453046799, 0.1284915655851364, -0.1298036277294159, 0.02161976881325245, -0.13674746453762054, 0.03682324290275574, 0.09493882954120636, -0.06973572820425034, 0.027142290025949478, -0.03212704136967659, 0.07349800318479538, -0.029618101194500923, -0.07259073853492737, 0.04972570389509201, 0.14808917045593262, -0.021961480379104614, -0.06657271087169647, 0.1282830536365509, 0.05252968147397041, 0.0392858162522316, -0.028396956622600555, 0.028278203681111336, 0.047628410160541534, 0.05869533121585846, 0.014541605487465858, 0.0028106621466577053, -0.09675808250904083, -0.009328417479991913, 0.10000817477703094, 0.18691793084144592, -0.03131541237235069, -0.07945490628480911, -0.03323914110660553, -0.059962622821331024, -0.21237877011299133, -0.1464560329914093, -0.013971485197544098, 0.017169538885354996, 0.06747515499591827, -0.13207095861434937, -0.03484342247247696, 0.1446848213672638, -0.08213941752910614, -0.14914943277835846, -0.10386267304420471, -0.03744198754429817, -0.022166211158037186, -0.045108359307050705, 0.04682501032948494, 0.13407272100448608, -0.006965738721191883, 0.007987945340573788, -0.014926068484783173, 0.017024867236614227, -0.03169412910938263, -0.06292049586772919, 0.015731438994407654, -0.20664411783218384, -0.09027603268623352, 0.0011146832257509232, -0.06171390041708946, -1.0069550882008116e-07, -0.12227648496627808, -0.03443118929862976, -0.07866743952035904, 0.0590011328458786, -0.02897886373102665, 0.027250634506344795, -0.03069520741701126, -0.03667006641626358, -0.029398266226053238, 0.20070171356201172, -0.006999232340604067, 0.06510517001152039, -0.15373080968856812, 0.05981071665883064, 0.033179085701704025, -0.09921865910291672, 0.08677510917186737, 0.04473252594470978, 0.057772196829319, 0.06416819989681244, 0.1215570867061615, 0.020376063883304596, 0.09022511541843414, -0.02053382806479931, 0.08552658557891846, -0.0033622607588768005, -0.018416162580251694, 0.048439498990774155, 0.12817730009555817, -0.04787085950374603, -0.013811296783387661, 0.0721745565533638, -0.0072249602526426315, -0.03226807713508606, -0.015658576041460037, 0.047821395099163055, 0.04568498954176903, 0.10281114280223846, -0.03819652274250984, 0.08997926115989685, -0.07026347517967224, 0.13400684297084808, 0.06458041816949844, 0.004402387887239456, -0.08151676505804062, 0.032019905745983124, -0.011622061021625996, 0.04722421616315842, 0.07029781490564346, -0.045095011591911316, 0.0006513474509119987, -0.005160336848348379, 0.08144024014472961, -0.005060181953012943, -0.007199967745691538, 0.06668105721473694, -0.09370462596416473, -0.05711475387215614, -0.12501764297485352, -0.03876986354589462, 0.039118193089962006, -0.1864491105079651, 0.013248758390545845, 0.15055565536022186], "changes": {"1wk": 5.259259541829428}}, {"text": "PREMIUM Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall MT Newswires Wed, Jan 22, 2025, 5:52 PM In This Article: EWTX +0.64% Edgewise Therapeutics (EWTX) said Wednesday it promoted Chief Business Officer Behrad Derakhshan to PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-22T14:52:05+00:00", "sentiment": {"score": 0.0001904219388961792, "confidence": 0.03838183358311653, "probabilities": {"positive": 0.03838183358311653, "negative": 0.03819141164422035, "neutral": 0.9234267473220825}}, "embedding": [-0.13409535586833954, -0.05349574238061905, -0.028043678030371666, -0.06083528324961662, 0.04899480566382408, -0.09946814924478531, 0.10168744623661041, 0.11921904981136322, -0.056184519082307816, 0.0034903434570878744, 0.04892010986804962, 0.015958711504936218, -0.01569424755871296, 0.020011017099022865, 0.08670200407505035, 0.03664042055606842, 0.16994823515415192, 0.02921445481479168, -0.011267957277595997, -0.09210595488548279, -0.1666131615638733, -0.027900179848074913, -0.033643558621406555, -0.056913215667009354, 0.030285440385341644, -0.009061448276042938, -0.07453921437263489, -0.008921077474951744, 0.021454336121678352, -0.06763042509555817, 0.1052616611123085, 0.013070475310087204, -0.004232874605804682, 0.0012260169023647904, -0.1263037919998169, 0.06270771473646164, -0.09098243713378906, -0.01297888346016407, -0.0029797747265547514, 0.07278288155794144, 0.015452418476343155, -0.08177373558282852, -0.157628133893013, 0.01962883770465851, 0.001890024752356112, -0.11863557249307632, -0.10575013607740402, -0.05503561720252037, 0.03918369114398956, 0.05993745103478432, -0.009496388956904411, -0.19939230382442474, -0.043140266090631485, -0.09470265358686447, -0.08664539456367493, -0.11290602385997772, -0.21466414630413055, -0.01153190154582262, 0.0007175459177233279, 0.02292420156300068, 0.040696922689676285, -0.12514497339725494, 0.05524791032075882, 0.24202083051204681, -0.022596504539251328, 0.11196208745241165, 0.0989174172282219, 0.13630960881710052, -0.07016034424304962, -0.11871736496686935, 0.10137071460485458, -0.008557929657399654, 0.0212795902043581, -0.011935863643884659, 0.08055471628904343, 0.09170419722795486, 0.11551085859537125, 0.11316793411970139, 0.05936581641435623, -0.11513563245534897, -0.009145676158368587, 0.020180359482765198, 0.1408437192440033, 0.019995614886283875, 0.00942947342991829, 0.1374591588973999, 0.01589827612042427, 0.03866253420710564, -0.07178308069705963, -0.047042105346918106, 0.2091962844133377, 0.05181654542684555, -0.05129528418183327, 0.04775019362568855, -0.010286987759172916, 0.009135885164141655, -0.1784760057926178, -0.008550046943128109, -0.23248468339443207, 0.04313609004020691, -0.15351636707782745, 0.002997793722897768, -0.2571628987789154, 0.10959481447935104, -0.027663808315992355, -0.1671215295791626, 0.11819624900817871, 0.16742604970932007, 0.10782849043607712, -0.039838578552007675, -0.1406053751707077, -0.09036047011613846, 0.04159162566065788, -0.11621202528476715, -0.1666715145111084, 0.06276856362819672, -0.16412866115570068, 0.05806999281048775, 0.29616600275039673, -0.08687210828065872, 0.1567980796098709, 0.07478342950344086, -0.15601186454296112, -0.02910100296139717, -0.1388881951570511, 0.04388187825679779, 0.0033932169899344444, 1.5542038066370854e-32, -0.11850398778915405, 0.25497186183929443, 0.15001678466796875, -0.02074471302330494, 0.0007566050626337528, 0.016279224306344986, -0.06314343214035034, -0.14154142141342163, -0.22654873132705688, -0.15099209547042847, -0.18614661693572998, 0.21480809152126312, 0.00013736476830672473, 0.11876170337200165, -0.12467045336961746, -0.20228368043899536, -0.03723252937197685, 0.13283288478851318, 0.08670200407505035, -0.004261891357600689, 0.11582397669553757, 0.008593828417360783, -0.042118847370147705, 0.025189343839883804, -0.175938680768013, 0.1315385103225708, 0.020711597055196762, 0.034124042838811874, 0.24361319839954376, 0.09710156172513962, -0.26069360971450806, 0.0005081046256236732, 0.06952311098575592, 0.044093918055295944, -0.01203445065766573, 0.2513638138771057, -0.07144995033740997, -0.10336912423372269, -0.054089296609163284, -0.14232976734638214, 0.020593609660863876, 0.1288495510816574, -0.1626015454530716, -0.06362222135066986, -0.12400880455970764, -0.04795905202627182, -0.08125676959753036, -0.16816751658916473, 0.1120242327451706, -0.1678539365530014, -0.1708909273147583, 0.21712376177310944, -0.020586663857102394, -0.08088640868663788, -0.0025235493667423725, -0.08330543339252472, -0.10569192469120026, 0.1267634481191635, 0.23024874925613403, 0.04086245596408844, 0.11919351667165756, 0.030536144971847534, -0.09104035794734955, 0.0034293089993298054, -0.07419873028993607, 0.06933024525642395, 0.047751542180776596, -0.15888331830501556, -0.10280996561050415, -0.08471839129924774, -0.0719853937625885, 0.12896333634853363, 0.12544362246990204, 0.08384577929973602, -0.015090088360011578, -0.024201979860663414, -0.0723966509103775, -0.029939735308289528, -0.005425513256341219, 0.04745548963546753, 0.005842335522174835, -0.038501668721437454, 0.04988433048129082, -0.03206180781126022, 0.10977350175380707, -0.000514926970936358, -0.08709567040205002, 0.00772384786978364, -0.06035589426755905, 0.106002077460289, 0.05259503796696663, 0.046669453382492065, -0.01114621851593256, 0.2664966285228729, -0.04114455729722977, -1.6435083165209624e-32, -0.12319792807102203, 0.06315016746520996, -0.04584738612174988, -0.05162765085697174, -0.04838516190648079, 0.20077477395534515, 0.019005777314305305, 0.10015977919101715, 0.20800361037254333, 0.15597771108150482, 0.2697771489620209, 0.04281391575932503, -0.0736701637506485, -0.040592048317193985, -0.037542857229709625, 0.018209222704172134, 0.03958450257778168, -0.08342193812131882, -0.15293483436107635, -0.09059110283851624, 0.16741913557052612, 0.18031637370586395, -0.20457376539707184, 0.1697022020816803, 0.0942409411072731, 0.13320942223072052, 0.12758269906044006, 0.1912483274936676, -0.010418718680739403, -0.07097531110048294, 0.030030425637960434, -0.21936778724193573, -0.3149416148662567, 0.07791996002197266, -0.06924371421337128, 0.03915688395500183, 0.10406734049320221, 0.05854285880923271, -0.0893944650888443, 0.0035157979000359774, 0.09332331269979477, -0.16725102066993713, -0.027502046898007393, 0.08259102702140808, 0.13905398547649384, 0.07490461319684982, -0.09688764810562134, 0.08581458777189255, 0.036857638508081436, -0.02195526659488678, -0.09148509800434113, 0.19370609521865845, -0.03955072909593582, 0.025033999234437943, 0.01349585223942995, -0.013280482962727547, 0.018058132380247116, 0.02099662832915783, -0.1134696826338768, -0.06712052971124649, 0.07481697201728821, 0.109858937561512, -0.018544286489486694, 0.0604984275996685, 0.013877873308956623, 0.03646276518702507, 0.030715415254235268, -0.13798628747463226, -0.056586675345897675, -0.010658595710992813, 0.00826969463378191, -0.023474402725696564, -0.31029418110847473, -0.3311476409435272, -0.019861767068505287, 0.1202370673418045, -0.039973028004169464, -0.212195485830307, -0.21897536516189575, 0.07338863611221313, 0.05260131135582924, -0.06635662913322449, 0.060427695512771606, 0.12621204555034637, 0.0014288845704868436, -0.09779272973537445, 0.16108421981334686, -0.007116594817489386, -0.032738424837589264, -0.07614783197641373, -0.06108846887946129, -0.2337113916873932, -0.22038523852825165, 0.124674953520298, 0.05005547031760216, -9.999858008313822e-08, -0.016321048140525818, -0.1513088196516037, 0.00915211346000433, -0.16532617807388306, -0.017210859805345535, -0.019435377791523933, 0.03362615406513214, -0.0025700947735458612, -0.001768125919625163, 0.12271104007959366, 0.03223069757223129, -0.0993916466832161, -0.03746241331100464, -0.003408439690247178, -0.003931966610252857, -0.0488324873149395, 0.05589268356561661, 0.2360694855451584, 0.05561191216111183, -0.19671356678009033, -0.1327696442604065, -0.0030441090930253267, 0.32468804717063904, -0.2242618203163147, -0.006404958199709654, -0.049907781183719635, 0.13755901157855988, -0.019010525196790695, 0.05925412103533745, -0.06243967264890671, -0.16148525476455688, 0.016934752464294434, 0.10492826998233795, 0.03736798092722893, -0.11591853946447372, 0.036040764302015305, -0.007844125851988792, 0.24894633889198303, 0.04814683645963669, 0.218528613448143, 0.02663339115679264, -0.016633162274956703, 0.11551797389984131, 0.10775143653154373, -0.02932269684970379, 0.1389261931180954, 0.07331112027168274, -0.06828910857439041, 0.1960134655237198, -0.173822283744812, 0.15910203754901886, -0.11877050250768661, 0.11395828425884247, -0.09463823586702347, -0.0775427296757698, 0.05894368141889572, -0.09249802678823471, 0.020376645028591156, -0.05367179587483406, 0.015094920061528683, 0.030199047178030014, -0.27157267928123474, 0.13303786516189575, 0.10713557153940201], "changes": {"1wk": 4.7162885609117495}}, {"text": "PREMIUM Stifel Nicolaus Initiates Coverage on Edgewise Therapeutics With Hold Rating, $30 Price Target MT Newswires Wed, Jan 22, 2025, 3:42 PM In This Article: EWTX +0.64% Edgewise Therapeutics (EWTX) has an average rating of Buy and mean price target of $47, according to PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-22T12:42:59+00:00", "sentiment": {"score": 0.030460147187113762, "confidence": 0.044933151453733444, "probabilities": {"positive": 0.044933151453733444, "negative": 0.014473004266619682, "neutral": 0.9405938386917114}}, "embedding": [-0.03392888978123665, -0.06786563992500305, -0.07028611749410629, 0.06290452182292938, 0.08809508383274078, 0.008757291361689568, 0.016177555546164513, 0.2336180955171585, 0.06223313882946968, 0.0034281951375305653, -0.08599896728992462, 0.05122021213173866, -0.006130394991487265, -0.10194046795368195, 0.04828163608908653, -0.04163115471601486, 0.16017018258571625, -0.019898835569620132, 0.08096039295196533, 0.08188248425722122, -0.19379082322120667, 0.03287018835544586, -0.00764027563855052, -0.023234829306602478, 0.03762229532003403, 0.04066845774650574, -0.05765588581562042, -0.07912404835224152, 0.05088150501251221, -0.06142182648181915, 0.10764317214488983, -0.056953880935907364, 0.021060219034552574, -0.054121483117341995, -0.09286485612392426, -0.07136305421590805, -0.17648610472679138, -0.0987546369433403, -0.24446792900562286, 0.06456456333398819, 0.031740009784698486, -0.12332490086555481, -0.3215140402317047, -0.013130705803632736, -0.0035497210919857025, -0.13008838891983032, -0.08354253321886063, 0.18767432868480682, 0.12970317900180817, 0.10699325054883957, -0.014222805388271809, -0.2966717481613159, -0.06089387461543083, -0.1250809133052826, -0.08086934685707092, -0.016414517536759377, -0.1929175704717636, -0.03744935616850853, 0.038595739752054214, 0.009343464858829975, 0.08954016119241714, -0.11007793247699738, -0.031393058598041534, 0.10197532922029495, 0.053831398487091064, 0.2105913758277893, 0.018890459090471268, 0.015165972523391247, 0.01665128953754902, -0.04196321964263916, 0.058149710297584534, 0.03368544206023216, 0.07415158301591873, 0.04799222946166992, 0.07233002036809921, 0.22519108653068542, 0.1779301017522812, -0.05542434751987457, 0.05413946136832237, 0.1160481795668602, -0.06691599637269974, -0.18425334990024567, 0.032961517572402954, -0.007122168783098459, 0.15642954409122467, 0.04687974601984024, 0.16844287514686584, 0.08023247867822647, 0.0653253048658371, 0.043423350900411606, 0.22425928711891174, 0.008791785687208176, -0.146182581782341, 0.039254821836948395, 0.024240784347057343, -0.07083495706319809, -0.2530340552330017, -0.06296189874410629, -0.11417526751756668, -0.026098616421222687, -0.05890168249607086, -0.008282093331217766, -0.04308287054300308, 0.16031798720359802, -0.04333176836371422, -0.16923916339874268, 0.06497495621442795, -0.015651576220989227, 0.041037216782569885, -0.014208575710654259, -0.1714416891336441, -0.09984243661165237, 0.030684027820825577, -0.13633278012275696, -0.1530248075723648, 0.085280641913414, -0.09997566044330597, -0.0072914790362119675, 0.35070931911468506, -0.04049254208803177, 0.09822479635477066, 0.14848966896533966, -0.09767132252454758, -0.011670446023344994, -0.1759306639432907, -0.06608764082193375, -0.05622588470578194, 1.1446811908725798e-32, -0.1734691858291626, 0.10319056361913681, 0.09777470678091049, -0.1451471745967865, -0.01940525323152542, 0.07980787754058838, -0.025965705513954163, -0.15722845494747162, -0.17662166059017181, -0.07018023729324341, -0.1910577267408371, 0.18598172068595886, 0.022628100588917732, 0.23205150663852692, -0.06814326345920563, -0.24157105386257172, 0.02863047830760479, 0.1523563414812088, 0.08235630393028259, 0.079571932554245, 0.08030588924884796, -0.12720702588558197, -0.003668872406706214, 0.04336510971188545, -0.19590432941913605, 0.13673527538776398, 0.004905964247882366, 0.06557199358940125, 0.25094202160835266, 0.07703755050897598, -0.37687578797340393, -0.048528995364904404, 0.08345050364732742, -0.0009981028269976377, -0.07541903108358383, 0.19932596385478973, -0.031845077872276306, -0.10179349035024643, 0.04621867090463638, -0.10697370022535324, -0.08313722163438797, 0.1987277865409851, 0.01336838211864233, -0.025798287242650986, -0.13314296305179596, -0.19203932583332062, -0.12767136096954346, -0.2328510582447052, -0.06667251884937286, -0.19685637950897217, -0.19730383157730103, 0.12849408388137817, -0.13543926179409027, 0.041297316551208496, -0.09591000527143478, -0.05109072104096413, -0.05265270173549652, 0.09978138655424118, 0.10077820718288422, 0.09782985597848892, 0.14287318289279938, 0.06238434091210365, 0.1339864581823349, -0.14652246236801147, -0.0451374389231205, 0.3769853711128235, -0.10408074408769608, -0.118621826171875, -0.25065356492996216, 0.026539182290434837, 0.014548314735293388, 0.28539785742759705, 0.1906769871711731, -0.11868993192911148, 0.019002875313162804, -0.005788218695670366, -0.019131191074848175, 0.025506779551506042, 0.15987645089626312, 0.10368559509515762, -0.026176441460847855, -0.06660149991512299, -0.035806141793727875, 0.019464675337076187, 0.16886784136295319, -0.07513893395662308, -0.23750610649585724, 0.11488684266805649, -0.16837641596794128, 0.12076273560523987, 0.08209342509508133, -0.05156815052032471, -0.09893279522657394, 0.1851808875799179, 0.007039256393909454, -1.2865610814965252e-32, -0.2356366664171219, 0.0850590243935585, 0.19442808628082275, 0.0816090852022171, -0.05612010508775711, 0.13206380605697632, -0.05993427708745003, 0.055345866829156876, 0.1507730334997177, 0.23864489793777466, 0.056834906339645386, 0.061912402510643005, -0.13662660121917725, 0.017063558101654053, -0.06338725239038467, 0.054824236780405045, -0.09490470588207245, -0.12176108360290527, 0.00212080217897892, -0.10640927404165268, 0.04047507047653198, 0.1781984120607376, -0.0778844878077507, 0.20544365048408508, 0.05242106691002846, 0.0331062451004982, 0.1163775846362114, 0.05006818473339081, 0.025605298578739166, -0.20019634068012238, 0.02766781859099865, -0.13823296129703522, -0.23396773636341095, 0.06410273909568787, -0.06433422118425369, 0.06264778226613998, 0.1875164657831192, 0.10580515116453171, 0.11299688369035721, -0.10675996541976929, 0.13871082663536072, -0.08268952369689941, -0.020936351269483566, -0.012725455686450005, 0.2715883255004883, 0.044322941452264786, -0.012872063554823399, 0.044483255594968796, 0.11026784032583237, 0.016296779736876488, -0.07905378937721252, 0.2160024791955948, 0.03490705043077469, 0.19482827186584473, -0.193611279129982, -0.13431409001350403, 0.021265491843223572, 0.016354989260435104, -0.07295049726963043, -0.024292469024658203, 0.11596609652042389, 0.13799037039279938, -0.12303262203931808, 0.03806183487176895, 0.05713443085551262, 0.03409700095653534, 0.09020858258008957, -0.0037931599654257298, -0.0651317909359932, 0.01789647340774536, -0.03812649846076965, -0.034435201436281204, -0.09647759795188904, -0.20029990375041962, 0.08651012182235718, 0.22844623029232025, 0.012700001709163189, -0.12410493195056915, 0.0008974898955784738, 0.06739862263202667, 0.001658382941968739, -0.15913477540016174, 0.01486215740442276, -0.014285464771091938, 0.06798651069402695, -0.15725135803222656, 0.17727747559547424, -0.0517493300139904, -0.11945139616727829, 0.12282301485538483, -0.11642720550298691, -0.12487563490867615, -0.1761680543422699, 0.03757575526833534, 0.1059851422905922, -9.960920266394169e-08, 0.007668341509997845, -0.03211886063218117, 0.045289359986782074, -0.04807531461119652, 0.03736256808042526, -0.023911675438284874, -0.004574703983962536, -0.009922209195792675, -0.006512122228741646, 0.14554820954799652, -0.036245401948690414, -0.1715703159570694, -0.06269652396440506, -0.0992034450173378, -0.17524388432502747, -0.10966895520687103, 0.03797474503517151, 0.20594283938407898, 0.15117911994457245, -0.10297908633947372, -0.016029514372348785, 0.06370344758033752, 0.26780569553375244, -0.21765750646591187, 0.009015497751533985, -0.05317985266447067, 0.12179587036371231, 0.09646639227867126, -0.05344143137335777, -0.0032837458420544863, -0.13613668084144592, 0.005429018288850784, 0.08898738026618958, 0.0026081553660333157, -0.13193334639072418, -0.10422986000776291, -0.06584356725215912, 0.19499903917312622, 0.036276523023843765, 0.18685723841190338, 0.048203244805336, -0.06063421070575714, 0.02356763370335102, -0.012298949994146824, -0.04155115410685539, 0.21524180471897125, -0.03895608335733414, -0.0830560177564621, 0.14495329558849335, -0.12524592876434326, 0.1703186333179474, -0.017316371202468872, 0.07385680824518204, -0.016406649723649025, -0.1281813681125641, 0.12273363023996353, -0.03867322579026222, -0.002837605308741331, -0.054888803511857986, 0.10846022516489029, -0.01434471644461155, -0.41038307547569275, -0.05365836247801781, 0.1330970674753189], "changes": {"1wk": 2.4318344224570696}}, {"text": "Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development Business Wire Wed, Jan 22, 2025, 4:00 PM 4 min read In This Article: EWTX +0.64% Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo: Business Wire) Behrad Derakhshan, Ph.D., Chief Operating Officer, Edgewise Therapeutics (Photo: Business Wire) - Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) - - Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - BOULDER, Colo., January 22, 2025 --( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company\u2019s focus on late-stage clinical development. These changes include the addition of Robert Blaustein, M.D., Ph.D., joining the Company as Chief Development Officer and the promotion of Behrad Derakhshan, Ph.D. from Chief Business Officer to Chief Operating Officer. \"These leadership changes signify our organization's progression into late-stage clinical development, setting the stage for the future commercialization of our novel therapeutics,\" said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. \"As we welcome Rob, it\u2019s an exciting time for the Company, and we are fortunate to have a highly experienced executive team guiding us forward.\" Robert Blaustein, M.D., Ph.D., joins the Company as Chief Development Officer, responsible for leading EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development, as well as the cardiovascular and cardiometabolic pipeline. With significant depth of experience in cardiovascular drug development, Dr. Blaustein joins from Merck where he was most recently Associate Vice President and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department, leading all late phase development efforts in this area. During his 15+ years at Merck, Dr. Blaustein contributed to clinical programs across a range of cardiovascular targets and led clinical development in the atherosclerosis and heart failure spaces. Importantly, he led the vericiguat development team through the completion of the Phase 3 VICTORIA heart failure trial, subsequent regulatory filing and global approval of vericiguat for the treatment of patients with worsening heart failure, a collaborative effort with Bayer AG. Dr. Blaustein obtained his undergraduate degree in mathematics from Wesleyan University. His post-graduate training included medical residency at Brigham and Women\u2019s Hospital, cardiology fellowship at Massachusetts General Hospital, and an HHMI post-doctoral fellowship in the Biochemistry Department at Brandeis University. He subsequently served on the faculty of Tufts Medical Center prior to joining Merck. Dr. Semigran, current CDO, will depart from the Company and will serve as a clinical advisor for a period to ensure a smooth transition. \"On behalf of the Board of Directors and the entire Edgewise organization, I want to thank Marc for his leadership and contributions to our cardiovascular program,\" said Dr. Koch. \"Marc played a prominent role in successfully advancing EDG-7500 in the clinic.\" Most recently the Company reported positive topline data of EDG-7500 in the Phase 1 trial in healthy subjects and from the single-dose arm (part A) of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Further, the Company opened and began enrolling the 28-day arms (parts B and C) and the 12-week open label extension (part D) of the CIRRUS-HCM trial in patients with obstructive HCM and non-obstructive HCM. There are no changes in previously described milestone timelines for the Company\u2019s cardiovascular program. Story Continues Behrad Derakhshan, Ph.D., joined Edgewise in 2020 as Chief Business Officer, leading the Company\u2019s efforts in strategic planning, business development, capital formation, investor relations, corporate communications and commercial planning. He was instrumental through the Company\u2019s highly successful initial public offering, played a key role securing several additional funding rounds and driving the strategic direction of the organization. Dr. Derakhshan\u2019s leadership and vision have been instrumental in fueling Edgewise\u2019s growth and success to date. As COO, Dr. Derakhshan will be responsible for enabling the operational readiness of the organization as the Company approaches significant milestones in the muscular dystrophy and cardiovascular programs, moving toward a commercial-ready biopharmaceutical company. These changes to the Edgewise executive team are effective immediately. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company\u2019s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram . View source version on businesswire.com: https://www.businesswire.com/news/home/20250122879951/en/ Contacts Edgewise Contacts Investors: Michael Carruthers, Chief Financial Officer ir@edgewisetx.com Media: Maureen Franco, VP Corporate Communications media@edgewisetx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-22T13:00:00+00:00", "sentiment": {"score": 0.455006486736238, "confidence": 0.46532294154167175, "probabilities": {"positive": 0.46532294154167175, "negative": 0.01031645480543375, "neutral": 0.5243605375289917}}, "embedding": [-0.15242719650268555, -0.10005101561546326, -0.03945889323949814, -0.10337059199810028, -0.028605826199054718, -0.09989137947559357, -0.058071814477443695, 0.23547998070716858, 0.060030557215213776, 0.04599449783563614, -0.10978660732507706, 0.04647356644272804, 0.006199967116117477, 0.06543126702308655, 0.05380287021398544, 0.037048760801553726, -0.01745814085006714, 0.08356346189975739, -0.12478446215391159, 0.007746225222945213, -0.014204150065779686, 0.025387855246663094, 0.009227247908711433, 0.024729404598474503, -0.03963460773229599, 0.01816553622484207, 0.00712695624679327, -0.051245927810668945, -0.22577336430549622, -0.13874155282974243, 0.09684525430202484, 0.04838573932647705, 0.001803231774829328, -0.04896629601716995, -0.03330057114362717, 0.10164238512516022, -0.03678973764181137, 0.06109316647052765, -0.16623800992965698, -0.07387295365333557, -0.026266761124134064, -0.056478921324014664, -0.15475627779960632, 0.005857623182237148, -0.0020186277106404305, -0.15799017250537872, -0.09800887107849121, -0.06669069826602936, -0.03639576584100723, 0.13014313578605652, -0.09996148943901062, -0.14537112414836884, -0.07092146575450897, 0.03458726033568382, 0.015293269418179989, 0.04388564079999924, -0.17152011394500732, -0.0006689531728625298, 0.023551838472485542, -0.02749643847346306, 0.04304664582014084, -0.07872001826763153, 0.012148838490247726, 0.039917465299367905, 0.08582805842161179, 0.027434032410383224, 0.10200624167919159, 0.018971633166074753, -0.03783728554844856, -0.07214687019586563, 0.14018142223358154, -0.12455634772777557, -0.058654800057411194, 0.0982518121600151, 0.0927436426281929, 0.13567884266376495, 0.11330096423625946, 0.20322749018669128, 0.1187242642045021, -0.12395630776882172, 0.12150454521179199, 0.10939951241016388, 0.05563414469361305, 0.0713103786110878, -0.08481533080339432, 0.18566547334194183, 0.011417359113693237, 0.11377938836812973, -0.06865943968296051, 0.06847861409187317, 0.16165712475776672, -0.0066649895161390305, -0.05257490277290344, 0.022072700783610344, 0.009612124413251877, -0.03125891461968422, -0.07551948726177216, -0.01225244253873825, 0.013909600675106049, 0.034626491367816925, -0.05118759348988533, -0.02407613769173622, -0.13964340090751648, 0.005860336124897003, -0.0035524030681699514, -0.10133633017539978, 0.13346892595291138, -0.018180668354034424, 0.08187904953956604, -0.1036234050989151, -0.023634664714336395, -0.017607685178518295, 0.009576074779033661, -0.01669885218143463, -0.025791021063923836, 0.12260138988494873, -0.14391683042049408, 0.06097864359617233, 0.17899775505065918, 0.005409484729170799, 0.1857430785894394, 0.07190786302089691, -0.002855445723980665, -0.0528380461037159, -0.024084892123937607, 0.1270926594734192, -0.12487168610095978, 4.8476362143774014e-33, 0.04891633242368698, 0.06436716020107269, 0.1458745300769806, 0.11429519951343536, -0.02553272619843483, 0.02087862603366375, -0.05214744806289673, -0.0473899319767952, -0.2164328247308731, -0.09827207773923874, -0.2600565552711487, 0.06069961190223694, -0.016843905672430992, 0.16257576644420624, -0.08338074386119843, -0.1913105845451355, 0.00015552621334791183, 0.006513390690088272, 0.041801657527685165, -0.019476164132356644, 0.026472458615899086, 0.0001190470065921545, -0.08962439000606537, 0.11917739361524582, -0.04932797700166702, 0.15189148485660553, -0.028518375009298325, 0.0728406012058258, 0.12590578198432922, 0.06322406232357025, -0.21574658155441284, -0.00606363033875823, -0.02150638960301876, -0.07307036966085434, -0.08749496936798096, 0.031369827687740326, -0.06229935586452484, -0.10039890557527542, 0.01432503666728735, 0.008652338758111, -0.010625732131302357, 0.060748469084501266, -0.17406919598579407, -0.10176743566989899, -0.03385450690984726, -0.05432946979999542, 0.036919932812452316, -0.08066664636135101, 0.0020809336565434933, -0.045911017805337906, -0.023989763110876083, 0.015948055312037468, 0.20995110273361206, -0.10394302010536194, 0.04274308681488037, 0.03229169920086861, -0.1645682454109192, 0.0013599968515336514, 0.11072148382663727, 0.1332978755235672, 0.1008920818567276, 0.15321245789527893, -0.16698497533798218, 0.11443068087100983, -0.10871434211730957, 0.0732855349779129, 0.07943861931562424, -0.05548218637704849, -0.01708265393972397, -0.0719272717833519, -0.10259085893630981, 0.023243218660354614, 0.18666082620620728, 0.014976924285292625, 0.06849082559347153, -0.06505150347948074, -0.014929600059986115, 0.1521330028772354, -0.09261368960142136, -0.048705779016017914, -0.07723888009786606, 0.06473243981599808, -0.09877415001392365, 0.05847775936126709, 0.06665880233049393, -0.11077612638473511, 0.020817955955863, -0.0284380204975605, -0.14260241389274597, 0.06271624565124512, 0.08183199167251587, -0.07613963633775711, 0.02546890825033188, 0.32479915022850037, -0.09566060453653336, -6.032245054522377e-33, -0.0037278663367033005, 0.013348404318094254, 0.033318206667900085, -0.1053822785615921, 0.033849503844976425, 0.17758959531784058, 0.20310282707214355, -0.12345518171787262, 0.08939456939697266, -0.07046646624803543, 0.1955823004245758, 0.041707638651132584, -0.09042572975158691, -0.06416108459234238, -0.045204296708106995, 0.08999781310558319, -0.052107468247413635, -0.14723441004753113, -0.10043302923440933, -0.021086014807224274, 0.09000585228204727, 0.18333220481872559, -0.1496686339378357, 0.10098224878311157, 0.03038867563009262, 0.11261215806007385, 0.06750436872243881, 0.12236350774765015, 0.03982575610280037, -0.059868648648262024, 0.025055620819330215, -0.04081590101122856, -0.24089127779006958, 0.006034377031028271, -0.0799202024936676, 0.10040666162967682, -0.047369640320539474, -0.04589695483446121, -0.0269429050385952, -0.028159478679299355, 0.07426594197750092, -0.007105661556124687, 0.008609216660261154, 0.010419052094221115, 0.11297035217285156, 0.022952402010560036, 0.0480620339512825, -0.012838328257203102, -0.03774306923151016, -0.009181978181004524, -0.06949491798877716, 0.1537948101758957, -0.028057951480150223, -0.04375811666250229, -0.004891332238912582, -0.039626531302928925, 0.0794980376958847, -0.024474209174513817, -0.07955314964056015, 0.02001667395234108, -0.0014708712697029114, 0.00705634243786335, 0.16267064213752747, 0.022495262324810028, 0.060873448848724365, 0.10796505957841873, 0.04496348649263382, -0.10021764785051346, -0.05705039203166962, 0.02334476076066494, -0.03965536132454872, -0.028130797669291496, -0.10433556139469147, -0.11663345992565155, 0.02885637804865837, 0.00086158886551857, -0.16782860457897186, -0.23012122511863708, -0.2434605211019516, 0.007551079150289297, -0.016016095876693726, -0.05498984456062317, -0.014098595827817917, 0.0826253592967987, -0.03595511242747307, 0.055217161774635315, 0.12360058724880219, -0.019214659929275513, 0.06391408294439316, 0.0007387236692011356, -0.09117439389228821, -0.16363458335399628, -0.11998669803142548, 0.26205509901046753, 0.058543529361486435, -1.0001024008943205e-07, 0.05147147551178932, -0.04880008473992348, -0.043618157505989075, -0.1997525691986084, 0.0422375313937664, -0.06491415202617645, -0.0016202486585825682, 0.07589990645647049, 0.049700602889060974, 0.1178765520453453, 0.054989077150821686, 0.04417094215750694, -0.03904672712087631, 0.005059275776147842, 0.042869724333286285, 0.09297783672809601, -0.04206554591655731, 0.08429750800132751, -0.03287274390459061, -0.10542909801006317, -0.06621966511011124, 0.030180618166923523, 0.0828063040971756, -0.09412745386362076, 0.07669232040643692, -0.206631600856781, 0.03230118751525879, 0.02271442674100399, 0.03489244729280472, 0.02852782979607582, -0.0559985376894474, 0.03432139381766319, 0.022797908633947372, 0.10770770162343979, -0.05058667063713074, -0.11428657919168472, -0.00688711553812027, 0.15033960342407227, -0.00535086914896965, 0.2339400053024292, -0.007631760090589523, 0.04809785261750221, 0.037478007376194, 0.025838807225227356, -0.04113615304231644, -0.07553990185260773, 0.009172097779810429, 0.055880893021821976, 0.03018096089363098, -0.16829021275043488, 0.025876134634017944, 0.01799587719142437, -0.06688397377729416, -0.05726044252514839, -0.07060565054416656, 0.1529671847820282, -0.10635853558778763, 0.003268945263698697, -0.036192312836647034, -0.0658019408583641, -0.0016399584710597992, -0.12650804221630096, 0.10886974632740021, 0.06294727325439453], "changes": {"1wk": 2.4318344224570696}}, {"text": "Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans editorial-team@simplywallst.com (Simply Wall St) Fri, Jan 17, 2025, 5:19 PM 3 min read In this article: EWTX +0.64% We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics ( NASDAQ:EWTX ) shareholders have done very well over the last year, with the share price soaring by 176%. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So notwithstanding the buoyant share price, we think it's well worth asking whether Edgewise Therapeutics' cash burn is too risky. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. Check out our latest analysis for Edgewise Therapeutics How Long Is Edgewise Therapeutics' Cash Runway? A company's cash runway is calculated by dividing its cash hoard by its cash burn. In September 2024, Edgewise Therapeutics had US$493m in cash, and was debt-free. In the last year, its cash burn was US$110m. So it had a cash runway of about 4.5 years from September 2024. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time. NasdaqGS:EWTX Debt to Equity History January 17th 2025 How Is Edgewise Therapeutics' Cash Burn Changing Over Time? Edgewise Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 28%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years . How Hard Would It Be For Edgewise Therapeutics To Raise More Cash For Growth? Given its cash burn trajectory, Edgewise Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Story continues Edgewise Therapeutics' cash burn of US$110m is about 4.1% of its US$2.7b market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan. How Risky Is Edgewise Therapeutics' Cash Burn Situation? As you can probably tell by now, we're not too worried about Edgewise Therapeutics' cash burn. For example, we think its cash runway suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. On another note, Edgewise Therapeutics has 3 warning signs (and 2 which are concerning) we think you should know about. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View comments Terms and Privacy Policy Privacy Dashboard Recommended stories", "symbol": "EWTX", "date": "2025-01-17T14:19:12+00:00", "sentiment": {"score": 0.13910416327416897, "confidence": 0.16009388864040375, "probabilities": {"positive": 0.16009388864040375, "negative": 0.02098972536623478, "neutral": 0.8189164400100708}}, "embedding": [-0.004093291237950325, -0.04310036450624466, 0.03437172994017601, -0.046386461704969406, 0.02533154934644699, -0.05856836587190628, -0.010958580300211906, 0.08024147152900696, 0.09357864409685135, 0.08067092299461365, -0.03251230716705322, 0.06009620428085327, -0.0018600155599415302, -0.024544501677155495, -0.04075835645198822, -0.03861066326498985, -0.0643698126077652, -0.023581430315971375, -0.08963032811880112, 0.1247825175523758, 0.013284449465572834, -0.049292854964733124, -0.017836447805166245, 0.021162036806344986, 0.028655925765633583, 0.012341395951807499, -0.06190858781337738, 0.039388369768857956, -0.07577374577522278, -0.08692431449890137, 0.09992340207099915, 0.24352338910102844, 0.07637280225753784, -0.024130873382091522, -0.016334718093276024, -0.002524255309253931, -0.05152033641934395, 0.1546178162097931, -0.009345347061753273, 0.025191767141222954, -0.04259399697184563, -0.027670161798596382, -0.09095543622970581, -0.06104615330696106, 0.006014193873852491, -0.2201201617717743, 0.02773211896419525, -0.04976554587483406, -0.043334972113370895, 0.0771111249923706, -0.03489874303340912, -0.0303916335105896, -0.023751163855195045, 0.03975537046790123, -0.03408513218164444, -0.012056058272719383, -0.0859084203839302, -0.03568610921502113, -0.048281289637088776, -0.019349494948983192, 0.06677325814962387, -0.027135152369737625, 0.07759685814380646, -0.022659828886389732, 0.10714119672775269, 0.09182567894458771, 0.040339402854442596, 0.05568604916334152, -0.1345721185207367, 0.04795023053884506, 0.0698016881942749, -0.10353599488735199, -0.06469539552927017, -0.04426557943224907, -0.05520317703485489, 0.11879172176122665, 0.10391994565725327, 0.1728450357913971, 0.07193438708782196, -0.10014437139034271, 0.0706864669919014, -0.0019429149106144905, 0.018290027976036072, -0.04378558695316315, -0.06262821704149246, 0.07295367121696472, 0.10959160327911377, -0.060952648520469666, 0.04626700282096863, 0.062192268669605255, 0.11195105314254761, 0.059627629816532135, -0.07311394810676575, 0.041019558906555176, 0.10153982788324356, -0.009780856780707836, -0.15590369701385498, -0.013339527882635593, -0.010074909776449203, 0.035103559494018555, 0.06493552029132843, 0.1150125116109848, -0.13927343487739563, -0.06185289844870567, 0.05803074687719345, -0.07863225042819977, 0.05059041082859039, -0.027251074090600014, 0.0318833589553833, -0.06852931529283524, -0.08934962749481201, 0.07818005979061127, -0.04826388880610466, -0.0659392848610878, -0.038202233612537384, 0.01767626404762268, -0.18344298005104065, -0.01450797077268362, 0.1263693869113922, -0.003694320097565651, 0.12933936715126038, 0.18871554732322693, -0.041485369205474854, 0.01131899282336235, -0.1099928617477417, -0.029790397733449936, -0.08974450081586838, 1.2916678697668788e-32, -0.09064696729183197, 0.03449399024248123, 0.10280101001262665, -0.10497887432575226, 0.034969814121723175, -0.023264016956090927, -0.05141477659344673, -0.04652196541428566, -0.08871221542358398, 0.029989279806613922, -0.08698628842830658, 0.11136160045862198, 0.03694617375731468, -0.023256264626979828, 0.05030359327793121, -0.0691225528717041, -0.08024300634860992, -0.06283055990934372, 0.03357940912246704, -0.10905172675848007, -0.017175890505313873, -0.018848318606615067, -0.024305857717990875, -0.018938351422548294, -0.03481903299689293, -0.05210522189736366, -0.1105031967163086, -0.030703306198120117, 0.01703891158103943, 0.0522303469479084, -0.12197992205619812, -0.013620896264910698, -0.04090678691864014, -0.15335039794445038, -0.03814483433961868, 0.06091829389333725, -0.05005748197436333, -0.012272091582417488, 0.04154849052429199, -0.0006434929091483355, -0.04953121021389961, 0.09706059843301773, -0.0011776573956012726, -0.034789830446243286, -0.018935365602374077, 0.04576603323221207, -0.02557716891169548, -0.06180277839303017, -0.05237279087305069, -0.005571033805608749, 0.03935086727142334, -0.006732547655701637, 0.09911955893039703, -0.060974471271038055, -0.03205392509698868, 0.05581017583608627, -0.027310039848089218, -0.018871605396270752, 0.05188994109630585, 0.10766732692718506, 0.042231496423482895, 0.00997636653482914, -0.07193481922149658, 0.01273405086249113, -0.21647006273269653, 0.32974058389663696, 0.05083155259490013, -0.018091214820742607, -0.040163978934288025, -0.08450166881084442, -0.05428402125835419, 0.06484613567590714, 0.11147317290306091, -0.038775451481342316, 0.026119325309991837, -0.06639669835567474, 0.016143567860126495, 0.0509866327047348, -0.013179205358028412, 0.09030309319496155, -0.028234634548425674, -0.0018457244150340557, 0.039952464401721954, -0.022528409957885742, 0.07547697424888611, -0.12007521092891693, 0.04848167300224304, -0.001013282686471939, -0.037375953048467636, 0.09463915973901749, 0.016219649463891983, -0.06618411093950272, 0.011575274169445038, 0.22608068585395813, -0.008974636904895306, -1.1369732540090473e-32, -0.008349848911166191, 0.08412018418312073, 0.0274512842297554, -0.004239876754581928, -0.020923756062984467, 0.005777692422270775, 0.10730545222759247, -0.0074050547555089, -0.04922088235616684, -0.03564528375864029, -0.0296480692923069, 0.022238343954086304, -0.10659676045179367, 0.04715985432267189, -0.027943819761276245, -0.016450095921754837, 0.10807279497385025, -0.10101191699504852, -0.06948314607143402, -0.11073146760463715, 0.04699435085058212, 0.18601447343826294, -0.13402873277664185, 0.0788290947675705, -0.012025777250528336, 0.1351885348558426, -0.033673785626888275, 0.08222197741270065, -0.0065868329256772995, -0.10090789198875427, -0.00219081062823534, 0.013221795670688152, -0.16033557057380676, -0.0012453356757760048, 0.005727279465645552, -0.04858371987938881, 0.018080059438943863, -0.10664746165275574, -0.03669586777687073, -0.07480376213788986, 0.05882560461759567, 0.04638753458857536, -0.03912350535392761, 0.040574658662080765, 0.06598970293998718, -0.005634865257889032, 0.03157008811831474, 0.0033949315547943115, 0.20853190124034882, 0.10387308895587921, 0.0760975331068039, 0.10517094284296036, -0.0194449033588171, 0.15590959787368774, -0.0077432431280612946, 0.04336070641875267, 0.05442002788186073, -0.05310261622071266, -0.10419121384620667, 0.001112992875277996, -0.020301539450883865, 0.05269326642155647, -0.021318119019269943, 0.05468444153666496, 0.018837813287973404, -0.0030738897621631622, -0.03761456906795502, -0.11709825694561005, -0.08318239450454712, -0.0026032559107989073, -0.04163229465484619, -0.0071579329669475555, -0.12630720436573029, -0.08773080259561539, 0.03339553251862526, 0.27072930335998535, -0.01626640185713768, -0.18143558502197266, -0.10847385227680206, 0.007393432781100273, -0.09838356822729111, -0.045624859631061554, 0.054921530187129974, 0.05035886541008949, -0.09617827087640762, -0.03217374533414841, -0.0023034270852804184, -0.13781386613845825, -0.05343703180551529, 0.017602302134037018, -0.028940895572304726, -0.318869948387146, -0.126947283744812, -0.00466288672760129, 0.05274766683578491, -1.0001741657106322e-07, -0.06403788179159164, -0.04805983603000641, 0.0012930468656122684, -0.06421541422605515, 0.06245402619242668, -0.11262870579957962, 0.1334383487701416, 0.08901237696409225, 0.09408661723136902, 0.12488548457622528, 0.1570529341697693, 0.08307497203350067, -0.1285364031791687, 0.08719059824943542, -0.16748705506324768, 0.06735013425350189, -0.06726434081792831, 0.0014873165637254715, 0.0027410397306084633, -0.08386550843715668, 0.004831160418689251, 0.05168416351079941, 0.06305371224880219, -0.015513475984334946, 0.03588021919131279, -0.15523245930671692, 0.027467241510748863, 0.1216585710644722, -0.01724940352141857, 0.01624361425638199, 0.013711933977901936, -0.01994020864367485, 0.08258891105651855, 0.03350767493247986, -0.029900772497057915, -0.14313426613807678, 0.008499810472130775, 0.13899970054626465, 0.0017864666879177094, 0.18177849054336548, -0.00649375282227993, 0.03985273465514183, 0.054366335272789, -0.08663477748632431, 0.020403150469064713, -0.0934964269399643, -0.09073752164840698, 0.13854321837425232, 0.05411066859960556, -0.16538436710834503, 0.15522290766239166, -0.02206885814666748, 0.04007759690284729, 0.056389182806015015, 0.06429502367973328, 0.012105259113013744, -0.11655684560537338, 0.105106420814991, -0.0568142905831337, 0.04878096282482147, 0.003201732411980629, -0.14081332087516785, 0.05171430855989456, 0.0641385018825531], "changes": {"1wk": 2.8179732089426324}}, {"text": "Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 Business Wire Mon, Jan 13, 2025, 4:00 PM 8 min read In This Article: EWTX +0.64% - Advancing robust clinical pipeline of novel therapeutics for serious muscular dystrophies and cardiac conditions - - Presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - BOULDER, Colo., January 13, 2025 --( BUSINESS WIRE )--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the Annual J.P. Morgan Healthcare Conference. \"We were pleased with our progress in 2024 as we advanced our drug pipeline and have great momentum heading into 2025. With positive Phase 2 results and enrollment nearing completion in our pivotal cohort for individuals with Becker muscular dystrophy, we are optimistic about the potential of sevasemten,\" said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. \"Additionally, we are thrilled with initial results from EDG-7500 in patients with obstructive hypertrophic cardiomyopathy and look forward to sharing additional, longer-term data across HCM populations in 2025.\" 2025 Priorities Muscular Dystrophy Program Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder. Complete recruitment of the GRAND CANYON pivotal placebo-controlled cohort in the first quarter of 2025 Seek end of Phase 2 feedback from the U.S. Food and Drug Administration (FDA) on CANYON results for sevasemten in Becker in the first half of 2025 Report data from the Phase 2 LYNX and FOX trials in the first half of 2025 and outline potential Phase 3 plans in individuals with Duchenne Cardiovascular and Cardiometabolic Programs EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. Report initial CIRRUS-HCM 28-day data in the first quarter of 2025 Release data from the 12-week CIRRUS-HCM trial in individuals with obstructive HCM and non-obstructive HCM by the second half of 2025 File an investigational new drug application for a second-generation heart failure candidate Select a proprietary cardiometabolic drug candidate from preclinical proof of concept data Story Continues 2024 Accomplishments Financial Strengthened balance sheet with net proceeds of approximately $232 million from January 2024 public follow-on offering supporting our muscular dystrophy and cardiovascular programs\u200b Muscular Dystrophy Program / Sevasemten Reported positive topline data from the CANYON Phase 2 placebo-controlled trial in adults with Becker Substantially enrolled the GRAND CANYON global pivotal cohort of sevasemten in adults with Becker; data from GRAND CANYON, if positive, could support a marketing application Advanced the MESA Phase 2 open label extension trial in adults with Becker, which to date has enrolled 99% of eligible participants completing prior Edgewise Becker trials Reported positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker Advanced the LYNX Phase 2 trial, a 2-part, dose-finding trial to evaluate the effect of sevasemten in children aged 4 to 9 years with Duchenne Advanced the FOX Phase 2 trial, a Phase 2 placebo-controlled trial to assess the effect of sevasemten in children and adolescents aged 6 to 17 years with Duchenne who have been previously treated with gene therapy Obtained Fast Track designation for sevasemten for the treatment of Duchenne from the FDA and Orphan Drug Designations for sevasemten for the treatment of Becker and for the treatment of Duchenne from the European Medicines Agency Cardiovascular Program / EDG-7500 Reported positive topline data of EDG-7500 in the Phase 1 trial in healthy subjects Reported positive topline data of EDG-7500 from the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM Opened and began enrolling the 28-day arms of CIRRUS-HCM in patients with obstructive HCM and non-obstructive HCM J.P. Morgan Healthcare Conference Presentation and Webcast Edgewise management will highlight these updates in a corporate presentation today at the 43 rd Annual J.P. Morgan Healthcare Conference at 1:30 pm PT (4:30 pm ET). The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company\u2019s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise\u2019s product candidates and programs, including sevasemten and EDG-7500; statements regarding Edgewise\u2019s expectations relating to its clinical trials, including timing of reporting data (including the LYNX and FOX Phase 2 trials, CIRRUS-HCM 28-day and 12-week data); the timing of the completion of recruitment of the GRAND CANYON trial; statements regarding the advancement of Edgewise\u2019s research and development programs; the timing of the initiation of a Phase 3 trial of sevasemten in Duchenne; the timing of receiving Phase 2 feedback from the FDA on sevasemten in Becker; the timing of filing an investigational new drug application for a second-generation heart failure candidate; the timing of selecting a proprietary cardiometabolic drug candidate; Edgewise\u2019s 2025 priorities; the possibility of data from GRAND CANYON to support a marketing application; statements regarding Edgewise\u2019s pipeline of product candidates and programs; statements regarding Edgewise\u2019s anticipated milestones; and statements by Edgewise\u2019s President and Chief Executive Officer. Words such as \"believes,\" \"anticipates,\" \"plans,\" \"expects,\" \"intends,\" \"will,\" \"goal,\" \"potential\" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise\u2019s limited operating history, its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having generated any revenue to date; Edgewise\u2019s ability to achieve objectives relating to the discovery, development and commercialization of its product candidates, if approved; Edgewise\u2019s need for substantial additional capital to finance its operations; Edgewise\u2019s substantial dependence on the success of sevasemten; Edgewise\u2019s ability to develop and commercialize sevasemten and EDG-7500 and discover, develop and commercialize product candidates in future programs, including risks relating to recruiting patients for its trials; risks related to Edgewise\u2019s clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise\u2019s product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise\u2019s clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks relating to interim, topline and preliminary data from Edgewise\u2019s clinical trials changing as more patient data becomes available; risks related to the regulatory approval processes being lengthy, time consuming and inherently unpredictable; risks related to regulatory authorities not accepting data from trials conducted in locations outside of their jurisdiction; risks relating to Edgewise\u2019s ability to attract and retain highly skilled executive officers and employees; Edgewise\u2019s ability to obtain and maintain intellectual property protection for its product candidates; Edgewise\u2019s reliance on third parties; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled \"Risk Factors\" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law . This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20250113992573/en/ Contacts Edgewise Contacts Investors: Behrad Derakhshan, Ph.D., Chief Business Officer ir@edgewisetx.com Media: Maureen Franco, VP Corporate Communications media@edgewisetx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-13T13:00:00+00:00", "sentiment": {"score": 0.5811400357633829, "confidence": 0.5931451320648193, "probabilities": {"positive": 0.5931451320648193, "negative": 0.012005096301436424, "neutral": 0.39484986662864685}}, "embedding": [-0.17293202877044678, -0.12047016620635986, 0.02726508490741253, -0.11348724365234375, -0.12351945787668228, -0.2235184609889984, -0.2050703763961792, 0.26888972520828247, 0.004998346790671349, -0.0021496834233403206, -0.11474867165088654, 0.10405043512582779, 0.039785586297512054, 0.06504938006401062, 0.03082004189491272, 0.02011188678443432, 0.08294393122196198, 0.08105108886957169, -0.12160521000623703, 0.10643227398395538, 0.036680109798908234, 0.009573457762598991, 0.06339070200920105, 0.031207406893372536, -0.08189123868942261, -0.015254314988851547, -0.07632015645503998, -0.022685164585709572, -0.24123094975948334, -0.06566177308559418, -0.0032601747661828995, 0.062161363661289215, 0.013903086073696613, 0.010821081697940826, 0.015204258263111115, 0.03764589875936508, -0.03883681446313858, 0.057514458894729614, -0.14609113335609436, -0.09902061522006989, -0.03993416577577591, -0.09532004594802856, -0.10369996726512909, 0.007014722563326359, 0.03830867260694504, -0.17167729139328003, -0.1383020579814911, -0.00321792159229517, -0.07933568209409714, 0.2717857360839844, -0.14648336172103882, -0.18989890813827515, -0.0023359041661024094, 0.08213607966899872, 0.0199937354773283, -0.01862906664609909, -0.17989426851272583, 0.018727105110883713, -0.025821924209594727, -0.013649036176502705, 0.07721216976642609, -0.12356417626142502, -0.04704318940639496, -0.02080819010734558, 0.04175158590078354, 0.09544451534748077, 0.156061589717865, 0.013577474281191826, 0.013430524617433548, -0.03363921120762825, 0.16461944580078125, -0.12130201607942581, 0.08684609085321426, 0.14214059710502625, 0.08585520088672638, 0.10692138969898224, 0.1515059620141983, 0.16352802515029907, 0.21669483184814453, -0.21971003711223602, 0.06924602389335632, 0.08930221199989319, 0.04692652076482773, -0.013959214091300964, -0.04350978881120682, 0.1830120086669922, 0.030852187424898148, 0.17984162271022797, 0.02253318578004837, 0.08602326363325119, 0.17055490612983704, 0.008805086836218834, -0.04409082233905792, 0.01398828998208046, -0.01755339466035366, -0.03281749412417412, -0.10011838376522064, 0.018384572118520737, -0.031322941184043884, -0.021130405366420746, 0.10791423171758652, 0.03467412665486336, -0.037984371185302734, -0.027100861072540283, 0.018107743933796883, -0.0774296373128891, 0.1173139214515686, -0.02766028791666031, 0.05877695977687836, -0.09241388738155365, 0.018872415646910667, 0.046491388231515884, 0.0061324359849095345, -0.02026621252298355, -0.06423552334308624, 0.2071407586336136, -0.003998173400759697, 0.053762637078762054, 0.1782100945711136, 0.03510022908449173, 0.06688033044338226, -0.023425105959177017, -0.0013939938507974148, -0.09263449162244797, -0.08373260498046875, 0.15110158920288086, -0.1998269259929657, 8.892662518428607e-33, 0.004719898104667664, 0.04342252016067505, 0.12999606132507324, 0.01481492631137371, -0.03869716078042984, -0.06068350374698639, -0.06172328442335129, -0.02134740725159645, -0.17569556832313538, -0.14642947912216187, -0.2553759813308716, 0.0033566914498806, 0.07782444357872009, 0.1930059790611267, -0.09684402495622635, -0.18821322917938232, -0.07433085143566132, 0.0005324529483914375, -0.07646806538105011, 0.018310140818357468, 0.22652411460876465, -0.013446066528558731, -0.04729844629764557, 0.038317229598760605, -0.018381372094154358, 0.10152044147253036, -0.04232943803071976, 0.057138316333293915, 0.15441419184207916, 0.07769850641489029, -0.23413529992103577, -0.08698384463787079, 0.05514732003211975, -0.07247462123632431, -0.009826679714024067, 0.023099161684513092, -0.07828803360462189, -0.10020163655281067, 0.11136888712644577, 0.0012920999433845282, 0.05736321210861206, 0.0136325154453516, -0.13192827999591827, -0.11134568601846695, 0.03132996708154678, -0.11510409414768219, 0.08170580863952637, -0.06596723198890686, -0.057734619826078415, -0.1187792718410492, 0.04068417102098465, -0.0250579621642828, 0.0967470109462738, -0.10772265493869781, -0.06656569987535477, 0.05310994014143944, -0.13196519017219543, -0.03332648426294327, 0.11325937509536743, 0.13224877417087555, 0.18700245022773743, 0.0766536295413971, -0.015205979347229004, -0.008459453471004963, -0.12771856784820557, 0.06904296576976776, -0.08750677108764648, -0.0032806117087602615, -0.1601562201976776, -0.030818844214081764, -0.0077134668827056885, -0.06711474806070328, 0.055342815816402435, -0.06228408217430115, 0.14828325808048248, -0.06784875690937042, 0.08531501889228821, 0.20011550188064575, -0.09933905303478241, -0.0008902903646230698, 0.009950932115316391, 0.07829414308071136, -0.1443043053150177, 0.14709320664405823, 0.10346292704343796, -0.06851232051849365, 0.11457954347133636, -0.039018817245960236, -0.1330655813217163, 0.06862057745456696, 0.16724100708961487, -0.05014725774526596, 0.017779536545276642, 0.204434335231781, -0.02627020701766014, -9.228568110699738e-33, -0.023887336254119873, 0.10721179842948914, 0.07141229510307312, -0.07110689580440521, -0.057995423674583435, 0.09364160150289536, 0.14351001381874084, -0.13277478516101837, 0.1182011291384697, -0.20703744888305664, 0.14128661155700684, 0.026050228625535965, -0.030236300081014633, -0.03265964612364769, -0.0747591108083725, 0.09715695679187775, -0.18012955784797668, -0.23199370503425598, -0.10212500393390656, 0.08350887894630432, 0.07584376633167267, 0.1393795907497406, -0.0962684378027916, 0.18212926387786865, 0.041661351919174194, 0.08683975040912628, 0.0731462836265564, 0.11052161455154419, 0.15108375251293182, -0.08501726388931274, -0.048266563564538956, 0.001443217508494854, -0.23479263484477997, -0.03944951295852661, -0.017968451604247093, 0.08633175492286682, 0.019085094332695007, -0.055001698434352875, -0.030987752601504326, -0.10686761140823364, 0.02793705463409424, 0.03457486256957054, -0.0749998390674591, 0.1346251666545868, 0.03715851530432701, 0.07547873258590698, 0.09463892132043839, -0.029564540833234787, -0.034055307507514954, -0.055765505880117416, -0.004488268867135048, 0.15863114595413208, -0.0031450092792510986, 0.0467371866106987, -0.0070201558992266655, -0.02505459263920784, 0.09684881567955017, -0.0027396385557949543, -0.20542427897453308, 0.06062440574169159, -0.19144216179847717, 0.05324910581111908, 0.09477943181991577, -0.007955539971590042, 0.17392893135547638, 0.12358704209327698, 0.05902961641550064, -0.06042111665010452, -0.03529529273509979, -0.03464144468307495, -0.03897622600197792, 0.036145105957984924, -0.1237112358212471, -0.11718243360519409, 0.030201034620404243, 0.09509280323982239, -0.010204922407865524, -0.14090809226036072, -0.20974993705749512, -0.057905614376068115, 0.007907935418188572, -0.05626244097948074, -0.03646685928106308, 0.0014493949711322784, -0.003888925537467003, 0.014009501785039902, 0.11323562264442444, 0.00608699768781662, -0.02722938172519207, 0.06831786036491394, -0.06697281450033188, -0.13840027153491974, -0.10968835651874542, 0.24113759398460388, 0.09922430664300919, -9.982173310163489e-08, 0.0940103679895401, 0.04282558709383011, -0.024046264588832855, -0.1747160255908966, -0.004548479802906513, -0.09498772025108337, 0.043772656470537186, 0.06633608043193817, -0.018377922475337982, 0.15108782052993774, 0.09962409734725952, 0.13395369052886963, -0.04120844975113869, -0.1062539666891098, -0.07533939182758331, 0.05426979064941406, -0.034694939851760864, 0.09318935871124268, 0.004729552194476128, -0.012827355414628983, -0.051630280911922455, -0.06154881417751312, 0.029630430042743683, -0.09890751540660858, 0.14103087782859802, -0.1288815587759018, 0.04265270382165909, 0.07889965176582336, 0.07532057911157608, -0.11845096945762634, -0.06137391924858093, -0.029330682009458542, -0.010775717906653881, 0.0024093124084174633, -0.05958002805709839, -0.14492282271385193, -0.05792342126369476, 0.1456664800643921, 0.020523659884929657, 0.19239841401576996, 0.09301920235157013, 0.028356056660413742, -0.019980594515800476, 0.004793275147676468, 0.007571429014205933, -0.12037546187639236, -0.05685105547308922, 0.02227034792304039, 0.13334277272224426, -0.05133770778775215, -0.053595710545778275, -0.0032641123980283737, 0.00678473524749279, -0.09351345896720886, -0.05020884424448013, 0.20238511264324188, -0.17194071412086487, -0.036440201103687286, 0.03336752951145172, 0.05259598046541214, 0.012683538720011711, -0.18521606922149658, -0.011247741058468819, 0.018279096111655235], "changes": {"1wk": 3.6715369442437495}}, {"text": "Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More Zacks Equity Research Thu, Jan 9, 2025, 9:48 PM 4 min read In This Article: HOTH -3.97% NMRA -3.63% TEVA -2.14% It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on study data. Recap of the Week\u2019s Most Important Stories : NMRA Stock Crashes on Study Failure Neumora Therapeutics announced the failure of its lead pipeline candidate, navacaprant, in a late-stage study for major depressive disorder (MDD). Shares of the company plummeted on the same. The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint. Treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale. The study also failed to show statistically significant improvement in the reduction of anhedonia (the inability to feel pleasure), as assessed by the Snaith-Hamilton Pleasure Scale. The KOASTAL-1 study is one of the three late-stage studies in the KOASTAL program evaluating navacaprant in the MDD indication. Management continues to analyze the study results further, as it claimed that the drug showed an efficacy signal in female patients. HOTH Stock Soars on Study Data Hoth Therapeutics announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being developed to address skin toxicities linked to cancer patients undergoing treatment with EGFR inhibitors. Shares of HOTH surged on the data announcement. Per the data readout from the ongoing phase IIa study, all patients treated with the candidate achieved the primary efficacy endpoint of an ARIGA score \u22641, showing significant skin toxicity improvement by the six-week mark. Additionally, 66% of patients treated with HT-001 reported reduced pain and itching scores, which significantly improved their quality of life. Importantly, all patients retained their full EGFR inhibitor dosage, ensuring the cancer treatment's complete therapeutic efficacy. This is a significant improvement over previous reports that highlighted frequent dose reductions or treatment interruptions caused by skin-related side effects. HOTH currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . CPRX Stock Gains on Patent Litigation With Teva Catalyst Pharmaceuticals CPRX and its licensor, SERB, announced entering into a settlement agreement with Teva Pharmaceuticals TEVA. The agreement resolves the patent litigation brought by Catalyst and SERB on Teva for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version of Firdapse 10 mg tablets before applicable patents expire. Story Continues Per the terms, Teva has agreed not to market its generic version of Firdapse in the United States, subject to approval, before Feb. 25, 2035, unless specific exceptions outlined in the agreement arise. Additionally, Catalyst/SERB and Teva will end all ongoing patent litigation over Firdapse patents in the U.S. District Court in New Jersey. However, litigation against the remaining defendants continues. While Hetero faces claims for all Orange Book-listed patents for the drug, Lupin does the same for the Catalyst Firdapse patent expiring in 2037. VIR Stock Gains on Study Data Vir Biotechnology VIR presented encouraging safety and efficacy data in ongoing dose escalation studies for two of its dual-masked T-cell engagers (TCEs) \u2014 VIR-5818, targeting a variety of HER2-expressing solid tumors, and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). VIR-5818 is being evaluated in a phase I study for safety and pharmacokinetics alone, and in combination with pembrolizumab, in participants with a variety of HER2-expressing cancers, including breast and colorectal cancer. Early efficacy data indicate that 50% (10/20) of participants receiving VIR-5818 doses \u2265400 \u00b5g/kg experienced dose-dependent tumor shrinkage across multiple HER2-positive tumor types. A phase I study is assessing the safety, pharmacokinetics, and preliminary efficacy of VIR-5500 in mCRPC patients. Early efficacy data show encouraging signs of prostate-specific antigen (PSA) responses. PSA reductions were observed in 100% of participants after an initial dose \u2265120 \u00b5g/kg. Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome. The maximum tolerated dose has not been reached as dose escalation continues, and early clinical response signals are observed in heavily pretreated participants. Performance The Nasdaq Biotechnology Index has gained 0.85% in the past four trading sessions and Regeneron\u2019s shares have gained 2.57%. In the past six months, shares of MRNA have lost 62.93%. (See the last biotech stock roundup here: Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains ) Zacks Investment Research Image Source: Zacks Investment Research What's Next in Biotech? Stay tuned for more pipeline updates. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report Hoth Therapeutics, Inc. (HOTH) : Free Stock Analysis Report Vir Biotechnology, Inc. (VIR) : Free Stock Analysis Report Neumora Therapeutics, Inc. (NMRA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-09T18:48:00+00:00", "sentiment": {"score": 0.8806557804346085, "confidence": 0.9179348349571228, "probabilities": {"positive": 0.9179348349571228, "negative": 0.03727905452251434, "neutral": 0.04478611797094345}}, "embedding": [0.01310773380100727, -0.08796161413192749, -0.0078072575852274895, 0.0720880776643753, -0.043238840997219086, 0.005873505026102066, -0.17933854460716248, 0.22495439648628235, 0.023638244718313217, -0.04221488535404205, -0.06977001577615738, 0.0352528914809227, 0.06907249242067337, 0.020964451134204865, 0.03981820493936539, -0.018408048897981644, 0.08800245821475983, 0.01502965111285448, -0.04121587425470352, 0.08606360852718353, 0.044859059154987335, 0.030934374779462814, 0.013083484955132008, 0.030137810856103897, -0.14430823922157288, 0.02013453096151352, -0.14913222193717957, -0.006361417472362518, -0.13424241542816162, -0.0204659104347229, 0.0481768399477005, 0.13287094235420227, -0.01307905837893486, -0.05728381872177124, 0.03065679594874382, 0.013296432793140411, -0.2698237895965576, 0.07696951925754547, -0.10244899988174438, -0.04487811028957367, 0.00940118171274662, 0.0027030690107494593, -0.04681001603603363, -0.027638114988803864, 0.025844521820545197, -0.2009865641593933, -0.0710003525018692, -0.031816765666007996, 0.023255569860339165, 0.09428256750106812, -0.0863506868481636, -0.07393232733011246, 0.033843595534563065, 0.1209430992603302, -0.04898042976856232, 0.012507105246186256, -0.11793655157089233, -0.05155386030673981, -0.08900169283151627, 0.10212290287017822, 0.047582484781742096, 0.004424356389790773, -0.04121219366788864, -0.0632191151380539, 0.218703031539917, 0.020384592935442924, 0.0768057331442833, -0.16504716873168945, -0.011568991467356682, 0.015478067100048065, 0.023738820105791092, -0.19516846537590027, 0.08273809403181076, 0.11171895265579224, -0.04714283347129822, 0.08728644251823425, 0.10214001685380936, 0.07217422127723694, 0.029388565570116043, 0.039399404078722, -0.010003533214330673, 0.12556320428848267, 0.03628052771091461, -0.0026482357643544674, -0.05136791244149208, -0.012425316497683525, 0.00385575694963336, 0.07619725167751312, 0.037767816334962845, 0.07758122682571411, 0.026669511571526527, 0.0889957845211029, -0.12314317375421524, -0.01061798632144928, 0.05221915990114212, -0.08553469926118851, -0.22795897722244263, 0.0513911098241806, 0.022266816347837448, 0.0008052177727222443, 0.12011907994747162, 0.061354801058769226, -0.17011375725269318, -0.05556008964776993, -0.06576655805110931, -0.03485430032014847, 0.03359048441052437, -0.11023063957691193, -0.024211842566728592, 0.11107988655567169, -0.14139385521411896, -0.03660978749394417, 0.019183101132512093, -0.07130442559719086, -0.002332247793674469, 0.08985956013202667, -0.011468227952718735, 0.12066659331321716, 0.1648716926574707, -0.05036386847496033, 0.07381732761859894, -0.08256854861974716, 0.11098968982696533, -0.16847676038742065, 0.06642921268939972, 0.14047932624816895, -0.06969913840293884, 1.058522524276694e-32, 0.05097188428044319, -0.01359272189438343, 0.06957107782363892, 0.05163387954235077, 0.06371528655290604, 0.0262155719101429, 0.012613062746822834, 0.04268892481923103, -0.04154389351606369, -0.06427422910928726, -0.06158842146396637, 0.003956660628318787, -0.022549062967300415, 0.07626961171627045, -0.10731430351734161, -0.10582093894481659, 0.07274448871612549, -0.0834151953458786, -0.12301109731197357, -0.03594181314110756, 0.008651535026729107, -0.009027066640555859, 0.023479407653212547, 0.11427779495716095, -0.12699761986732483, 0.029427580535411835, -0.09447291493415833, 0.0474897176027298, -0.10265688598155975, 0.014609938487410545, -0.07144521921873093, -0.09012099355459213, 0.05060136690735817, -0.09735279530286789, -0.0994386225938797, -0.045192547142505646, -0.012759942561388016, 0.019609902054071426, 0.06244395673274994, -0.09388010203838348, -0.03488224744796753, 0.1308586299419403, -0.016913549974560738, 0.031978338956832886, 0.02725379914045334, 0.02349206805229187, -0.08421554416418076, -0.04082109034061432, 0.043531760573387146, -0.0067827170714735985, -0.04524147883057594, -0.09028100222349167, 0.023843053728342056, -0.0498834103345871, -0.1353217363357544, 0.06811917573213577, -0.10132261365652084, -0.061514947563409805, 0.14157602190971375, 0.11126112937927246, -0.06542744487524033, 0.04526202008128166, 0.0302288681268692, -0.04954468831419945, -0.004227090626955032, 0.0041703591123223305, -0.0035492051392793655, -0.14610356092453003, -0.10918852686882019, 0.038747452199459076, -0.06326466798782349, 0.1266860067844391, 0.1651134490966797, 0.09038536250591278, 0.09272141754627228, -0.11848701536655426, 0.06802868843078613, 0.09884262830018997, -0.01109173521399498, -0.01437265332788229, 0.03166471794247627, -0.06346991658210754, -0.04894789308309555, 0.0654292106628418, 0.05616256967186928, -0.05935550481081009, -0.023392319679260254, 0.01589355617761612, -0.036806728690862656, -0.019361121580004692, 0.11324769258499146, 0.013769291341304779, 0.020360734313726425, 0.0964721068739891, 0.022411955520510674, -1.0838160770337188e-32, -0.03090614825487137, 0.01782585121691227, -0.04824880138039589, -0.030774733051657677, 0.03528226912021637, 0.08941130340099335, -0.04427007585763931, -0.05093450844287872, 0.04748689383268356, -0.13317815959453583, 0.07403524219989777, 0.01596309244632721, 0.01876845397055149, -0.05791082978248596, -0.09761259704828262, 0.03498624637722969, -0.004524624906480312, -0.05373015254735947, -0.13698792457580566, 0.033741388469934464, 0.013252916745841503, 0.14369532465934753, -0.11285768449306488, -0.01418370846658945, 0.038334738463163376, -3.1910836696624756e-05, 0.11102208495140076, 0.008067367598414421, 0.04035634547472, 0.07414299249649048, 0.164926216006279, 0.0401114746928215, -0.2676755487918854, 0.03099692240357399, 0.05246980860829353, -0.00011337362229824066, 0.06689471751451492, -0.1036837175488472, -0.09997867047786713, -0.06373219192028046, 0.14680123329162598, 0.09755805879831314, -0.014293425716459751, 0.01732940413057804, 0.0541689470410347, 0.03244974464178085, -0.013797168619930744, -0.09024123847484589, 0.018547484651207924, 0.0736885517835617, 0.0351167693734169, -0.0002716686576604843, 0.006934208795428276, 0.07212285697460175, 0.11784430593252182, -0.050469912588596344, 0.03692386671900749, -0.131978839635849, -0.16387414932250977, 0.04542617127299309, 0.003042265772819519, 0.07865455746650696, -0.032977394759655, -0.07495671510696411, 0.01519889384508133, -0.03859845921397209, 0.06549181044101715, -0.002820352092385292, 0.1132785901427269, 0.027385924011468887, -0.14180904626846313, 0.003908677026629448, -0.010260260663926601, -0.09133176505565643, -0.013364333659410477, 0.0911056399345398, -0.10333263874053955, -0.04831867665052414, -0.1002769023180008, -0.023346954956650734, -0.07599915564060211, -0.05713954567909241, -0.05220808833837509, 0.0070162368938326836, 0.044674329459667206, 0.06393931806087494, 0.05883921682834625, 0.06528287380933762, -0.024205857887864113, 0.005408008582890034, -0.0835103690624237, -0.057658109813928604, -0.181147962808609, 0.14501023292541504, 0.022127702832221985, -1.0096358238342873e-07, 0.05269814282655716, -0.18753188848495483, -0.008565830066800117, -0.04723235219717026, 0.02483590692281723, 0.02144000120460987, 0.07485628128051758, 0.014348075725138187, -0.043476834893226624, 0.12147677689790726, 0.04896865040063858, 0.12844830751419067, -0.069161057472229, -0.007339932024478912, -0.13336238265037537, -0.022948794066905975, 0.19900661706924438, 0.22390662133693695, 0.008756562136113644, -0.020704012364149094, -0.07015423476696014, -0.04666111245751381, 0.004047751426696777, -0.1444798707962036, 0.026930231600999832, 0.03415972366929054, 0.11808595061302185, 0.11495117098093033, -0.0632060319185257, -0.12941065430641174, 0.06675217300653458, -0.05640139430761337, 0.13606961071491241, -0.007085472345352173, 0.014897705987095833, -0.010299485176801682, 0.12260858714580536, 0.11629819869995117, 0.007411176338791847, 0.12301626801490784, -0.006188726518303156, 0.035979460924863815, -0.05075014755129814, 0.04553113877773285, -0.08132707327604294, -0.05729003995656967, -0.02551421895623207, -0.020764579996466637, 0.05257628858089447, -0.07482863962650299, 0.02820921316742897, 0.10145191848278046, -0.0584588423371315, -0.004345455206930637, -0.07083223760128021, 0.07688752561807632, -0.046218469738960266, -0.03082956187427044, -0.006097517907619476, -0.10681500285863876, 0.041730478405952454, -0.10162251442670822, -0.009104624390602112, 0.06803285330533981], "changes": {"1wk": 10.641820850598524}}, {"text": "Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 Business Wire Tue, Jan 7, 2025, 4:00 PM 1 min read In This Article: EWTX +0.64% BOULDER, Colo., January 07, 2025 --( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 pm PT (4:30 pm ET). The discussion will include updates on its cardiovascular and muscular dystrophy programs and 2025 key milestones. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company\u2019s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram . View source version on businesswire.com: https://www.businesswire.com/news/home/20250107119700/en/ Contacts Edgewise Contacts Investors: Behrad Derakhshan, Ph.D., Chief Business Officer ir@edgewisetx.com Media: Maureen Franco, VP Corporate Communications media@edgewisetx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2025-01-07T13:00:00+00:00", "sentiment": {"score": 0.14477475360035896, "confidence": 0.15287962555885315, "probabilities": {"positive": 0.15287962555885315, "negative": 0.008104871958494186, "neutral": 0.839015543460846}}, "embedding": [-0.17058852314949036, -0.11848713457584381, -0.0572664774954319, -0.10685907304286957, -0.02213859185576439, -0.18390795588493347, -0.11732911318540573, 0.25554901361465454, 0.058210961520671844, 0.000260933768004179, -0.048241227865219116, 0.06639774143695831, 0.02065194770693779, 0.13360121846199036, 0.021708212792873383, 0.046986933797597885, 0.029256083071231842, 0.08121980726718903, -0.0896565243601799, 0.07914073765277863, 0.05555734410881996, 0.05124421417713165, -0.012609092518687248, 0.020659763365983963, -0.10117092728614807, -0.020261183381080627, -0.06755727529525757, 0.015557748265564442, -0.19141170382499695, -0.10015717148780823, 0.02200958877801895, 0.03753795847296715, 0.012706981971859932, 0.0015092035755515099, 0.06518468260765076, 0.07272882759571075, -0.03116581402719021, 0.025361284613609314, -0.12712401151657104, -0.061551325023174286, 0.02483787015080452, -0.11594593524932861, -0.042571697384119034, -0.04620823264122009, 0.07168006896972656, -0.08801819384098053, -0.14393311738967896, -0.014203174039721489, -0.01985212229192257, 0.20517611503601074, -0.12629419565200806, -0.1423131376504898, -0.04421526938676834, 0.026104874908924103, 0.03704230859875679, 0.012094296514987946, -0.17173485457897186, 0.07016904652118683, -0.03282270208001137, -0.04273726046085358, 0.09927883744239807, -0.08728422224521637, -0.04258474335074425, 0.018540892750024796, 0.018777865916490555, 0.06273128092288971, 0.05938166379928589, 0.07341744005680084, -0.023539483547210693, -0.03945757821202278, 0.08582719415426254, -0.08234305679798126, -0.003002807032316923, 0.1128172054886818, 0.11014734208583832, 0.08649089932441711, 0.08223125338554382, 0.13691970705986023, 0.1130492091178894, -0.15091320872306824, 0.06683714687824249, 0.05404534935951233, 0.04116322100162506, 0.023708652704954147, 0.011720279231667519, 0.17621733248233795, 0.04423339664936066, 0.10779006779193878, -0.01175571046769619, 0.06750158220529556, 0.09050286561250687, 0.041372351348400116, -0.08800163865089417, 0.015424057841300964, 0.05533641576766968, -0.018925316631793976, -0.10066074132919312, 0.016188962385058403, -0.008900351822376251, 0.043417252600193024, 0.021598175168037415, -0.040761470794677734, -0.04980744421482086, -0.04658682644367218, 0.03868576139211655, -0.07749401032924652, 0.07333273440599442, 0.03354156017303467, 0.0677385926246643, -0.06379617750644684, 0.01233205758035183, 0.02531081810593605, 0.050929613411426544, -0.013194145634770393, -0.014597759582102299, 0.1580793857574463, -0.01948167383670807, 0.020435163751244545, 0.1913566291332245, 0.030528374016284943, 0.07447215169668198, -0.023071885108947754, -0.016595376655459404, -0.06309347599744797, -0.07269738614559174, 0.13789787888526917, -0.15169058740139008, 8.17129028800377e-33, 0.030707892030477524, -0.004381317645311356, 0.0725390762090683, 0.024823911488056183, 0.028223944827914238, -0.07185259461402893, -0.04415133595466614, -0.06836006045341492, -0.18595418334007263, -0.11224181950092316, -0.21573662757873535, 0.002597430720925331, 0.0983012318611145, 0.1636352837085724, -0.08626256883144379, -0.10958831012248993, -0.0628710612654686, 0.030605029314756393, -0.019499003887176514, -0.026413675397634506, 0.17367735505104065, 0.0015247073024511337, -0.04882989823818207, 0.07621689140796661, -0.04542909190058708, 0.1169658973813057, -0.0866289734840393, 0.04066316783428192, 0.1929604709148407, 0.0540449321269989, -0.2374504804611206, -0.05637770891189575, 0.02403656765818596, -0.08871135860681534, 0.030808212235569954, 0.04483615979552269, -0.024718429893255234, -0.09281471371650696, 0.014884443953633308, 0.026580531150102615, 0.008390367031097412, 0.010722680017352104, -0.15910595655441284, -0.09920749068260193, -0.0156507920473814, -0.08702477812767029, 0.042197518050670624, -0.054491590708494186, -0.07772542536258698, -0.08083725720643997, 0.0713229775428772, -0.04921911656856537, 0.13867546617984772, -0.12277962267398834, -0.033737316727638245, 0.019384730607271194, -0.172672837972641, 0.0004143648548051715, 0.0590948723256588, 0.14248722791671753, 0.17401140928268433, 0.0244322307407856, -0.03022461198270321, 0.022237490862607956, -0.10457373410463333, 0.04837101325392723, -0.058198779821395874, -0.012182016856968403, -0.08040347695350647, -0.048762448132038116, -0.042335495352745056, -0.010127529501914978, 0.06966467946767807, -0.042607199400663376, 0.12409806251525879, -0.09285083413124084, 0.021275902166962624, 0.15653732419013977, -0.1034984216094017, -0.013541159220039845, 0.006071385927498341, 0.056218184530735016, -0.1233782172203064, 0.08538635075092316, 0.02848094515502453, -0.08668285608291626, 0.06398631632328033, -0.09200561791658401, -0.11467473208904266, 0.010742729529738426, 0.09935350716114044, -0.04586217552423477, -0.0027858801186084747, 0.1779365837574005, -0.07060243934392929, -9.207607577056638e-33, -0.017319589853286743, 0.0806238055229187, 0.11013137549161911, -0.03587398678064346, -0.026734333485364914, 0.15372046828269958, 0.12621459364891052, -0.1015537828207016, 0.1179463267326355, -0.07773533463478088, 0.13834866881370544, -0.006792593281716108, -0.046259913593530655, -0.04942597076296806, -0.06141455098986626, 0.06105088070034981, -0.1545281559228897, -0.19296769797801971, -0.09781941026449203, 0.09374147653579712, 0.08136995881795883, 0.11842908710241318, -0.07695609331130981, 0.09807044267654419, 0.07532437145709991, 0.09399507194757462, 0.0303196981549263, 0.11696495115756989, 0.08417876064777374, -0.06261024624109268, -0.011544518172740936, 0.023956457152962685, -0.21103988587856293, -0.06991465389728546, -0.04025069996714592, 0.15893346071243286, 0.05895284190773964, -0.04268097132444382, -0.008035160601139069, -0.11491018533706665, 0.030888674780726433, -0.009054798632860184, -0.06816383451223373, 0.13667032122612, 0.02056703343987465, 0.08512169122695923, 0.017316432669758797, 0.030949927866458893, -0.0861976146697998, -0.05261363834142685, -0.07043813169002533, 0.11681218445301056, 0.038351524621248245, 0.04123154282569885, -0.032777633517980576, -0.010203629732131958, 0.07839250564575195, 0.010471955873072147, -0.15003198385238647, 0.034334294497966766, -0.15297280251979828, -0.07068465650081635, 0.011966176331043243, 0.032922618091106415, 0.13142332434654236, 0.1576022058725357, 0.03348296880722046, -0.052257344126701355, -0.0607340931892395, 0.0363137386739254, -0.008724786341190338, 0.06157688423991203, -0.09727728366851807, -0.08300235122442245, 0.03818034753203392, 0.02568954788148403, -0.03776618465781212, -0.15911459922790527, -0.1914319097995758, 0.013696365989744663, -0.0473116934299469, -0.017029954120516777, -0.0024468814954161644, -0.008010216988623142, -0.0069968849420547485, 0.019593121483922005, 0.12114511430263519, 0.0660490021109581, -0.04339555650949478, 0.016264185309410095, -0.036610186100006104, -0.1206822618842125, -0.0795338898897171, 0.22874146699905396, 0.08963744342327118, -1.0005756223563367e-07, 0.06648285686969757, -0.017569415271282196, -0.08263818919658661, -0.19353517889976501, -0.11176416277885437, -0.05484943091869354, 0.04559973627328873, 0.06233886629343033, -0.020544618368148804, 0.11103716492652893, 0.061324141919612885, 0.08949840068817139, -0.0121277691796422, -0.09050881117582321, -0.027387158945202827, 0.012805838137865067, -0.026772012934088707, 0.0895918756723404, -0.005103438161313534, -0.07391820847988129, 0.04581768810749054, -0.06692740321159363, 0.0398927740752697, -0.09218969941139221, 0.14273014664649963, -0.17609983682632446, 0.023516878485679626, 0.07020585238933563, 0.03476637601852417, -0.08745048195123672, -0.0692305788397789, 0.010067353025078773, 0.02963634952902794, 0.0028894124552607536, -0.09822139143943787, -0.12507319450378418, -0.05156473070383072, 0.07493874430656433, -0.012589209713041782, 0.1449819952249527, 0.07951487600803375, 0.026728328317403793, -0.030049869790673256, -0.028331749141216278, -0.0006862517911940813, -0.05242161080241203, 0.07173632830381393, 0.07150392979383469, 0.11883336305618286, -0.027252743020653725, -0.05306132882833481, -0.0004041409119963646, 0.04761187732219696, -0.08791486918926239, -0.08969148993492126, 0.17771707475185394, -0.11021652817726135, -0.02435469627380371, 0.04176366329193115, 0.030077189207077026, -0.004107233136892319, -0.04986821487545967, 0.02607741206884384, 0.025297576561570168], "changes": {"1wk": -0.2755893538405854}}, {"text": "EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study Zacks Equity Research Tue, Dec 17, 2024, 5:18 PM 4 min read In This Article: EWTX +0.64% SPRO -6.27% Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic disorder called Becker Muscular Dystrophy (\u201cBMD\u201d). The study met its primary endpoint of change from baseline in creatine kinase (CK), a biomarker associated with skeletal muscle damage. Data from the study showed a significant reduction in CK levels in the sevasemten-treated group, with an average decrease of 28% compared to placebo between six and 12 months. The drug was also well-tolerated by study participants. Treatment with sevasemten showed a trend toward improvement in the key secondary endpoint of the North Star Ambulatory Assessment, a scale commonly used to rate motor function. Patients who received the drug also showed a significant reduction in plasma levels of fast skeletal muscle troponin I (TNNI2), a target-specific biomarker for fast skeletal muscle damage. Per EWTX, the sevasemten-treated group included patients with more advanced disease compared to those in the placebo group. Edgewise remains on schedule to complete recruitment for a pivotal cohort of the CANYON study, called GRAND CANYON, which is expected to be achieved in the first quarter of 2025. If data from this cohort is also positive, management intends to start discussions with the FDA and EMA for seeking approval for sevasemten in the BMD indication. EWTX Stock Performance Investors were impressed with the CANYON study results and management\u2019s plans for sevasemten, which sent the stock price soaring. Some investors believe that the drug has the potential to become the first approved therapy for BMD. EWTX\u2019s shares have skyrocketed nearly 200% year to date against the industry\u2019s 11.4% decline. Zacks Investment Research Image Source: Zacks Investment Research More on EWTX\u2019s Sevasemten Other than BMD, Edgewise is also evaluating sevasemten in other muscular disorders. The drug is also being evaluated in separate mid-stage studies for Duchenne muscular dystrophy (DMD), Limb-Girdle muscular dystrophy (LGMD) and McArdle Disease. Sevasemten has achieved significant regulatory milestones from the FDA. These include the orphan drug and fast-track designations in both BMD and DMD indications and a rare pediatric disease designation for DMD. Other Candidates in EWTX\u2019s Pipeline Apart from sevasemten, Edgewise is also evaluating another candidate, EDG-7500, in a mid-stage study for patients with obstructive hypertrophic cardiomyopathy (HCM). In September, management reported positive top-line data for EDG-7500 from an early-stage study in healthy subjects and Part A (single-dose arm) of a mid-stage study in patients with HCM. While the early-stage data showed that treatment with the drug was well-tolerated with no changes in left ventricle ejection fraction (an important predictor of mortality), the mid-stage data showed gradient relief without reductions in left ventricular outflow tract (part of the heart that directs blood from the left ventricle to the aorta). Story Continues Based on the above results, EWTX started the part B portion of the mid-stage study on EDG-7500 in patients with obstructive HCM. Initial data from this study is expected in the first quarter of 2025. EWTX\u2019s Zacks Rank Edgewise currently carries a Zacks Rank #3 (Hold). Edgewise Therapeutics, Inc. Price Edgewise Therapeutics, Inc. Price Edgewise Therapeutics, Inc. price | Edgewise Therapeutics, Inc. Quote Our Key Picks Among Biotech Stocks Some better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Bottom-line estimates for Castle Biosciences have improved from a loss of 58 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.84. Year to date, shares of Castle Biosciences have surged 33.6%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 60 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. Year to date, CTMX stock has lost 25.8%. CytomX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. In the past 60 days, estimates for Spero Therapeutics\u2019 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. Year to date, Spero\u2019s shares have lost 27.2%. SPRO\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report Edgewise Therapeutics, Inc. (EWTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-17T14:18:00+00:00", "sentiment": {"score": 0.9121902175247669, "confidence": 0.9457409977912903, "probabilities": {"positive": 0.9457409977912903, "negative": 0.03355078026652336, "neutral": 0.020708274096250534}}, "embedding": [-0.10705175995826721, -0.07856607437133789, 0.062121178954839706, -0.0763912945985794, -0.12486866116523743, -0.14987444877624512, -0.13203522562980652, 0.29875606298446655, 0.05977066606283188, -0.00019446760416030884, -0.026838522404432297, 0.004617678001523018, 0.13086587190628052, -0.023040426895022392, 0.005142685957252979, 0.021990705281496048, 0.11353069543838501, 0.05998300760984421, -0.12891200184822083, 0.09347899258136749, -0.008838213980197906, -0.005386160220950842, 0.049896709620952606, 0.06580619513988495, -0.07367345690727234, -0.014007795602083206, -0.09843970835208893, 0.03174528107047081, -0.1269923448562622, 0.001529474277049303, -0.021602189168334007, 0.05011896416544914, 0.0741947740316391, 0.008181840181350708, -0.07431164383888245, 0.01326095499098301, -0.11278843879699707, 0.021773895248770714, -0.13207466900348663, -0.042922936379909515, -0.0055408840999007225, -0.0812888890504837, -0.149338498711586, -0.052758846431970596, 0.014705708250403404, -0.1471198946237564, -0.02276020124554634, 0.060895852744579315, -0.027661819010972977, 0.23754987120628357, -0.12164320051670074, -0.15286245942115784, 0.00012723170220851898, 0.08722752332687378, 0.0007723402231931686, -0.02071484550833702, -0.1499495655298233, 0.004515332635492086, -0.04977221414446831, 0.029529567807912827, 0.0799672082066536, -0.09195151925086975, -0.0043352385982871056, -0.06393656134605408, 0.19989103078842163, 0.03541148826479912, 0.11768552660942078, -0.04615175724029541, -0.009568561799824238, -0.06079860031604767, 0.1322903335094452, -0.02130807936191559, 0.044308166950941086, 0.10561594367027283, -0.020723165944218636, 0.140048086643219, 0.079503133893013, 0.18189126253128052, 0.0872202068567276, -0.18481123447418213, 0.047051120549440384, 0.06254416704177856, 0.07962308824062347, -0.05663471668958664, 0.05282244831323624, 0.13447736203670502, 0.04686712101101875, 0.16577082872390747, -0.06532184779644012, 0.14201165735721588, 0.1551537811756134, 0.01971435546875, -0.06748174130916595, -0.0516124852001667, 0.06543923169374466, -0.0010122000239789486, -0.130788192152977, 0.0712515115737915, -0.002810843987390399, -0.06407219171524048, 0.08120402693748474, 0.005298523232340813, 0.0010097920894622803, 0.026307402178645134, -0.056044310331344604, -0.10471543669700623, 0.12863996624946594, -0.06803462654352188, 0.013086352497339249, -0.02571745216846466, -0.056814245879650116, 0.008245207369327545, -0.012941233813762665, 0.02761108987033367, -0.07761431485414505, 0.21672511100769043, -0.02245437540113926, 0.10463137924671173, 0.09909304976463318, 0.06884206831455231, 0.06086491793394089, -0.03682374209165573, 0.010391561314463615, -0.04604649543762207, -0.004522738978266716, 0.12709848582744598, -0.1346750408411026, 1.286775903089138e-32, -0.021951675415039062, 0.0032853533048182726, 0.020214766263961792, -0.05023402348160744, -0.12600229680538177, -0.05749472975730896, -0.12182873487472534, -0.007845080457627773, -0.12204408645629883, -0.1665230542421341, -0.1440693736076355, -0.029264606535434723, 0.1933293342590332, 0.1335919052362442, -0.018791988492012024, -0.09301520884037018, -0.054200924932956696, -0.03900115564465523, 0.012838948518037796, -0.07027719914913177, 0.1357158124446869, -0.02333925850689411, -0.04276958853006363, 0.01871524751186371, -0.09765532612800598, 0.030098939314484596, -0.04281310737133026, 0.05764608457684517, -0.056337710469961166, 0.016745559871196747, -0.14473581314086914, -0.12217431515455246, 0.04990287870168686, -0.12814800441265106, -0.011453414335846901, -0.06567169725894928, 0.027533119544386864, -0.024953223764896393, 0.006881748791784048, 0.04748055711388588, -0.011568915098905563, 0.027507130056619644, -0.16566509008407593, -0.08118091523647308, 0.039694130420684814, -0.1048143059015274, -0.011352865025401115, -0.0948190987110138, -0.0395190604031086, -0.07553361356258392, 0.02989239990711212, -0.01094035804271698, 0.14245840907096863, -0.13155898451805115, -0.09703440964221954, 0.1318119466304779, -0.08688180148601532, -0.08449748158454895, 0.049060456454753876, 0.14389106631278992, 0.16059796512126923, 0.1071910709142685, 0.053466640412807465, -0.013039307668805122, -0.1286017745733261, 0.09270472824573517, -0.05458631366491318, -0.018297871574759483, -0.12565352022647858, 0.03915006294846535, 0.0031330420169979334, -0.05264739692211151, 0.14491508901119232, -0.03918581083416939, 0.082803875207901, -0.03284332901239395, -0.01331496424973011, 0.11788710951805115, -0.13764795660972595, -0.025669245049357414, 0.013463418930768967, 0.00560596352443099, -0.06072439253330231, 0.08016420900821686, 0.0627201497554779, -0.07537005841732025, -0.021699558943510056, -0.048064325004816055, -0.05599367991089821, -0.018645739182829857, 0.1579439491033554, -0.10730400681495667, -0.1588539481163025, 0.10038405656814575, 0.012100232765078545, -1.2894476548117632e-32, -0.04967840015888214, 0.14438971877098083, 0.0720212459564209, -0.034522973001003265, -0.01402304321527481, 0.14053130149841309, 0.10024187713861465, -0.07581020146608353, 0.0613534189760685, -0.10076117515563965, 0.07573997229337692, 0.0321291983127594, -0.06766204535961151, -0.03737447410821915, 0.020335370674729347, 0.12848389148712158, -0.175618514418602, -0.09487687051296234, -0.07742416858673096, -0.003026635153219104, 0.10310167074203491, 0.07809215784072876, 0.046521030366420746, 0.16288885474205017, -0.0016623511910438538, 0.07215722650289536, 0.018197907134890556, 0.08190415799617767, 0.0795162245631218, -0.07388247549533844, -0.04947245866060257, 0.004382889252156019, -0.13328981399536133, 0.01037215068936348, -0.058843210339546204, 0.04675682261586189, 0.005723441019654274, -0.09896130859851837, -0.051139213144779205, -0.046151287853717804, 0.08647714555263519, 0.08445994555950165, 0.06377507746219635, 0.03276560455560684, 0.029380643740296364, -0.02050265297293663, 0.05130673572421074, 0.0027267886325716972, -0.005487887188792229, -0.03411796689033508, 0.06414046883583069, 0.20359638333320618, -0.0006876196712255478, 0.06517194211483002, 0.06996461749076843, -0.026013022288680077, 0.09531906247138977, -0.05975314974784851, -0.27035146951675415, 0.07140428572893143, -0.07816613465547562, 0.04283487796783447, 0.014866417273879051, 0.07913149148225784, 0.1718294322490692, 0.03298373892903328, 0.07102682441473007, -0.007362390868365765, 0.006985567510128021, -0.004237581975758076, -0.04187120497226715, -0.0478043332695961, -0.09134291112422943, -0.09302759915590286, 0.02478335052728653, 0.13215473294258118, -0.02536545693874359, -0.059845685958862305, -0.1752786934375763, -0.004244547337293625, -0.0717790350317955, -0.06449209153652191, 0.033159054815769196, -0.030426613986492157, -0.06717007607221603, 0.07770992815494537, 0.018927566707134247, 0.022212564945220947, 0.051817215979099274, -0.0008575664833188057, -0.020185045897960663, -0.11763332039117813, -0.08803004026412964, 0.12926651537418365, 0.09574362635612488, -1.0045771148270433e-07, 0.10149342566728592, -0.05454270541667938, 0.02965390868484974, -0.017719490453600883, 0.016635535284876823, -0.052579209208488464, 0.0020443489775061607, 0.08183196187019348, -0.04124247655272484, 0.15142762660980225, 0.05357589200139046, 0.026361951604485512, -0.10299687832593918, -0.04163467884063721, -0.05546221137046814, -0.04377831891179085, -0.010477565228939056, 0.05601724237203598, -0.03077833354473114, -0.03335512802004814, -0.054414693266153336, -0.07241757214069366, 0.08826316893100739, -0.06201337277889252, 0.14380690455436707, -0.1290428638458252, -0.055739931762218475, 0.06935317814350128, 0.04752495884895325, -0.05774930119514465, -0.04908674210309982, -0.08144494891166687, -0.02562878280878067, -0.053111542016267776, -0.09510976821184158, -0.0741524025797844, 0.034209705889225006, 0.14927154779434204, -0.07791832089424133, 0.2799208462238312, 0.03335119038820267, 0.0005054762586951256, 0.0668267235159874, 0.018513018265366554, 0.031757012009620667, -0.028106391429901123, -0.012040806002914906, -0.010937303304672241, 0.18757396936416626, -0.1598030924797058, -0.04284697026014328, -0.02838347852230072, -0.019289366900920868, -0.04730931669473648, -0.13962092995643616, 0.17731860280036926, -0.186445415019989, -0.0211494080722332, 0.061277635395526886, -0.025929540395736694, 0.08769546449184418, -0.12482096999883652, 0.002528747543692589, 0.01387917809188366], "changes": {"1wk": -0.6297664354562265, "1mo": -6.529662937927593}}, {"text": "PREMIUM Edgewise Therapeutics Insider Sold Shares Worth $2,737,470, According to a Recent SEC Filing MT Newswires Wed, Jan 1, 2025, 1:16 AM In This Article: EWTX +0.64% Alan J Russell, Director, Chief Scientific Officer, on December 30, 2024, sold 100,000 shares in Edg PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-31T22:16:20+00:00", "sentiment": {"score": 0.02741790935397148, "confidence": 0.0422632209956646, "probabilities": {"positive": 0.0422632209956646, "negative": 0.014845311641693115, "neutral": 0.9428914189338684}}, "embedding": [-0.09258215129375458, -0.08107096701860428, 0.02349134162068367, 0.07354948669672012, -0.011603853665292263, -0.05662718415260315, 0.05144938826560974, 0.21255339682102203, 0.04839002341032028, 0.07339055836200714, -0.055502794682979584, 0.09676415473222733, 0.08884405344724655, -0.05365448072552681, 0.01017624232918024, 0.01801139861345291, 0.04190021753311157, -0.06404121220111847, -0.09770747274160385, -0.027803078293800354, -0.21126464009284973, -0.06966546177864075, -0.029306134209036827, -0.11738672852516174, 0.15269087255001068, 0.014211904257535934, -0.0721430853009224, -0.07350073754787445, 0.09752442687749863, -0.06508597731590271, 0.14378230273723602, -0.052947547286748886, 0.02300407551229, -0.0026206080801784992, -0.04199424386024475, -0.04468807578086853, -0.02724110148847103, -0.009910481050610542, -0.05924878641963005, -0.05757700279355049, 0.1508590430021286, 0.015249304473400116, -0.1872721016407013, -0.01796664670109749, -0.02154426835477352, -0.09286650270223618, -0.1508464515209198, -0.032038573175668716, 0.10990383476018906, 0.1394820362329483, -0.010327532887458801, -0.1393118053674698, 0.05552596598863602, -0.14307555556297302, 0.0563221201300621, -0.04759516194462776, -0.2042473703622818, -0.045924633741378784, -0.05568038299679756, 0.037444259971380234, 0.1684519201517105, -0.14454402029514313, -0.0030293853487819433, 0.027036041021347046, -0.02025974728167057, 0.08447308093309402, 0.06902440637350082, 0.024819860234856606, -0.06111793965101242, -0.09409830719232559, 0.09498085081577301, 0.06921398639678955, -0.07516399025917053, 0.040622398257255554, 0.038625672459602356, 0.07109638303518295, 0.14358574151992798, -0.0682683065533638, 0.014964140951633453, 0.002664347877725959, -0.005163726396858692, -0.00903235375881195, -0.027354422956705093, 0.011750646866858006, -0.006070448085665703, 0.02718256413936615, 0.10591018944978714, 0.0905199721455574, -0.00858520157635212, 0.030307643115520477, 0.16648449003696442, -0.03331322968006134, -0.06934893876314163, -0.023140529170632362, -0.01879248581826687, 0.10723480582237244, -0.24311614036560059, -0.032653097063302994, -0.14712071418762207, 0.05587512254714966, -0.021215416491031647, 0.04147098585963249, -0.031641971319913864, -0.006750467233359814, 0.037787746638059616, -0.08443080633878708, 0.02203291840851307, 0.13057459890842438, 0.01493684109300375, -0.06612472981214523, -0.06884177774190903, -0.09024059027433395, -0.06690721958875656, -0.0014387629926204681, -0.06888027489185333, 0.017365122213959694, -0.09307215362787247, 0.02851196564733982, 0.25622814893722534, -0.08202463388442993, 0.10958070307970047, 0.06440836191177368, -0.05873435363173485, 0.0929192379117012, -0.15074674785137177, -0.014798484742641449, -0.06347674131393433, 1.0025987478783084e-32, -0.08860858529806137, 0.12244702875614166, 0.10990101099014282, -0.0499417670071125, 0.03240956738591194, 0.054438523948192596, 0.05474337935447693, -0.12340062111616135, -0.10421678423881531, -0.03143804892897606, -0.23714040219783783, 0.21986936032772064, 0.07114150375127792, 0.1397952139377594, -0.15077351033687592, -0.19695927202701569, 0.060510531067848206, 0.02774791233241558, 0.09922795742750168, -0.03364165127277374, 0.10137026011943817, -0.02590964548289776, -0.03233326971530914, -0.0012912057572975755, -0.19247713685035706, 0.07963123172521591, 0.01435243058949709, -0.011269601993262768, 0.28900209069252014, 0.05943719670176506, -0.2456350028514862, -0.0005672782426699996, 0.027041055262088776, 0.07395367324352264, 0.01076660118997097, 0.22703446447849274, -0.005327541846781969, -0.02841111272573471, 0.1605289727449417, -0.04993288964033127, 0.03920578211545944, 0.15273967385292053, 0.018488554283976555, -0.17764942348003387, -0.16514497995376587, 0.05687405541539192, -0.08943520486354828, -0.10869179666042328, 0.11656581610441208, -0.10242769122123718, -0.08011569827795029, 0.11817026883363724, -0.06305337697267532, -0.03592628240585327, -0.05130555480718613, 0.013208026997745037, -0.038954850286245346, 0.12094273418188095, 0.1453302502632141, 0.049017880111932755, 0.0863744243979454, 0.0994548350572586, 0.028388895094394684, 0.025988223031163216, -0.19331605732440948, 0.2506963312625885, -0.08173815906047821, -0.14158962666988373, -0.1747761070728302, 0.04264933243393898, -0.020226823166012764, 0.12279026210308075, 0.07777726650238037, -0.12720271944999695, 0.014218444935977459, -0.08437429368495941, -0.0662752017378807, -0.0036642570048570633, 0.1007503867149353, 0.20522503554821014, -0.026562824845314026, 0.016080062836408615, 0.03615082427859306, 0.027995051816105843, 0.10113539546728134, -0.02846616320312023, -0.17889131605625153, 0.18289147317409515, -0.003436699276790023, 0.03871972858905792, 0.17293985188007355, -0.010244447737932205, -0.09883684664964676, 0.14002031087875366, -0.07276973128318787, -1.0577082005651619e-32, -0.17811638116836548, 0.06713543832302094, 0.046424757689237595, -0.05549017712473869, -0.022235514596104622, 0.07939302176237106, -0.004190352745354176, 0.13912566006183624, -0.031309597194194794, 0.1745315045118332, 0.17757153511047363, 0.1078728586435318, -0.06927083432674408, -0.002639290178194642, -0.050056107342243195, -0.07324913889169693, -0.03678017854690552, -0.08986985683441162, 0.06800618767738342, -0.0888998731970787, -0.036008335649967194, 0.11417023092508316, -0.008016281761229038, 0.2710006833076477, 0.13459502160549164, 0.06848591566085815, 0.08833810687065125, 0.13369295001029968, 0.06013718992471695, -0.07394010573625565, 0.007945084944367409, -0.03844212368130684, -0.19506262242794037, -0.001716728089377284, -0.05032968521118164, 0.000721885880921036, 0.15111567080020905, 0.01016551535576582, -0.005273331422358751, -0.05784643441438675, 0.03527720272541046, -0.04914209246635437, 0.08814053982496262, 0.11731518805027008, 0.22888986766338348, 0.08278698474168777, 0.044113826006650925, -0.09224607050418854, 0.01928620971739292, -0.009856310673058033, -0.010250992141664028, 0.13611845672130585, 0.041347526013851166, 0.1583770215511322, -0.14788980782032013, 0.00035387786920182407, -0.0009976518340408802, 0.0867791697382927, 0.018887244164943695, -0.06590352952480316, 0.0005851707537658513, 0.1195959746837616, -0.1281937062740326, 0.09093062579631805, -0.13343824446201324, 0.03521477431058884, 0.003561596851795912, -0.022879313677549362, -0.20345145463943481, -0.0703936219215393, 0.05754491686820984, -0.11566680669784546, -0.12979568541049957, -0.35880085825920105, 0.056553393602371216, 0.26102495193481445, -0.09758369624614716, -0.1625877320766449, -0.05015000328421593, 0.13855993747711182, -0.006356439553201199, -0.04683811962604523, 0.06609814614057541, 0.06373893469572067, -0.05507177859544754, -0.09495073556900024, 0.056454289704561234, 0.02773013897240162, -0.16796115040779114, 0.01360827311873436, -0.22392472624778748, -0.1914335936307907, -0.1514739692211151, 0.04797849804162979, 0.1127314418554306, -9.95771927136957e-08, -0.04537332057952881, -0.010663327760994434, 0.03383024409413338, -0.12547223269939423, -0.001958191394805908, -0.04677867516875267, 0.057538680732250214, 0.1326696127653122, -0.0037626929115504026, 0.162943497300148, -0.04883277416229248, -0.17126062512397766, -0.19435495138168335, -0.029158765450119972, -0.13684935867786407, 0.012027191929519176, -0.014759860001504421, 0.13354627788066864, 0.13432560861110687, -0.024376504123210907, 0.07492778450250626, 0.1016671359539032, 0.2248866707086563, -0.1378834843635559, -0.049114540219306946, -0.019446590915322304, 0.020930077880620956, -0.018840216100215912, 0.014891351573169231, 0.007327547762542963, -0.07290006428956985, -0.013821061700582504, 0.015881000086665154, 0.07787022739648819, -0.07811258733272552, -0.07824873924255371, -0.01589149981737137, 0.1272258311510086, -0.029951458796858788, 0.15334120392799377, 0.012600715272128582, -0.07083237916231155, 0.025023914873600006, -0.021679462864995003, -0.012120375409722328, 0.14417342841625214, -0.06178735941648483, -0.07549617439508438, 0.11748302727937698, -0.17951150238513947, 0.18561774492263794, -0.058612145483493805, 0.004068506415933371, -0.08492924273014069, -0.11611678451299667, 0.008127330802381039, -0.09661362320184708, 0.0041243149898946285, -0.12107251584529877, 0.018716048449277878, -0.052316270768642426, -0.3053775429725647, -0.05944925919175148, 0.09824927151203156], "changes": {"1wk": -4.868918004727653, "1mo": 4.868910861100019}}, {"text": "PREMIUM Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell MT Newswires Mon, Dec 16, 2024, 3:55 PM In This Article: EWTX +0.64% Edgewise Therapeutics (EWTX) said Monday that a phase 2 trial of sevasemten to treat patients with B PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-16T12:55:29+00:00", "sentiment": {"score": 0.18850454408675432, "confidence": 0.19689799845218658, "probabilities": {"positive": 0.19689799845218658, "negative": 0.008393454365432262, "neutral": 0.7947085499763489}}, "embedding": [-0.05951666831970215, -0.05188237503170967, 0.04460816830396652, -0.03194845840334892, -0.03576771914958954, -0.14319366216659546, -0.15165401995182037, 0.2649686336517334, 0.008112743496894836, -0.11016698181629181, 0.009325461462140083, 0.08144086599349976, 0.12115279585123062, -0.05164683982729912, 0.1352108120918274, 0.009324855171144009, 0.20870591700077057, 0.015066740103065968, 0.032593920826911926, 0.04378356412053108, -0.0659162625670433, 0.006817321293056011, 0.07157963514328003, -0.07834625989198685, -0.014624524861574173, -0.06391728669404984, -0.15528501570224762, -0.05558359995484352, 0.028679855167865753, -0.0936719998717308, 0.11510869860649109, -0.08070825785398483, 0.00409006467089057, -0.0955946072936058, -0.019622717052698135, -0.15848848223686218, -0.00776344770565629, -0.021735548973083496, -0.29205673933029175, 0.0677357092499733, 0.02292454242706299, -0.14618071913719177, -0.26230761408805847, 0.04618360847234726, -0.037089940160512924, -0.1505218744277954, -0.09675972908735275, 0.04840411990880966, 0.011981889605522156, 0.22967064380645752, -0.0747048631310463, -0.29469946026802063, -0.016160335391759872, -0.00792270340025425, -0.020616862922906876, -0.0912645012140274, -0.16089077293872833, 0.03656306862831116, -0.014729190617799759, 0.04204520583152771, 0.19500230252742767, -0.12912523746490479, -0.12033684551715851, 0.06505855917930603, 0.01565166562795639, 0.06888014078140259, 0.16803237795829773, 0.0666239783167839, 0.01952297054231167, -0.1376391500234604, -0.06869377195835114, -0.04802176356315613, 0.11335437744855881, 0.11783429980278015, 0.190536767244339, 0.16714350879192352, 0.1019551083445549, 0.030356798321008682, 0.1310533583164215, -0.12093912810087204, -0.054454702883958817, 0.025774531066417694, 0.10545244067907333, 0.045016948133707047, 0.04828694835305214, 0.0900803729891777, 0.016921795904636383, 0.08142376691102982, -0.12745456397533417, 0.04435664042830467, 0.2151816189289093, -0.007257298566401005, -0.05217895656824112, -0.03208821639418602, 0.03322635591030121, 0.016023609787225723, -0.22357068955898285, -0.014979779720306396, -0.09821345657110214, -0.0227129515260458, -0.0626775398850441, -0.026438897475600243, 0.005361459217965603, 0.02051420882344246, -0.03808791935443878, -0.23602023720741272, 0.0447348989546299, 0.0419902540743351, 0.035355325788259506, -0.08849380165338516, 0.0277568232268095, 0.0011066520819440484, 0.12297513335943222, -0.07851293683052063, -0.05262882262468338, 0.21726596355438232, -0.034995462745428085, 0.061038002371788025, 0.22565679252147675, -0.04739464819431305, 0.1477537453174591, 0.03509603440761566, -0.02485400065779686, -0.12567928433418274, -0.03040139563381672, 0.06687700748443604, -0.06396845728158951, 1.2984390111012029e-32, -0.010536018759012222, 0.12089021503925323, 0.011490573175251484, 0.010268132202327251, -0.05716385692358017, 0.04376882314682007, -0.11286525428295135, -0.06361954659223557, -0.12019797414541245, -0.13930296897888184, -0.21858634054660797, 0.02735060080885887, 0.1601492315530777, 0.19771629571914673, -0.10078085958957672, -0.1859712153673172, -0.14999818801879883, 0.10625889152288437, 0.09419861435890198, 0.017628217115998268, 0.33276644349098206, -0.09840556979179382, -0.019745219498872757, 0.021207839250564575, -0.1014157235622406, 0.059984512627124786, 0.10776084661483765, -0.0345366932451725, 0.2059638947248459, 0.10088440775871277, -0.30313029885292053, -0.09539993852376938, 0.04613351821899414, -0.09174396097660065, 0.03028944507241249, 0.18730023503303528, 0.10422159731388092, -0.005255165044218302, -0.0343112051486969, -0.13062147796154022, -0.021263018250465393, 0.007787441369146109, -0.09624392539262772, -0.11061879247426987, -0.034521885216236115, -0.14588341116905212, -0.021623576059937477, -0.22677935659885406, 0.07912910729646683, -0.23234760761260986, -0.03928181901574135, 0.04965187609195709, 0.04173910245299339, -0.10183466225862503, 0.03538995981216431, 0.17202717065811157, -0.02767655998468399, 0.007557677570730448, 0.1353028267621994, 0.06053101643919945, 0.2856617569923401, 0.03415728360414505, 0.014800063334405422, -0.11646431684494019, -0.07602538168430328, 0.05382125452160835, -0.0885920524597168, -0.2255820333957672, -0.2702954411506653, -0.08021599799394608, 0.019346265122294426, 0.06732513755559921, 0.1157708615064621, -0.07576756924390793, -0.08549699187278748, -0.05079980194568634, -0.04226800054311752, 0.11805133521556854, 0.0337231270968914, -0.027085820212960243, 0.06548942625522614, -0.05235482007265091, -0.06611578911542892, 0.06887494772672653, 0.1778140664100647, -0.003385447198525071, -0.08293738961219788, -0.006386823020875454, -0.1833377629518509, 0.06435808539390564, 0.1490577906370163, -0.03563954681158066, -0.06536939740180969, 0.17054221034049988, 0.016332855448126793, -1.4032928133209632e-32, -0.12467344850301743, 0.09371200203895569, 0.05671413615345955, -0.016321422532200813, -0.007888462394475937, 0.10713056474924088, 0.06809137016534805, 0.12772484123706818, 0.16697661578655243, 0.08143134415149689, 0.13513022661209106, 0.05900435894727707, -0.07563918083906174, -0.004467484541237354, -0.020646177232265472, 0.05955606326460838, -0.14699077606201172, -0.30336350202560425, -0.10225258767604828, 0.04521041736006737, 0.0169950183480978, 0.1487215906381607, 0.04852099344134331, 0.19922947883605957, 0.157080739736557, 0.049242474138736725, 0.11929136514663696, 0.14422619342803955, 0.03527510538697243, -0.0897124707698822, -0.05424139276146889, -0.10467473417520523, -0.11103489249944687, -0.06577301770448685, -0.1865273416042328, 0.11147259920835495, 0.1276496946811676, -0.041743144392967224, -0.027753306552767754, -0.08005350828170776, 0.10199785232543945, -0.1272546350955963, -0.09561339765787125, 0.022835325449705124, 0.15110254287719727, 0.09546615928411484, -0.039674993604421616, 0.031539544463157654, 0.032867882400751114, -0.11637062579393387, 0.010187620297074318, 0.15973243117332458, 0.07930044829845428, 0.0891868993639946, -0.037342436611652374, -0.08384950459003448, 0.06646846979856491, -0.10496355593204498, -0.22302432358264923, 0.027763256803154945, -0.07676049321889877, 0.12472028285264969, -0.11978906393051147, 0.06376219540834427, 0.17478549480438232, 0.06713241338729858, 0.0686047375202179, -0.024448897689580917, -0.08615187555551529, -0.02608381025493145, -0.08556735515594482, -0.019398421049118042, -0.26026734709739685, -0.3138868808746338, 0.06987283378839493, 0.14544041454792023, -0.09254190325737, -0.022502945736050606, -0.23208460211753845, 0.015122664161026478, -0.038766659796237946, -0.10214085876941681, 0.06563545763492584, 0.04752552509307861, -0.0013303933665156364, -0.07269993424415588, 0.06717280298471451, -0.015211761929094791, -0.04118730500340462, 0.09356085956096649, -0.14556878805160522, -0.15220093727111816, -0.12787370383739471, 0.2816847562789917, 0.162107452750206, -1.0064559319289401e-07, 0.032306622713804245, 0.009360441006720066, 0.07720215618610382, -0.07836051285266876, 0.019080422818660736, -0.06457281857728958, -0.09713780879974365, 0.11348892748355865, -0.059136565774679184, 0.2118626981973648, -0.11452784389257431, -0.0012598939938470721, -0.04145791009068489, 0.0018368621822446585, 0.01198936253786087, -0.020091380923986435, 0.11013489216566086, 0.1358766108751297, 0.05019290745258331, -0.16732333600521088, -0.042813993990421295, -0.04024818539619446, 0.19607259333133698, -0.1823820024728775, 0.12567944824695587, -0.051339130848646164, 0.034719280898571014, 0.025824563577771187, 0.11860433220863342, -0.1244640052318573, -0.15211069583892822, 0.03513386845588684, -0.11008303612470627, 0.027517996728420258, -0.2594982385635376, -0.11177816987037659, 0.02583901770412922, 0.19025325775146484, 0.05910146236419678, 0.2332450896501541, 0.1146124079823494, 0.08319972455501556, 0.0653938502073288, 0.08488679677248001, -0.03483566269278526, 0.1087607815861702, -0.0882798507809639, -0.07342730462551117, 0.17797952890396118, -0.14427001774311066, 0.018397949635982513, -0.09081558883190155, 0.0990794450044632, -0.008930711075663567, -0.1809941679239273, 0.24933119118213654, -0.12266619503498077, -0.017587820068001747, 0.024272559210658073, 0.14725875854492188, 0.09063074737787247, -0.15844812989234924, -0.0039059938862919807, 0.04606595262885094], "changes": {"1wk": -5.842759315697661, "1mo": -15.815229079640355}}, {"text": "Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease Vandana Singh Mon, Dec 16, 2024, 7:56 PM 2 min read In This Article: EWTX +0.64% Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease On Monday, Edgewise Therapeutics, Inc., (NASDAQ: EWTX ) revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is\u00a0a genetic disorder that causes progressive muscle weakness . Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Also Read: Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment The company adds that CANYON is the largest interventional trial to date in BMD and the first to achieve its primary endpoint. The trial was conducted among 40 adults and 29 adolescents. The trial met its primary endpoint of change from baseline in creatine kinase\u00a0(CK). The results demonstrated a significant change from baseline in CK in the sevasemten-treated group (difference vs. placebo, 28% average decrease over months 6 through 12; p=0.02). North Star Ambulatory Assessment\u00a0(NSAA, a change in motor function), the key secondary endpoint of function, showed a trend towards improvement over time in the sevasemten-treated group. Plasma fast skeletal muscle troponin I (TNNI2), a target-specific biomarker of fast skeletal muscle damage, showed a significant reduction compared to placebo. Additional functional measures, including the 10-meter walk/run, 4-stair climb, and 100-meter timed test, showed trends toward improvement compared to the placebo. The treatment population had more advanced disease than placebo. Sevasemten was well-tolerated, and no new safety concerns were observed. The company is on track to complete recruitment in the GRAND CANYON cohort by the first quarter of 2025. Price Action: EWTX stock is up 8.62% at $30 at last check Monday. Also Read: FDA Approves Checkpoint Therapeutics\u2019 Skin Cancer Drug One Year After Rejection UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-16T16:56:24+00:00", "sentiment": {"score": 0.9315275195986032, "confidence": 0.9525395631790161, "probabilities": {"positive": 0.9525395631790161, "negative": 0.021012043580412865, "neutral": 0.026448456570506096}}, "embedding": [-0.07783006876707077, -0.057037703692913055, -0.013778707943856716, -0.04222274571657181, -0.04429140314459801, -0.15050041675567627, -0.19131411612033844, 0.32572829723358154, 0.06624196469783783, -0.015476914122700691, -0.030041836202144623, -0.0182636845856905, 0.0932316705584526, -0.008925187401473522, 0.017035987228155136, -0.001978806219995022, 0.116264708340168, 0.06418490409851074, -0.0011579431593418121, 0.01968637853860855, -0.06268959492444992, 0.02270060032606125, 0.0587066113948822, 0.10439518094062805, -0.08636999875307083, -0.010624024085700512, -0.11646005511283875, 0.008084549568593502, -0.13036242127418518, -0.031614676117897034, -0.011152185499668121, -0.055147670209407806, 0.05962774157524109, 0.05829045921564102, -0.04862307384610176, 0.07124783843755722, -0.09881536662578583, 0.021230952814221382, -0.21674756705760956, -0.06617452204227448, 0.04669555276632309, -0.13687767088413239, -0.08511800318956375, -0.05052783340215683, 0.047439124435186386, -0.14243397116661072, -0.06362184882164001, 0.04903371259570122, -0.02128451131284237, 0.29789018630981445, -0.12038469314575195, -0.149427592754364, -0.03536031022667885, 0.08839615434408188, 0.03719088435173035, -0.02752084657549858, -0.17826038599014282, 0.027986863628029823, -0.005845970939844847, 0.029482487589120865, 0.0642058402299881, -0.11627240478992462, -0.04836322367191315, -0.04852902144193649, 0.10406161844730377, 0.038004983216524124, 0.07925879210233688, -0.057299040257930756, 0.048849400132894516, -0.03733169287443161, 0.13807526230812073, -0.016270902007818222, 0.08178552985191345, 0.09774760901927948, 0.024353094398975372, 0.10571141541004181, 0.04769245535135269, 0.13644084334373474, -0.000530904158949852, -0.1322629600763321, -0.0034325928427278996, 0.052452221512794495, 0.08030389249324799, 0.024217329919338226, 0.025364093482494354, 0.1735382378101349, 0.07398393750190735, 0.15325337648391724, -0.07903337478637695, 0.1118774563074112, 0.22682061791419983, 0.07782036066055298, -0.11632006615400314, 0.00849691778421402, 0.09951537102460861, -0.010288402438163757, -0.09392087161540985, 0.05337852984666824, -0.0366801954805851, -0.05385937541723251, 0.13112491369247437, -0.025677314028143883, -0.07047083228826523, -0.010209654457867146, 0.016777414828538895, -0.059808146208524704, 0.08343055844306946, -0.07005102932453156, -0.002760503441095352, 0.030888427048921585, 0.0027805943973362446, 0.0014342113863676786, -0.013113602064549923, 0.039339035749435425, -0.011938998475670815, 0.1688801348209381, -0.047347091138362885, 0.08125637471675873, 0.05867995321750641, 0.0672038272023201, 0.059399258345365524, -0.0774734616279602, 0.006019100081175566, -0.09187309443950653, -0.02505309507250786, 0.14748114347457886, -0.10867196321487427, 1.1111094395550799e-32, 0.038501761853694916, 0.022971484810113907, 0.05302583426237106, -0.06131159886717796, -0.04795611649751663, -0.1048746109008789, -0.09126272797584534, -0.011334079317748547, -0.15006256103515625, -0.10009275376796722, -0.11824040114879608, -0.06828298419713974, 0.1461637169122696, 0.14047002792358398, -0.04913889616727829, -0.06300017237663269, -0.022470299154520035, -0.07275451719760895, 0.016723815351724625, -0.05130809545516968, 0.09599442780017853, -0.09319597482681274, -0.04969482868909836, 0.016198869794607162, -0.1123887449502945, 0.1108279824256897, -0.05337568372488022, 0.07995951175689697, -0.02232462540268898, 0.02298613265156746, -0.175256609916687, -0.15184324979782104, 0.018515577539801598, -0.07014092803001404, -0.027795886620879173, -0.049927860498428345, -0.019396984949707985, -0.051975905895233154, -0.008496380411088467, 0.06941162049770355, -0.007321814075112343, 0.06741292029619217, -0.08513934165239334, -0.09823992848396301, 0.1282007098197937, -0.11981897801160812, -0.013453291729092598, -0.05885111540555954, -0.07421281188726425, -0.013560066930949688, -0.0381869338452816, -0.03200400620698929, 0.1456998586654663, -0.0709129273891449, -0.09344921261072159, 0.08971157670021057, -0.08105425536632538, 0.0004526376724243164, 0.01953187771141529, 0.1430467963218689, 0.11296701431274414, 0.09058292210102081, 0.0029337804298847914, 0.03558797389268875, -0.16299286484718323, 0.03594287112355232, -0.07816183567047119, -0.0909537822008133, -0.10431993007659912, 0.033487796783447266, 0.010725113563239574, -0.064580038189888, 0.07391206175088882, 0.030307382345199585, 0.07489809393882751, -0.0391833633184433, 0.028868883848190308, 0.1901572048664093, -0.11155582964420319, -0.024322520941495895, 0.024998746812343597, 0.03067772090435028, -0.08345811069011688, 0.07528312504291534, 0.05826358124613762, -0.0615985170006752, -0.04337393492460251, -0.11451033502817154, -0.0571061335504055, -0.01980011910200119, 0.13248583674430847, -0.09865547716617584, -0.11133858561515808, 0.14233995974063873, -0.0760025903582573, -1.0441273469881274e-32, 0.0006583842914551497, 0.12246526032686234, 0.15153610706329346, -0.014922717586159706, 0.019974129274487495, 0.11302889883518219, 0.09008275717496872, -0.09457248449325562, 0.14295104146003723, -0.10063138604164124, 0.13874855637550354, 0.051581043750047684, -0.08111263811588287, -0.03736352175474167, 0.02808450721204281, 0.12301469594240189, -0.16161403059959412, -0.11855216324329376, -0.10301634669303894, -0.016347579658031464, 0.07518772780895233, 0.13452652096748352, 0.03848351910710335, 0.11070504784584045, 0.02044333517551422, 0.05834076553583145, 0.04925781488418579, 0.07214546203613281, 0.07018214464187622, -0.07859698683023453, 0.023051848635077477, -0.012028252705931664, -0.1500234156847, 0.006523957476019859, -0.0412609800696373, 0.036541521549224854, -0.032735735177993774, -0.05981382727622986, -0.048823121935129166, 0.009151484817266464, 0.08466541022062302, 0.13659536838531494, 0.06848359107971191, 0.06077466532588005, -0.037895478308200836, 0.05574540048837662, 0.006094044074416161, 0.010142389684915543, -0.10119391977787018, -0.02710905484855175, -0.021646201610565186, 0.18652191758155823, 0.0022035473957657814, 0.08236263692378998, 0.05985141173005104, -0.02742602489888668, 0.1201363354921341, 0.02874002605676651, -0.21664440631866455, 0.06588692218065262, -0.08181500434875488, 0.026927029713988304, 0.03349332883954048, 0.056096095591783524, 0.1896074265241623, 0.10226137936115265, 0.07553058862686157, -0.009476063773036003, 0.033720821142196655, 0.05150729790329933, -0.03422961384057999, -0.027998119592666626, -0.09473833441734314, -0.08233478665351868, -0.03522248938679695, 0.08077707886695862, -0.04912453889846802, -0.06810024380683899, -0.13993903994560242, -0.06851186603307724, -0.05312662199139595, -0.08176733553409576, 0.009174469858407974, -0.11239282786846161, -0.021668456494808197, 0.10555440187454224, 0.05576004087924957, 0.05374635010957718, -0.0176240261644125, 0.04153035581111908, 0.010961402207612991, -0.1050824224948883, -0.10872822999954224, 0.17160099744796753, 0.10412096977233887, -9.99027420789389e-08, 0.040112704038619995, -0.0878838449716568, -0.018145576119422913, -0.07915614545345306, 0.02808714658021927, -0.03077148087322712, 0.020703595131635666, 0.08959589898586273, -0.0863615870475769, 0.15367141366004944, 0.04375297203660011, 0.007193626370280981, -0.03824174404144287, -0.058659374713897705, -0.10867635160684586, -0.03420037031173706, 0.030290799215435982, 0.1153518408536911, -0.04550696164369583, -0.03381491079926491, -0.033402323722839355, -0.0680553987622261, 0.05717187374830246, -0.11099904775619507, 0.13703367114067078, -0.14411237835884094, 0.006246823817491531, 0.1378677636384964, 0.053725868463516235, -0.0838255062699318, -0.05683442950248718, -0.04256417974829674, 0.02064412087202072, -0.00019572488963603973, -0.04092874377965927, 0.01726399175822735, 0.05101931840181351, 0.11445505917072296, -0.08611533045768738, 0.2564341425895691, 0.042557913810014725, -0.0008525922894477844, 0.04904378205537796, -0.010133907198905945, -0.03621978685259819, -0.05596286803483963, 0.03267271816730499, 0.013320645317435265, 0.13983260095119476, -0.1395415961742401, -0.03310515731573105, 0.007439475040882826, -0.01731068640947342, -0.09018933773040771, -0.10950493812561035, 0.16296124458312988, -0.18204879760742188, -0.03819987177848816, 0.06151799112558365, -0.017832202836871147, 0.05881309509277344, -0.17020529508590698, 0.0006386991590261459, -0.0068008992820978165], "changes": {"1wk": -8.289994488584906, "1mo": -13.73508122481544}}, {"text": "Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) Business Wire Mon, Dec 16, 2024, 2:00 PM 12 min read In This Article: EWTX +0.64% \u2013 Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date \u2013 \u2013 On the key secondary endpoint, sevasemten-treated patients showed stabilization of North Star Ambulatory Assessment (NSAA) with a trend towards improvement at 12 months compared to placebo \u2013 \u2013 Sevasemten was well-tolerated and no new safety concerns were observed \u2013 \u2013 Edgewise leadership to discuss CANYON findings on Monday, December 16 at 8:30 a.m. Eastern Time at a virtual investor event \u2013 BOULDER, Colo., December 16, 2024 --( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. The trial met its primary endpoint of change from baseline in CK. CANYON is the largest interventional trial to date in Becker and the first to achieve its primary endpoint. NSAA, the key secondary endpoint of function, showed a trend towards improvement over time in the sevasemten-treated group. Plasma fast skeletal muscle troponin I (TNNI2), a target-specific biomarker of fast skeletal muscle damage, showed a significant reduction, compared to placebo. Additional functional measures, including the 10-meter walk/run, 4-stair climb and 100-meter timed test, showed trends towards improvement compared to placebo. Notably, the treatment population had more advanced disease than placebo. Sevasemten was well-tolerated, and no new safety concerns were observed in either the adult or adolescent patient populations. Ninety-nine percent of eligible participants from CANYON and other sevasemten trials in Becker have enrolled in MESA, the ongoing open label extension trial. \"Becker muscular dystrophy is a devastating neuromuscular disease characterized by rapid progression once functional decline begins. This landmark study presents compelling biomarker data and promising signals that suggest the potential for functional stabilization with administration of sevasemten,\" said Craig M. McDonald, M.D., Distinguished Professor and Chair at the UC Davis Health Department of Physical Medicine and Rehabilitation, and a Principal Investigator in CANYON and GRAND CANYON. \"Becker has no approved therapies. I look forward to the results of the GRAND CANYON pivotal cohort with the hope of bringing the first treatment option to this patient population.\" Story Continues \"We are very encouraged by the CANYON results in Becker and the potential of this novel muscle-targeted therapeutic,\" said Joanne Donovan, Ph.D., M.D., Chief Medical Officer, Edgewise. \"This confirmed our previous observations in the ARCH study of significant decreases in biomarkers of muscle damage and similarly we are seeing evidence of preservation of function in Becker patients.\" The Company is on track to complete recruitment in the GRAND CANYON cohort by the first quarter of 2025. Based on these positive Phase 2 results, the Company plans to engage the U.S. Food and Drug Administration (FDA) and European Medicines Agency about marketing authorization filing strategies for sevasemten in Becker. The Company intends to submit the complete results of the CANYON study for publication at a future medical congress. Overview of CANYON and Clinical Results CANYON , the largest interventional Becker trial, is a Phase 2, double-blind, randomized, placebo-controlled study to investigate the effect of sevasemten on the safety, pharmacokinetics, biomarkers, and functional measures of participants ( NCT05291091 ). The trial was not powered for the functional endpoints. Forty adults and 29 adolescents with Becker muscular dystrophy were enrolled. This study had a 4-week screening period, a 12-month treatment period, followed by a 4-week follow-up period. The adult participants were randomized to sevasemten or placebo in a 3:1 ratio. The adolescent participants were randomized in a 2:1 ratio to sevasemten or placebo and were assessed for safety and tolerability. The data analysis included the complete adult safety population of 40 individuals. There was a notable imbalance between adult participants in the sevasemten and placebo groups with the sevasemten group having more advanced disease at baseline based on all functional measures and MRI. Primary Endpoint: The primary endpoint to assess the efficacy of sevasemten compared to placebo was change from baseline in CK over the treatment period for adults. The results demonstrated a significant change from baseline in CK in the sevasemten-treated group (difference vs. placebo, 28% average decrease over months 6 through 12; p=0.02). Key Secondary Endpoint: The key secondary endpoint was the change from baseline in NSAA total score in adults at month 12. NSAA is a scale commonly used to rate motor function. The between-group difference was 1.1 points, favoring sevasemten; p=0.16 across all adult participants. NSAA remained stable over time in the sevasemten treatment group, similar to the observations in the ARCH study. Further, while the placebo group was small in number (n=12), NSAA declined similarly to that observed in previous natural history studies. 1,2,3 Other Secondary Endpoints: Plasma TNNI2 decreased 77% from baseline in the sevasemten-treated group compared to placebo, averaged over months 6 through 12 in adults; p<0.001. The 10-meter walk/run, 4-stair climb and 100-meter timed test showed trends towards improvement, compared to placebo. The Company continues to evaluate additional secondary and exploratory endpoints. Safety and Tolerability: Sevasemten was well-tolerated, and no new safety concerns were identified. CANYON Implications to GRAND CANYON: The functional observations from the CANYON study support that the GRAND CANYON pivotal cohort\u2019s primary endpoint is powered at >95% to demonstrate a statistically significant NSAA difference at 18 months. MESA, open label extension trial in adults with Becker: The Company is advancing MESA, an open-label extension trial to assess the long-term effect of sevasemten in individuals with Becker. MESA provides continued access to sevasemten to participants who were previously enrolled in ARCH, or completed CANYON, GRAND CANYON, or DUNE. To date, 99% of eligible participants completing these trials have enrolled in MESA. GRAND CANYON, a global pivotal cohort in Becker: GRAND CANYON, an expansion of the CANYON placebo-controlled trial, is a multi-center, randomized, double-blind, placebo-controlled cohort to evaluate the safety and efficacy of sevasemten in adults with Becker. The primary endpoint of GRAND CANYON is change from baseline in NSAA at 18 months. In addition, other functional assessments, biomarkers of muscle damage, MRI, patient-reported outcomes and safety will be assessed. GRAND CANYON is an 18-month cohort anticipated to recruit approximately 120 individuals with Becker. Data from GRAND CANYON, if positive, could support a marketing application. To learn more, go to clinicaltrials.gov ( NCT05291091 ). Sevasemten has achieved notable regulatory milestones by securing FDA Orphan Drug Designation for the treatment of Becker and Duchenne, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designations for the treatment of Becker and Duchenne. Further, sevasemten secured the EMA Orphan Drug Designations for the treatment of Becker and Duchenne. Upcoming CANYON Data Presentations: Virtual Investor Event Members of the Edgewise management team will hold a live webcast on Monday, December 16, at 8:30 a.m. ET to discuss the CANYON data, and will be joined by Dr. McDonald, who will share his perspective of sevasemten and Becker. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page . Patient Community Webinar Members of Edgewise management will hold a community webinar on Wednesday, December 18, 2024, at 1 p.m. ET to discuss these data and the GRAND CANYON pivotal study. To register for the community webinar, please click here . About Becker Muscular Dystrophy Becker is a rare, genetic, life-shortening, debilitating and degenerative neuromuscular disorder. The disease predominantly affects males and imposes significant physical, emotional, financial, and social impacts on the individual and their caregivers. Individuals with Becker experience contraction-induced muscle damage, which is the primary driver of muscle loss and impaired motor function in muscular dystrophies. Functional decline can begin at any age, and once that muscle loss occurs, the decline in function is irreversible and continues throughout the individual\u2019s life. Some individuals living with Becker experience heart failure from cardiomyopathy, which may result in heart transplantation or early death. Currently, there is no cure for Becker; early and long-term multidisciplinary care is critical for optimized disease management. There is a great need for more Becker-specific scientific research, clinical programs, and treatment guidelines to improve management of this disease. To learn more about Becker, go to https://beckermusculardystrophy.com/ . About Sevasemten (EDG-5506) for Becker and Duchenne Muscular Dystrophies Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. Sevasemten presents a novel mechanism of action designed to selectively limit the exaggerated muscle damage caused by the absence or loss of functional dystrophin. By minimizing the progressive muscle damage that leads to functional impairment, sevasemten has the potential to benefit a broad range of patients suffering from debilitating neuromuscular disorders. Its unique mechanism of action provides the potential to establish sevasemten as a foundational therapy in dystrophinopathies, either as a single agent therapy or in combination with available therapies and those in development. Sevasemten is being studied in the Phase 2 CANYON study with a pivotal cohort GRAND CANYON in adults and adolescents with Becker muscular dystrophy. Sevasemten is also being studied in the ongoing Phase 2 trials, LYNX and FOX, in children and adolescents with Duchenne muscular dystrophy. For more information on Edgewise\u2019s clinical trials https://edgewisetx.com/clinical-trials . About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company\u2019s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram . References [1] Bello L, et al. Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. Sci Rep. 2016;6:32439. doi:10.1038/srep32439. [2] van de Velde NM, et al. Selection approach to identify the optimal biomarker using quantitative muscle MRI and functional assessments in Becker muscular dystrophy. Neurology. 2021;97(5):e513-e522. doi: 10.1212/WNL.0000000000012233. [3] De Wel B, et al. Lessons for future clinical trials in adults with Becker muscular dystrophy: disease progression detected by muscle magnetic resonance imaging, clinical and patient-reported outcome measures. Eur J Neurol. 2024:e16282. doi:10.1111/ene.16282. Online ahead of print. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding Edgewise\u2019s expectations relating to its clinical trials and clinical development of sevasemten, including statements regarding the number of individuals to be recruited, timing of completion of recruitment and over-enrollment of the GRAND CANYON trial; statements regarding the potential of, and expectations regarding, Edgewise\u2019s product candidates and programs, including sevasemten (EDG-5506) and EDG-7500; statements regarding Edgewise\u2019s milestones; statements regarding whether data from the GRAND CANYON trial could support a marketing application; statements regarding the Company\u2019s plans to engage the FDA and European Medicines Agency; statements about the submission of results of the CANYON trial for publication at a future medical congress; and statements by Edgewise\u2019s chief medical officer and Craig M. McDonald, M.D. Words such as \"believes,\" \"anticipates,\" \"plans,\" \"expects,\" \"intends,\" \"will,\" \"goal,\" \"potential\" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company, including the potential for Edgewise\u2019s product candidates to cause serious adverse events; Edgewise\u2019s ability to develop, initiate or complete clinical trials for, obtain approvals for and commercialize any of its product candidates; Edgewise\u2019s ability to take advantage of potential benefits associated with designations granted by FDA and/or to maintain qualifications for applicable designations over time; the timing, progress and results of clinical trials for sevasemten and EDG-7500; Edgewise\u2019s ability to enroll and maintain patients in clinical trials; Edgewise\u2019s ability to raise any additional funding it will need to continue to pursue its business and product development plans; the timing, scope and likelihood of regulatory filings and approvals; the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results, including that the primary endpoint of the GRAND CANYON trial (change from baseline in NSAA) will be met even though it was not met as a secondary endpoint in the CANYON trial; the potential that the outcome of preclinical testing and early clinical trials, including the results from the CANYON trial, may not be predictive of the success of later clinical trials, including that the trends from the CANYON trial will also be seen, and will be statistically significant, in the GRAND CANYON trial; Edgewise may gain further insights from its analysis of the CANYON trial results over time, including Edgewise\u2019s ongoing evaluation of additional secondary and exploratory endpoints; Edgewise\u2019s ability to develop a proprietary drug discovery platform to build a pipeline of product candidates; Edgewise\u2019s manufacturing, commercialization and marketing capabilities and strategy; the size of the market opportunity for Edgewise\u2019s product candidates; the loss of key scientific or management personnel; competition in the industry in which Edgewise operates; Edgewise\u2019s reliance on third parties; Edgewise\u2019s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled \"Risk Factors\" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20241216264915/en/ Contacts Edgewise Contacts Investors: Behrad Derakhshan, Ph.D., Chief Business Officer ir@edgewisetx.com Media: Maureen Franco, VP Corporate Communications media@edgewisetx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-16T11:00:00+00:00", "sentiment": {"score": 0.7027761340141296, "confidence": 0.791937530040741, "probabilities": {"positive": 0.791937530040741, "negative": 0.08916139602661133, "neutral": 0.1189010813832283}}, "embedding": [-0.09066277742385864, -0.05600689351558685, 0.006900262087583542, -0.04319339990615845, -0.11333924531936646, -0.16041557490825653, -0.20917794108390808, 0.32098981738090515, 0.12247270345687866, 0.0031028687953948975, -0.06032373756170273, 0.04006124287843704, 0.10918132960796356, 0.05270663648843765, -0.027251336723566055, 0.01056266576051712, 0.17312321066856384, 0.10371893644332886, -0.09084099531173706, 0.05484010651707649, 0.03484107181429863, -0.0028040623292326927, 0.04800746589899063, 0.09732046723365784, -0.08947832882404327, -0.02613849937915802, -0.156749427318573, 0.007438725791871548, -0.14581649005413055, -0.03560689836740494, -0.022371727973222733, -0.028525596484541893, 0.0774768814444542, 0.06483150273561478, -0.0018439146224409342, 0.06725697964429855, -0.08235754072666168, 0.04642900452017784, -0.160675048828125, -0.07146890461444855, -0.0246226005256176, -0.14592799544334412, -0.1293334662914276, -0.08555319160223007, -0.012072044424712658, -0.12438704073429108, -0.029328037053346634, 0.08236601948738098, -0.07857608050107956, 0.2947213053703308, -0.14712536334991455, -0.1473710983991623, -0.013183402828872204, 0.13145679235458374, 0.07060253620147705, 0.011521409265697002, -0.11437050998210907, 0.0600527785718441, -0.07148714363574982, 0.07739938795566559, 0.08495299518108368, -0.1372351050376892, -0.09114974737167358, -0.02274545654654503, 0.10236707329750061, 0.005335957743227482, 0.09529632329940796, -0.025409827008843422, 0.03490331023931503, -0.07683289051055908, 0.08729168772697449, -0.033746421337127686, 0.09518246352672577, 0.11422638595104218, 0.05871155112981796, 0.06992053985595703, 0.07450620085000992, 0.15254944562911987, 0.08548230677843094, -0.17803174257278442, 0.07442978024482727, 0.12615466117858887, 0.09647000581026077, 0.015887100249528885, 0.0225547906011343, 0.1601170301437378, 0.08672484755516052, 0.1497107297182083, -0.04068166762590408, 0.11957898736000061, 0.17704430222511292, 0.070453941822052, -0.06316480785608292, -0.08563246577978134, 0.08570639789104462, -0.05229857563972473, -0.08929597586393356, 0.0701916292309761, 0.0022530860733240843, -0.0064591653645038605, 0.1244976669549942, -0.04963363707065582, -0.05174899846315384, 0.006850327830761671, -0.006472306326031685, -0.0979103147983551, 0.0507223904132843, -0.06017407774925232, 0.022895572707057, 0.060700673609972, 0.020702050998806953, 0.023342419415712357, 0.019491052255034447, 0.05595352500677109, -0.016953717917203903, 0.19901642203330994, 0.0014941524714231491, 0.14669360220432281, 0.10809832811355591, 0.0298980250954628, 0.04015723615884781, -0.025878489017486572, 0.04542271047830582, -0.1141752302646637, -0.008765183389186859, 0.20139563083648682, -0.059377070516347885, 7.680888003836128e-33, 0.03572476655244827, -0.032085031270980835, 0.005162603687494993, -0.030178215354681015, -0.0942615419626236, -0.1008940264582634, -0.1612449288368225, 0.053626395761966705, -0.0712023377418518, -0.0812830775976181, -0.07501291483640671, -0.08940282464027405, 0.16666150093078613, 0.1429670751094818, 0.0284290574491024, -0.06301766633987427, -0.03809194266796112, -0.06946335732936859, -0.04385771602392197, -0.056283604353666306, 0.11958178877830505, -0.0861467570066452, -0.017922883853316307, 0.04575318098068237, -0.0886959657073021, 0.02922496572136879, -0.05006975308060646, 0.09314952790737152, -0.07914923876523972, -0.0055477200075984, -0.1503647267818451, -0.14417541027069092, 0.05922459438443184, -0.12896215915679932, 0.009206661954522133, -0.055490076541900635, 0.0007788422517478466, -0.08678069710731506, 0.02546190470457077, -0.022203579545021057, -0.007678335532546043, -0.013582863844931126, -0.11788806319236755, -0.08515578508377075, 0.10201142728328705, -0.13559672236442566, -0.017329365015029907, -0.08279107511043549, -0.06678900122642517, -0.08178270608186722, 0.02443852648139, -0.018429329618811607, 0.19597288966178894, -0.13676875829696655, -0.10180546343326569, 0.18172325193881989, -0.09262445569038391, -0.0951758548617363, 0.03706735745072365, 0.152506023645401, 0.09741707146167755, 0.08096849173307419, 0.0008855974301695824, -0.004634115844964981, -0.1410641074180603, 0.03354843705892563, -0.0817548930644989, -0.01553161907941103, -0.10838759690523148, 0.005337215028703213, -0.012585612013936043, -0.028568828478455544, 0.08936752378940582, 0.021395720541477203, 0.06432575732469559, -0.08570589125156403, 0.01651681214570999, 0.14949101209640503, -0.1556343287229538, -0.026721034198999405, 0.07146870344877243, 0.05292556434869766, -0.04232565686106682, 0.09118823707103729, 0.09384411573410034, -0.05825294554233551, 0.031310152262449265, -0.12897846102714539, -0.07239198684692383, -0.011833536438643932, 0.1150331050157547, -0.07681870460510254, -0.11350733786821365, 0.14183101058006287, 0.004698664415627718, -8.119822737220955e-33, 0.0262005478143692, 0.06182565912604332, 0.055919043719768524, -0.023689940571784973, -0.016023626551032066, 0.1366521269083023, 0.0802888497710228, -0.06872949004173279, 0.047978028655052185, -0.1764298379421234, 0.07766684889793396, 0.024335121735930443, -0.0848776325583458, -0.044975828379392624, 0.014724175445735455, 0.10226224362850189, -0.2375624179840088, -0.14044788479804993, -0.09014283120632172, 0.051905304193496704, 0.07777117192745209, 0.10334746539592743, 0.07496511191129684, 0.058480534702539444, 0.032943882048130035, 0.007302170153707266, 0.022732768207788467, 0.06636642664670944, 0.10020536184310913, -0.01166331022977829, 0.039331357926130295, 0.0015671637374907732, -0.13966356217861176, 0.00666932063177228, -0.03726021945476532, 0.0491345152258873, -0.05042627081274986, -0.14486677944660187, -0.02652941644191742, -0.005106814205646515, 0.07777571678161621, 0.11253007501363754, 0.0006912481039762497, 0.04345555603504181, 0.010296346619725227, 0.02302595227956772, 0.0006090477108955383, -0.01889803074300289, -0.1321248710155487, -0.08941362798213959, 0.028574936091899872, 0.15970179438591003, -0.0004781675525009632, 0.07203951478004456, 0.09505147486925125, -0.0477132685482502, 0.11017963290214539, -0.015230655670166016, -0.21691395342350006, 0.07871818542480469, -0.13792257010936737, 0.03311785310506821, 0.03923110291361809, 0.05436958745121956, 0.22543802857398987, 0.07443045824766159, 0.0365222804248333, -0.011865513399243355, -0.00947581510990858, 0.025721142068505287, -0.06920456886291504, -0.03926219791173935, -0.10241581499576569, -0.12262711673974991, 0.0017598436679691076, 0.11705157905817032, -0.06863631308078766, -0.035403620451688766, -0.23708117008209229, -0.08506007492542267, -0.06926461309194565, -0.08315721899271011, -0.005466156639158726, -0.04536578059196472, -0.04509690776467323, 0.069948211312294, 0.05601021647453308, 0.045913271605968475, 0.036010775715112686, 0.12425637245178223, 0.02249860018491745, -0.07675045728683472, -0.07985274493694305, 0.21931611001491547, 0.12563395500183105, -1.0018964502478411e-07, 0.09267623722553253, -0.02670835331082344, 0.002304135588929057, -0.08164370805025101, 0.00017066486179828644, -0.03924524039030075, 0.05558585003018379, 0.07782746851444244, -0.10753419995307922, 0.12235235422849655, -0.004061558283865452, 0.0474274568259716, -0.06520390510559082, -0.020947573706507683, -0.09477797150611877, -0.00865775253623724, 0.010615261271595955, 0.06812738627195358, -0.017313385382294655, 0.03771979734301567, -0.06672623753547668, -0.07225406169891357, -0.01371445320546627, -0.14531239867210388, 0.14720419049263, -0.13583898544311523, 0.015142043121159077, 0.09183084964752197, 0.03177247196435928, -0.13614526391029358, -0.040492232888936996, -0.014583166688680649, 0.009550925344228745, -0.03378051519393921, -0.09694092720746994, -0.00013309530913829803, 0.022658899426460266, 0.12716293334960938, -0.07620920240879059, 0.2805040776729584, 0.02930990234017372, 0.07988898456096649, 0.034718871116638184, -0.004511002451181412, -0.023009024560451508, -0.03266351670026779, -0.05673481896519661, 0.0199802964925766, 0.15084385871887207, -0.04400452598929405, -0.08027345687150955, 0.04128243774175644, 0.009986694902181625, -0.06252064555883408, -0.11021486669778824, 0.13124486804008484, -0.1490192413330078, -0.09592080116271973, 0.06028466671705246, 0.009915975853800774, 0.07866130769252777, -0.14657782018184662, -0.00445118173956871, -0.04616159945726395], "changes": {"1wk": -5.842759315697661, "1mo": -15.815229079640355}}, {"text": "Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains Zacks Equity Research Wed, Dec 18, 2024, 5:23 PM 6 min read In This Article: GILD +1.21% REGN -0.91% EWTX +0.64% It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc . GILD and GSK plc GSK had a few regulatory updates. Recap of the Week\u2019s Most Important Stories : Updates From Gilead Sciences Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The designation is based on results from the ES-SCLC cohort of the mid-stage study TROPiCS-03 study. Trodelvy demonstrated promising antitumor activity in both platinum-resistant and platinum-sensitive disease, and the safety profile was consistent with the previous studies. Gilead plans to initiate a phase III study in this patient population. Concurrently, GILD announced entering a strategic collaboration with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets. Per the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead. The latter will be responsible for further development and commercialization activities for products resulting from the collaboration if it exercises its option to exclusively license the compounds directed to a target. In exchange, Terray will receive an upfront payment and be eligible to receive milestone payments associated with achieving preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration. The Committee for Medicinal Products for Human Use (\u201cCHMP\u201d) of the European Medicines Agency (\u201cEMA\u201d) recommended approval of seladelpar. The CHMP adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. A final decision from the European Commission is expected in the first quarter of 2025. The drug is already approved in the United States under the brand name Livdelzi. Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Regeneron\u2019s Study Meets Goals Regeneron Pharmaceuticals REGN announced that the primary endpoint was met in the late-stage QUASAR trial on Eylea HD (aflibercept) injection 8 mg. QUASAR is a global, double-masked, active-controlled phase III study evaluating the efficacy and safety of Eylea HD, compared to Eylea 2 mg, D in patients with macular edema secondary to retinal vein occlusion (RVO), including those with central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion. Story Continues Eylea HD demonstrated non-inferior vision gains with an 8-week dosing regimen compared to Eylea injection of 2 mg dosed every 4 weeks.\u00a0 The safety data remains consistent with the known safety profiles of Eylea HD and Eylea. Regeneron plans to submit a supplementary biologics license application to the FDA in the first quarter of 2025. ANAB Stock Down on Study Results AnaptysBio, Inc. ANAB announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful. Shares of this clinical-stage biotechnology company were down on the results. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe atopic dermatitis (AD) or eczema.\u00a0 Patients were randomized to receive for 12 weeks either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W) or 400mg every two weeks (Q2W), or placebo. The primary and secondary endpoints were assessed at week 14. However, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in Eczema Area and Severity Index score (EASI-75), irrespective of the patient type. ANB032 did not meet any of the secondary endpoints at week 14, including EASI-90, the mean change in baseline EASI or a 4-point reduction in itch severity as measured by the peak Pruritus Numerical Rating Scale (PNRS), compared with placebo. Due to the disappointing efficacy data from the study, ANAB will discontinue further investment in this asset. Regulatory and Pipeline Updates From GSK GSK \u2019s HIV subsidiary, ViiV Healthcare, announced that the CHMP gave a positive opinion recommending marketing authorization to Vocabria (cabotegravir long-acting injections) in combination with Johnson & Johnson\u2019s Rekambys (rilpivirine long-acting injections) for the treatment of HIV-1 infection in virologically suppressed adolescents aged 12 years and above, weighing at least 35 kg. A decision from the European Commission is expected in the upcoming months. GSK also announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of all adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This population includes patients with mismatch repair proficient/microsatellite stable tumors, who represent 70-75% of patients diagnosed with endometrial cancer with limited treatment options. GSK announced that the FDA has granted Breakthrough Therapy designation to Jemperli for the treatment of patients with locally advanced mismatch repair deficient or microsatellite instability-high rectal cancer. Edgewise Stock Up on Study Data Edgewise Therapeutics EWTX announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic disorder called Becker Muscular Dystrophy (\u201cBMD\u201d). Shares gained on the news. The study met its primary endpoint of change from baseline in creatine kinase (CK), a biomarker associated with skeletal muscle damage. Data from the study showed a significant reduction in CK levels in the sevasemten-treated group, with an average decrease of 28% compared to placebo between six and 12 months. The drug was also well-tolerated by study participants. Treatment with sevasemten showed a trend toward improvement in the key secondary endpoint of the North Star Ambulatory Assessment, a scale commonly used to rate motor function. Edgewise remains on schedule to complete recruitment for a pivotal cohort of the CANYON study, called GRAND CANYON, expected to be achieved in the first quarter of 2025. If data from this cohort is also positive, management intends to start discussions with the FDA and EMA for seeking approval for sevasemten in the BMD indication. Performance The Nasdaq Biotechnology Index has declined 1.98% in the past five trading sessions and Regeneron\u2019s shares have lost 4.95%. In the past six months, shares of MRNA have plunged 70.44%. (See the last biotech stock roundup here: Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More) Zacks Investment Research Image Source: Zacks Investment Research What's Next in Biotech? Stay tuned for more pipeline updates. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report Edgewise Therapeutics, Inc. (EWTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-18T14:23:00+00:00", "sentiment": {"score": 0.6241016173735261, "confidence": 0.6338586211204529, "probabilities": {"positive": 0.6338586211204529, "negative": 0.009757003746926785, "neutral": 0.3563843369483948}}, "embedding": [-0.05475429445505142, -0.07938932627439499, -0.02616623416543007, -0.11948680877685547, -0.04971766844391823, -0.11602438986301422, -0.07738125324249268, 0.22309474647045135, 0.13319295644760132, 0.09202424436807632, -0.08226741850376129, 0.06109877675771713, 0.05401013419032097, -0.05258172005414963, -0.03124289959669113, 0.05119681358337402, 0.005308547522872686, 0.1346711963415146, -0.17138725519180298, 0.09700869023799896, -0.009614622220396996, -0.03319767490029335, 0.03788023442029953, 0.09209056198596954, -0.10670583695173264, -0.10595469176769257, -0.0769200399518013, -0.0734352320432663, -0.18765407800674438, 0.02665279619395733, 0.0967184454202652, 0.14543357491493225, 0.04068659991025925, -0.07396268844604492, -0.09238001704216003, -0.016582829877734184, -0.13694465160369873, 0.12867066264152527, -0.13695698976516724, -0.10276743769645691, 0.03472432494163513, -0.08317874372005463, -0.13722014427185059, -0.009095162153244019, -0.024150516837835312, -0.28333723545074463, -0.12193769961595535, -0.012474387884140015, -0.03627733141183853, 0.11584588140249252, -0.08445578813552856, -0.14648234844207764, -0.13567712903022766, 0.14099650084972382, -0.03304744139313698, 0.010979041457176208, -0.13815416395664215, -0.012599402107298374, 0.09862026572227478, -0.07184622436761856, -0.03031402826309204, -0.1459866166114807, 0.003605305217206478, -0.020958703011274338, 0.10695727169513702, 0.014491192996501923, 0.016626756638288498, -0.04037824273109436, -0.021298298612236977, 0.005847403779625893, 0.08175413310527802, -0.03197343647480011, 0.005901671480387449, 0.21965794265270233, -0.020657744258642197, 0.16041478514671326, 0.18577930331230164, 0.08704227209091187, 0.19947046041488647, -0.09703165292739868, 0.03047178126871586, 0.10966485738754272, 0.10238315910100937, -0.0019402897451072931, 0.0881883054971695, 0.002102094469591975, -0.012271244078874588, 0.1778661161661148, 0.02387864515185356, -0.02163170650601387, 0.1572733223438263, 0.06418158113956451, 0.01789390854537487, 0.08096437156200409, -0.1033269613981247, -0.04102391377091408, 0.004911461845040321, -0.011927027255296707, -0.015008633956313133, -0.03820788860321045, 0.04148687422275543, 0.010556824505329132, 0.045366235077381134, -0.09490586072206497, -0.07663390785455704, -0.06516896933317184, 0.021402668207883835, -0.04152557998895645, 0.029529932886362076, 0.010805556550621986, -0.08842359483242035, -0.012702373787760735, 0.01224675215780735, -0.07936981320381165, -0.10775301605463028, 0.28673529624938965, -0.09145336598157883, -0.06951650232076645, 0.12812834978103638, -0.039554014801979065, -0.02702243998646736, 0.04463525116443634, 0.02384837716817856, -0.12672285735607147, 0.09513978660106659, 0.1272869110107422, 0.03550708293914795, 1.1453295494754552e-32, 0.00658740010112524, 0.051101118326187134, 0.026393208652734756, 0.08747082948684692, 0.01659676805138588, -0.029768062755465508, -0.024485640227794647, -0.059252094477415085, -0.14604035019874573, -0.20327988266944885, -0.019073456525802612, 0.05729431286454201, 0.009766475297510624, 0.09612298011779785, -0.06546105444431305, -0.058673907071352005, -0.008198062889277935, 0.024585606530308723, 0.01241880003362894, -0.036174289882183075, -0.033440008759498596, -0.0264894962310791, -0.005489055998623371, 0.060897015035152435, -0.07213921844959259, -0.020149443298578262, -0.15645566582679749, 0.043243616819381714, 0.013794630765914917, 0.09924125671386719, -0.09661122411489487, 0.04365739971399307, 0.08739979565143585, -0.06894984841346741, -0.05087120085954666, -0.05676567181944847, -0.08988182246685028, -0.08160043507814407, 0.08440791815519333, 0.12146086990833282, -0.004344358574599028, 0.012179546058177948, -0.02291453815996647, 0.009785518981516361, 0.027217954397201538, -0.07822827249765396, -0.11895884573459625, 0.030635196715593338, -0.019550001248717308, 0.03701426833868027, 0.002537327818572521, -0.023560814559459686, -0.015908094123005867, 0.016582652926445007, -0.04565872624516487, 0.027299705892801285, -0.1525186002254486, -0.10491999983787537, 0.07697739452123642, 0.06493330001831055, 0.08751827478408813, 0.12300107628107071, 0.021307077258825302, 0.1255801022052765, -0.06548537313938141, 0.12493239343166351, -0.0856429859995842, -0.10672783851623535, -0.100887730717659, 0.1104503870010376, -0.0876256674528122, 0.02595578134059906, 0.17582617700099945, 0.10088513791561127, 0.16582368314266205, -0.08052554726600647, 0.1695486605167389, 0.08826017379760742, -0.035109203308820724, 0.10885435342788696, -0.06055325269699097, 0.08914361894130707, -0.17465004324913025, 0.10346406698226929, -0.09652659296989441, -0.12499919533729553, -0.09165643155574799, 0.07027046382427216, -0.05485467240214348, -0.0925583690404892, 0.04760336875915527, -0.058796465396881104, -0.14004501700401306, 0.10903958976268768, 0.0005968743935227394, -1.035701623886624e-32, -0.05438040941953659, 0.006828131154179573, 0.06197495013475418, 0.015338052064180374, 0.05012795329093933, 0.15498848259449005, 0.06314049661159515, -0.20098844170570374, 0.20599332451820374, -0.10865055024623871, 0.09826374799013138, -0.009919308125972748, -0.03702372685074806, -0.061452750116586685, -0.0287017785012722, 0.10861163586378098, -0.043390337377786636, -0.0811837688088417, -0.1524735987186432, 0.0253753699362278, -0.0028893332928419113, 0.09850731492042542, -0.18446895480155945, 0.1046425998210907, 0.006842872127890587, 0.01610257290303707, 0.057783640921115875, -0.023741934448480606, 0.1251228153705597, -0.03285422921180725, 0.05221337825059891, 0.09147147089242935, -0.24784806370735168, 0.0838661938905716, -0.027076363563537598, -0.0643858015537262, 0.13886737823486328, -0.1639895737171173, -0.024142827838659286, -0.11729197949171066, 0.0616191066801548, 0.053653471171855927, -0.07329204678535461, 0.014078862965106964, 0.050655003637075424, 0.050615593791007996, 0.11072607338428497, 0.021626198664307594, 0.047373831272125244, -0.018248476088047028, 0.042729467153549194, 0.038702577352523804, 0.013671573251485825, 0.031766101717948914, 0.05094441398978233, 0.0011490865144878626, 0.06241678074002266, -0.02617584727704525, -0.09765215963125229, 0.0063146017491817474, -0.019589126110076904, 0.09830824285745621, 0.05528521537780762, -0.08531235158443451, 0.006791573017835617, 0.12248058617115021, 0.01724780537188053, 0.04196925461292267, 0.0096921781077981, -0.05752096325159073, -0.03329804539680481, -0.03241096809506416, -0.04805826023221016, -0.12652316689491272, 0.02477647364139557, 0.14678555727005005, -0.028633296489715576, -0.1959317922592163, -0.14685535430908203, -0.043054986745119095, -0.031848520040512085, -0.0057110413908958435, 0.09477449953556061, -0.03185764327645302, 0.04435691982507706, 0.10636760294437408, -0.07546966522932053, 0.03356301039457321, -0.050376541912555695, 0.03858857601881027, -0.13168136775493622, -0.17916905879974365, -0.1257311850786209, 0.17053762078285217, 0.11695075035095215, -1.0058954558189726e-07, 0.1070873886346817, -0.03547924757003784, -0.040164392441511154, -0.07514780014753342, 0.014207922853529453, 0.053080178797245026, -0.01338120922446251, 0.08674383163452148, -0.011867170222103596, 0.1593555361032486, -0.01338166557252407, 0.17780816555023193, -0.09950678050518036, 0.014623581431806087, -0.056209489703178406, 0.10741343349218369, 0.06145161762833595, -0.0018968600779771805, -0.07542098313570023, -0.032508160918951035, -0.08123116940259933, 0.03562171012163162, -0.006793156266212463, -0.10381585359573364, 0.0693356916308403, -0.11681948602199554, 0.03459058329463005, 0.07084451615810394, -0.07354573905467987, -0.11622913181781769, 0.061291418969631195, -0.08794738352298737, -0.019482504576444626, 0.028285205364227295, 0.03572813421487808, -0.015471193939447403, 0.08011157065629959, 0.01265278272330761, 0.05082222819328308, 0.20441362261772156, 0.1014489158987999, 0.019052254036068916, -0.019207382574677467, 0.025105124339461327, -0.04887153208255768, -0.009491228498518467, -0.07003476470708847, -0.044219017028808594, 0.019424667581915855, -0.038065992295742035, -0.05173354968428612, -0.04523928463459015, 0.005241755861788988, -0.11723659187555313, -0.04406314343214035, 0.17909729480743408, -0.07197476178407669, -0.08611389994621277, 0.0617242157459259, -0.08736011385917664, 0.06259787827730179, -0.11244313418865204, 0.16156649589538574, 0.03336679935455322], "changes": {"1wk": -1.2995647673241246, "1mo": -10.963015296351193}}, {"text": "PREMIUM Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data MT Newswires Thu, Dec 5, 2024, 11:25 PM In This Article: EWTX +0.64% Edgewise Therapeutics (EWTX) said Thursday that the US Food and Drug Administration's warning to Han PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-05T20:25:51+00:00", "sentiment": {"score": 0.024557877331972122, "confidence": 0.043514981865882874, "probabilities": {"positive": 0.043514981865882874, "negative": 0.01895710453391075, "neutral": 0.9375279545783997}}, "embedding": [-0.04759705811738968, -0.09674472361803055, 0.012309510260820389, 0.040109116584062576, 0.1967030018568039, -0.09566172957420349, -0.04064349830150604, 0.2349807471036911, 0.05252760276198387, -0.012371162883937359, 0.04513724148273468, 0.10528967529535294, 0.024401556700468063, -0.06460876762866974, 0.10529588162899017, -0.010641871020197868, 0.1370551735162735, -0.0775250568985939, -0.038323305547237396, 0.08070474117994308, -0.05264339596033096, -0.03672461211681366, 0.0969284251332283, 0.014906009659171104, -0.044027794152498245, 0.012058592401444912, -0.17895737290382385, -0.016290806233882904, 0.020768390968441963, 0.0222378708422184, 0.15530620515346527, 0.035070616751909256, 0.04167149215936661, -0.11026684939861298, -0.035517267882823944, -0.17130185663700104, -0.09675813466310501, -0.020820755511522293, -0.08528007566928864, -0.014292770065367222, 0.16388030350208282, -0.17971640825271606, -0.22120428085327148, 0.16314177215099335, 0.003414356615394354, -0.17843006551265717, -0.20774990320205688, -0.08241922408342361, -0.047804929316043854, 0.21907299757003784, -0.04917382821440697, -0.25169703364372253, -0.01672227866947651, -0.10642492026090622, -0.01666015200316906, -0.14491446316242218, -0.2074134796857834, -0.06010883301496506, -0.015514013357460499, 0.042829740792512894, 0.007167397998273373, -0.17591577768325806, -0.028623336926102638, 0.11626297235488892, -0.00024338348885066807, 0.15880756080150604, -0.008546442724764347, 0.12976621091365814, -0.09935592114925385, -0.09083852171897888, 0.009429636411368847, -0.06431551277637482, 0.032582901418209076, 0.1630430519580841, 0.1383185088634491, 0.13510169088840485, 0.13716953992843628, 0.08071799576282501, 0.10786747187376022, -0.1504402458667755, -0.01576787419617176, -0.07175442576408386, 0.13204024732112885, -0.01850408874452114, 0.09588223695755005, 0.05208089202642441, -0.03202216327190399, 0.05178625509142876, -0.074273481965065, -0.059792306274175644, 0.24505376815795898, -0.09895788133144379, -0.0160985104739666, 0.2072533518075943, 0.005013176240026951, 0.0032518997322767973, -0.30692729353904724, -0.14666399359703064, -0.18972046673297882, -0.0001351396640529856, -0.06931836158037186, -0.04778197035193443, -0.16768600046634674, 0.07279182225465775, 0.05182100832462311, -0.12490474432706833, -0.01423128042370081, 0.06378938257694244, 0.05560192093253136, 0.053186722099781036, -0.048932354897260666, 0.02077571116387844, 0.1271134912967682, -0.05031507462263107, -0.2150152027606964, 0.12446612864732742, -0.15709005296230316, 0.022297268733382225, 0.2375604808330536, -0.005148990545421839, -0.0112625602632761, 0.07110651582479477, -0.04920325428247452, -0.039570361375808716, 0.003904334269464016, -0.025881489738821983, 0.043676938861608505, 1.0162527025102846e-32, -0.10750997811555862, 0.121614471077919, 0.16180619597434998, -0.19149598479270935, 0.09741957485675812, -0.010951015166938305, -0.030501410365104675, -0.19475743174552917, -0.13428057730197906, -0.10849157720804214, -0.2044672667980194, 0.15979896485805511, -0.03753645718097687, 0.24905283749103546, -0.08353366702795029, -0.13742531836032867, -0.006291461177170277, 0.11612188071012497, 0.1525169312953949, 0.020272891968488693, 0.08266284316778183, -0.21765942871570587, -0.011851959861814976, -0.0353553369641304, -0.2549663782119751, 0.18310679495334625, -0.036810748279094696, 0.021029721945524216, 0.21497376263141632, 0.10649857670068741, -0.3560287654399872, -0.012327034026384354, 0.16856816411018372, -0.08392929285764694, 0.039021141827106476, 0.1970478892326355, 0.013982822187244892, -0.022695735096931458, -0.07344024628400803, -0.014183221384882927, 0.037263430655002594, 0.05360112339258194, -0.0702071413397789, -0.02651042304933071, -0.032214149832725525, -0.04689856991171837, -0.16271314024925232, -0.17007580399513245, -0.061284348368644714, -0.06859812885522842, -0.09513939917087555, 0.12791210412979126, -0.0035956865176558495, -0.040122199803590775, -0.0494123212993145, 0.013853230513632298, -0.07722631841897964, 0.05014251172542572, 0.09786494076251984, -0.05012309178709984, 0.1580195426940918, 0.04394444078207016, -0.06672472506761551, -0.09651431441307068, -0.14774693548679352, 0.28054726123809814, -0.05544726178050041, -0.18299511075019836, -0.2825990915298462, -0.029146000742912292, -0.04010972008109093, 0.1102646216750145, 0.05003127083182335, 0.07085702568292618, -0.06294689327478409, -0.07268629968166351, 0.007651657797396183, 0.08450604230165482, 0.16687597334384918, -0.02506818249821663, 0.030965937301516533, -0.027684997767210007, -0.028849530965089798, 0.07122332602739334, -0.012104717083275318, -0.03180960193276405, -0.20264524221420288, 0.10459595173597336, -0.03747068718075752, 0.06951473653316498, 0.10505365580320358, -0.012111078016459942, -0.040082886815071106, 0.2480032742023468, -0.1471792608499527, -1.349713046126514e-32, -0.25679701566696167, 0.09901843965053558, 0.036024484783411026, -0.054636407643556595, -0.0621395967900753, 0.08252357691526413, -0.025510501116514206, 0.03890940919518471, 0.2582056224346161, 0.10998298227787018, 0.16396377980709076, 0.07840286940336227, -0.0742860659956932, -0.03601089492440224, -0.021765828132629395, 0.04829999431967735, -0.059671591967344284, -0.08176536858081818, -0.1464632749557495, -0.021868225187063217, 0.10854396969079971, 0.0889187902212143, -0.13776414096355438, 0.24263541400432587, 0.1002294272184372, 0.07338196784257889, 0.1768823117017746, 0.187676340341568, 0.06417565047740936, -0.2514808773994446, -0.028978658840060234, -0.08898411691188812, -0.21497757732868195, -0.04721648246049881, 0.0021144563797861338, -0.031491123139858246, 0.2534012496471405, -0.0013986387057229877, -0.14671914279460907, -0.07155254483222961, 0.07304169982671738, -0.10900585353374481, -0.2109513133764267, 0.07995837926864624, 0.10006577521562576, 0.10913936048746109, 0.0319761224091053, 0.00860571675002575, 0.05690274387598038, -0.044568564742803574, -0.0070478711277246475, 0.1983034759759903, 0.115789994597435, 0.09948063641786575, -0.1235683262348175, -0.05131521075963974, 0.028008198365569115, -0.04877793416380882, 0.0016162539832293987, -0.037917088717222214, 0.049800124019384384, 0.11762761324644089, -0.15189209580421448, -0.008275758475065231, 0.09822031855583191, 0.02603871189057827, 0.06787656992673874, -0.07972370088100433, 0.030634481459856033, 0.036166246980428696, 0.015492584556341171, 0.013539096340537071, -0.33137163519859314, -0.31206023693084717, 0.11067323386669159, 0.1643121838569641, -0.019211439415812492, -0.17160271108150482, -0.1759749799966812, 0.000285288377199322, 0.0846005231142044, -0.09499730169773102, 0.06311165541410446, 0.034112364053726196, 0.008439100347459316, -0.05389077961444855, 0.09218548238277435, -0.07565885037183762, -0.14443857967853546, 0.05228021368384361, -0.1394098550081253, -0.18353408575057983, -0.27676549553871155, 0.27259546518325806, 0.0739341676235199, -1.0047674692259534e-07, 0.13396233320236206, -0.08208063244819641, -0.0013512881705537438, -0.04425545036792755, 0.03302904590964317, -0.027351634576916695, -0.09150587022304535, -0.005078625865280628, 0.00838357675820589, 0.10298540443181992, 0.0009641554788686335, 0.07636640965938568, -0.09070048481225967, -0.0935339406132698, -0.023969069123268127, 0.016541866585612297, 0.08653188496828079, 0.148467019200325, 0.07226525247097015, -0.07457290589809418, -0.08416570723056793, 0.08819746971130371, 0.2729187309741974, -0.2216556817293167, 0.09142953157424927, -0.14054082334041595, 0.08874661475419998, 0.0826093927025795, 0.03727139160037041, -0.04948841780424118, -0.14204706251621246, -0.0012201177887618542, 0.0346219427883625, 0.06083046272397041, -0.14977917075157166, -0.061285343021154404, 0.07940346002578735, 0.10859549790620804, 0.09984095394611359, 0.12789997458457947, 0.02286369912326336, -0.0014475685311481357, 0.008723191916942596, 0.04366451874375343, -0.00591924786567688, 0.09352726489305496, 0.05906645208597183, -0.0015725778648629785, 0.20787496864795685, -0.11422478407621384, 0.010038372129201889, -0.08357105404138565, 0.10034620016813278, -0.12234089523553848, -0.07584665715694427, 0.1604783833026886, -0.10255579650402069, -0.05451221019029617, 0.006899986881762743, -0.021850207820534706, 0.15856841206550598, -0.26507097482681274, 0.15304115414619446, 0.08401858061552048], "changes": {"1wk": -10.833069716040072, "1mo": -12.19512327743519}}, {"text": "PREMIUM Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating MT Newswires Wed, Nov 27, 2024, 3:33 PM In This Article: EWTX +0.64% Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $45.86, according PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-11-27T12:33:17+00:00", "sentiment": {"score": 0.10464142635464668, "confidence": 0.11565053462982178, "probabilities": {"positive": 0.11565053462982178, "negative": 0.011009108275175095, "neutral": 0.873340368270874}}, "embedding": [-0.050867654383182526, -0.08524550497531891, -0.01930983178317547, 0.014812964014708996, 0.12283860892057419, -0.07018561661243439, 0.08412156254053116, 0.22791630029678345, 0.07289726287126541, 0.01971171796321869, 0.029064247384667397, 0.001592909567989409, 0.07861199229955673, -0.07047923654317856, 0.11512793600559235, 0.010829719714820385, 0.14366792142391205, -0.0010210261680185795, 0.021558864042162895, 0.03675610572099686, -0.15042343735694885, -0.003919748589396477, -0.01791401393711567, -0.06191463768482208, 0.12198363244533539, -0.027688462287187576, -0.07329360395669937, -0.05307125672698021, 0.08841954916715622, -0.057258762419223785, 0.06904277205467224, 0.0071489023976027966, 0.03527797758579254, -0.09387768059968948, -0.1077544093132019, -0.11790429055690765, -0.15249818563461304, 0.0077310120686888695, -0.14762304723262787, 0.07149269431829453, 0.06587902456521988, -0.032477643340826035, -0.33893388509750366, -0.0012606378877535462, -0.05767630413174629, -0.15229494869709015, -0.09213735163211823, 0.08659099042415619, 0.06043843924999237, 0.15472833812236786, -0.013838903978466988, -0.19856807589530945, -0.05335407331585884, -0.10727447271347046, -0.13959583640098572, -0.05452266335487366, -0.22114810347557068, -0.0018125359201803803, 0.07219269871711731, 0.027185596525669098, 0.043288882821798325, -0.10407821834087372, -0.024739034473896027, 0.08104541152715683, 0.04654761776328087, 0.07046853005886078, -0.016332747414708138, 0.08396643400192261, -0.06374440342187881, 0.00581940496340394, 0.026804674416780472, 0.010652747005224228, 0.0925222709774971, 0.05343381315469742, 0.15249940752983093, 0.17788882553577423, 0.16184388101100922, -0.0034276212099939585, 0.005266803782433271, 0.07106829434633255, -0.08336342871189117, -0.15974682569503784, 0.06064843386411667, -0.050290197134017944, 0.1965654194355011, -0.01324841845780611, 0.1743728220462799, 0.13406100869178772, 0.0097670191898942, 0.07264965027570724, 0.18036864697933197, -0.00863069761544466, -0.13180316984653473, 0.016287749633193016, 0.01734878309071064, 0.025174923241138458, -0.26046982407569885, -0.05663170665502548, -0.11502242088317871, -0.012206610292196274, -0.08313082903623581, -0.07032983005046844, -0.05844791978597641, 0.07531847059726715, 0.04616755619645119, -0.19806386530399323, 0.01945493370294571, 0.10601865500211716, 0.1000523641705513, -0.02505253255367279, -0.21651439368724823, -0.1154809221625328, 0.05266503989696503, -0.0964791551232338, -0.19034187495708466, 0.0868433266878128, -0.13056474924087524, -0.040319640189409256, 0.3244507908821106, -0.10582078993320465, 0.07590625435113907, 0.03254569321870804, -0.08596181124448776, 0.022832348942756653, -0.2096911072731018, -0.011540297418832779, -0.07618369162082672, 1.2571236172792642e-32, -0.11449514329433441, 0.11470243334770203, 0.032205116003751755, -0.2798052728176117, -0.002316562458872795, 0.023445967584848404, -0.01453762874007225, -0.12882348895072937, -0.19202686846256256, -0.03743034228682518, -0.20928089320659637, 0.17787908017635345, -0.0019658419769257307, 0.2726779878139496, -0.05665402114391327, -0.25141212344169617, -0.04412511736154556, 0.10465006530284882, 0.10616882145404816, 0.058904439210891724, -0.01181912049651146, -0.1013723760843277, -0.0723026767373085, -0.008122225292026997, -0.29410019516944885, 0.11315793544054031, 0.04365585744380951, 0.0242766086012125, 0.23165740072727203, 0.07932474464178085, -0.34757858514785767, -0.09271448105573654, 0.11434252560138702, -0.03906170278787613, -0.006617429666221142, 0.19956988096237183, 0.09836284816265106, -0.06098489463329315, -0.012990299612283707, -0.11235375702381134, -0.03549676388502121, 0.1657407432794571, 0.012313835322856903, -0.0872289314866066, -0.08811535686254501, -0.015920577570796013, -0.05579305812716484, -0.19896841049194336, -0.02236383594572544, -0.13728858530521393, -0.162727490067482, 0.13918134570121765, -0.05226313695311546, 0.01934880018234253, -0.12195003777742386, -0.017606673762202263, -0.09798477590084076, 0.09925220161676407, 0.14258745312690735, 0.01275547593832016, 0.07837583124637604, 0.011121563613414764, 0.1273912787437439, -0.12527155876159668, -0.06921394914388657, 0.33130985498428345, -0.07850740104913712, -0.21023091673851013, -0.2633156180381775, 0.002915994729846716, 0.02505599893629551, 0.2474059909582138, 0.1732809990644455, -0.1391412913799286, 0.06982993334531784, -0.0346476174890995, -0.03161577135324478, -0.01718485727906227, 0.1623995453119278, 0.006968138739466667, -0.08679439127445221, -0.017816221341490746, -0.005641707684844732, -0.024882635101675987, 0.15876777470111847, -0.06987512856721878, -0.2528154253959656, 0.08526118844747543, -0.13378512859344482, -0.010479695163667202, 0.12456148117780685, -0.03031756356358528, -0.13810674846172333, 0.17688427865505219, 0.02486897073686123, -1.2629590651103337e-32, -0.15107406675815582, 0.15658573806285858, 0.18375712633132935, 0.11137177795171738, -0.059307944029569626, 0.1732722371816635, -0.06709334254264832, 0.11742907017469406, 0.20177827775478363, 0.2339489907026291, 0.04112621396780014, 0.09980706870555878, -0.14649884402751923, 0.04323435202240944, -0.016240878030657768, -5.8779311075340956e-05, -0.057327430695295334, -0.11121663451194763, 0.018428971990942955, -0.14472311735153198, 0.01394694671034813, 0.16741053760051727, -0.07818416506052017, 0.25782111287117004, 0.058754581958055496, 0.08606179803609848, 0.11476811021566391, 0.1721825897693634, 0.03543231636285782, -0.13729040324687958, -0.0015965108759701252, -0.058109842240810394, -0.1718975305557251, 0.005205816123634577, -0.0932498499751091, 0.06196710094809532, 0.20932942628860474, 0.0896591916680336, -0.00040728767635300756, -0.06766929477453232, 0.07088921219110489, -0.18705566227436066, -0.011333519592881203, -0.03188277781009674, 0.22601118683815002, 0.004398306366056204, 0.02128688618540764, 0.014484302140772343, 0.08884549140930176, 0.0006897064740769565, -0.011401436291635036, 0.2326374650001526, 0.1233278214931488, 0.17346897721290588, -0.22388020157814026, -0.07168789207935333, 0.019030218943953514, 0.0674709677696228, -0.03499507158994675, -0.1070115715265274, 0.11028415709733963, 0.19333931803703308, -0.08404794335365295, 0.05307120829820633, 0.041588194668293, 0.11122460663318634, 0.06115218997001648, -0.022593751549720764, -0.0979156643152237, 0.03255678713321686, -0.0963880717754364, 0.02700270712375641, -0.12579724192619324, -0.23940259218215942, 0.09685107320547104, 0.16309936344623566, 0.009554632008075714, -0.17938527464866638, -0.056308433413505554, 0.056298986077308655, 0.024609625339508057, -0.059120528399944305, 0.014132685959339142, -0.06937210261821747, -0.08077070862054825, -0.18435333669185638, 0.04985450580716133, 0.05796404927968979, -0.11933165788650513, 0.0845152884721756, -0.12650468945503235, -0.13254204392433167, -0.15341104567050934, 0.08732031285762787, 0.09076019376516342, -9.992173488626577e-08, -0.02044682204723358, 0.0008040428510867059, -0.023636622354388237, 0.019339464604854584, -0.05517135560512543, -0.027144962921738625, 0.024311291053891182, 0.09306301921606064, -0.006299195345491171, 0.10402446985244751, -0.010615091770887375, -0.15577004849910736, -0.0702240839600563, -0.006682532373815775, -0.07519318163394928, -0.09397365897893906, 0.05582735314965248, 0.1917276382446289, 0.10555592179298401, -0.08805524557828903, -0.005681916605681181, 0.12644708156585693, 0.29638993740081787, -0.14352621138095856, -0.0007799839950166643, -0.030206914991140366, 0.10242892801761627, 0.0789172351360321, -0.004818855784833431, 0.04710566624999046, -0.14619529247283936, 0.09168575704097748, 0.02478145807981491, 0.0829860046505928, -0.14790092408657074, -0.09609737247228622, -0.10072077810764313, 0.12729303538799286, -0.060218021273612976, 0.1903875321149826, 0.08720313757658005, -0.08006969094276428, -0.0683724507689476, -0.0465107336640358, -0.02602394111454487, 0.18649433553218842, -0.03247144818305969, -0.0416194386780262, 0.1945858895778656, -0.14101482927799225, 0.19184714555740356, 0.030854009091854095, 0.03429268300533295, -0.0742056667804718, -0.08928444981575012, 0.04541798308491707, -0.12223920226097107, -0.012642774730920792, -0.053395166993141174, 0.10776931792497635, 0.0038177804090082645, -0.3389549255371094, 0.06345900148153305, 0.13307395577430725], "changes": {"1wk": -0.745346809876559, "1mo": -7.8882014141153505}}, {"text": "Edgewise Provides Statement Regarding Company\u2019s Relationship with Dr. Han Phan at Rare Disease Research Business Wire Thu, Dec 5, 2024, 10:32 PM 3 min read In This Article: EWTX +0.64% BOULDER, Colo., December 05, 2024 --( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company\u2019s relationship with Dr. Han Phan at Rare Disease Research. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dr. Phan based on a 2024 site inspection related to her work with another company. This warning letter is unrelated to any Edgewise clinical trial or data. None of the Edgewise clinical trials are the subject of the FDA\u2019s warning letter. Edgewise has audited Dr. Phan\u2019s site multiple times and believes that the data related to the Edgewise clinical trials at the site are being acquired and stored in accordance with FDA requirements. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company\u2019s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram . Cautionary Note Edgewise\u2019s statements are based only on limited and preliminary information and analysis. Additional information or further analysis may arise that could lead to different conclusions regarding Edgewise\u2019s compliance with FDA requirements. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding Edgewise\u2019s compliance with FDA requirements and the impact of the FDA\u2019s warning letter on Edgewise. Words such as \"believe\" and \"expects\" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the FDA being more likely to audit Edgewise\u2019s clinical activities as a result of the FDA\u2019s actions related to Dr. Han Phan; risks related to the regulatory approval processes being lengthier and more challenging as a result of the FDA\u2019s actions related to Dr. Han Phan; risks associated with the operations of Edgewise\u2019s clinical sites and Edgewise\u2019s advancement of its clinical trials as a result of the FDA\u2019s actions related to Dr. Han Phan; and risks associated with delays or difficulties in the enrollment and/or maintenance of patients in clinical trials as a result of the FDA\u2019s actions related to Dr. Han Phan. Story Continues Information regarding the foregoing and additional risks may be found in the section titled \"Risk Factors\" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law . View source version on businesswire.com: https://www.businesswire.com/news/home/20241205281873/en/ Contacts Edgewise Contacts Investors: Behrad Derakhshan, Ph.D., Chief Business Officer ir@edgewisetx.com Media: Maureen Franco, VP Corporate Communications media@edgewisetx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-05T19:32:00+00:00", "sentiment": {"score": 0.042018141597509384, "confidence": 0.05523499846458435, "probabilities": {"positive": 0.05523499846458435, "negative": 0.013216856867074966, "neutral": 0.9315481781959534}}, "embedding": [-0.18844261765480042, -0.07043133676052094, -0.08349939435720444, -0.09849729388952255, -0.059807874262332916, -0.18303601443767548, -0.14911863207817078, 0.3066275715827942, 0.023159384727478027, 0.006318709347397089, 0.05000413581728935, 0.09302586317062378, 0.0380333848297596, 0.1076953187584877, 0.00681100320070982, -0.008261927403509617, -0.01684325560927391, 0.1022905707359314, -0.13083398342132568, 0.1096658781170845, 0.06678315997123718, 0.08397100865840912, 0.03405053913593292, 0.03682560473680496, -0.16478347778320312, -0.06842885911464691, -0.0555868074297905, 0.007838360965251923, -0.2052689492702484, -0.06991109251976013, 0.09538687765598297, 0.11499715596437454, 0.02131395787000656, 0.010535262525081635, 0.055341318249702454, 0.04134397581219673, -0.09521472454071045, -0.0060865143314003944, -0.09344182908535004, -0.028641190379858017, -0.013888995163142681, -0.10866788029670715, -0.04801833629608154, -0.05332150310277939, 0.09833109378814697, -0.13870443403720856, -0.2289632260799408, -0.024485886096954346, -0.01380917988717556, 0.2277088761329651, -0.1437438428401947, -0.08195066452026367, 0.0023166686296463013, 0.06264397501945496, 0.010051264427602291, -0.030231770128011703, -0.19360116124153137, 0.0736905187368393, -0.05249805003404617, 0.025400251150131226, 0.08871135115623474, -0.08871863782405853, -0.05858774483203888, -0.019790982827544212, 0.01674402318894863, 0.08039471507072449, -0.0007017040625214577, 0.008049744181334972, -0.05413864552974701, -0.028542879968881607, 0.12951812148094177, -0.12533392012119293, 0.006561593152582645, 0.14710035920143127, 0.09546983242034912, 0.11578350514173508, 0.11229413747787476, 0.19848552346229553, 0.06102566421031952, -0.19365018606185913, 0.05082596093416214, 0.04343263804912567, 0.011671431362628937, -0.004674313124269247, -0.023409157991409302, 0.15565861761569977, -0.00043519982136785984, 0.10855042934417725, -0.007797331549227238, 0.08521740138530731, 0.1887015402317047, -0.01207680907100439, -0.054066069424152374, 0.04447896033525467, 0.08554261922836304, -0.016223710030317307, -0.13507594168186188, -0.0031484514474868774, 0.03424938768148422, 0.007481913082301617, 0.03897713124752045, -0.09582081437110901, -0.059431955218315125, -0.030605994164943695, 0.04417795687913895, -0.08038873970508575, 0.0874035656452179, -0.04840169847011566, 0.07261896878480911, -0.06245759129524231, -0.008416200056672096, 0.030761366710066795, 0.023853428661823273, -0.02762383595108986, -0.04874028265476227, 0.11067372560501099, -0.06521767377853394, -0.00023780879564583302, 0.21464097499847412, -0.01086486503481865, 0.03902997076511383, -0.021255910396575928, 0.0067040324211120605, -0.09868665039539337, -0.05812394991517067, 0.07943136245012283, -0.16381537914276123, 8.088742666585214e-33, 0.033462636172771454, 0.016360314562916756, 0.08968901634216309, -0.06589829176664352, 0.021298810839653015, -0.07662665843963623, -0.055947788059711456, -0.10805656015872955, -0.10482904314994812, -0.14470800757408142, -0.24885305762290955, 0.022560473531484604, 0.05532217398285866, 0.10897275805473328, -0.06403601169586182, -0.05479542538523674, -0.012625610455870628, -0.01807628571987152, 0.033371903002262115, 0.019027352333068848, 0.14797362685203552, -0.04635400325059891, -0.03693877533078194, 0.08738990128040314, -0.049875352531671524, 0.09945406764745712, -0.11528006196022034, -0.028279360383749008, 0.14215071499347687, 0.041959479451179504, -0.20018573105335236, -0.031054403632879257, 0.09500110149383545, -0.12514260411262512, -0.024179205298423767, 0.10073241591453552, -0.054906077682971954, -0.07854676991701126, -0.00022887391969561577, 0.08658535778522491, 0.06816872954368591, 0.018560193479061127, -0.061295755207538605, -0.03278939053416252, -0.012683097273111343, -0.057499658316373825, -0.011722197756171227, -0.04248359054327011, -0.06802217662334442, -0.01859673112630844, -0.02086547389626503, -0.029727282002568245, 0.16965776681900024, -0.10703723132610321, -0.013597823679447174, -0.04323972761631012, -0.18764662742614746, -0.014313631691038609, 0.08642508089542389, 0.1341484636068344, 0.17797154188156128, 0.04337218031287193, -0.06010455638170242, 0.0804663747549057, -0.15815019607543945, 0.07425384223461151, -0.028565267100930214, -0.07155783474445343, -0.12651804089546204, -0.0889878123998642, -0.11048541963100433, -0.0433138832449913, 0.09792547672986984, 0.01090968120843172, 0.12183628976345062, -0.16081973910331726, 0.06508693844079971, 0.19467449188232422, -0.049385346472263336, -0.07637044042348862, -0.05686790868639946, 0.09809546172618866, -0.0886010006070137, 0.12892767786979675, -0.026577938348054886, -0.05740654468536377, 0.005416983738541603, -0.07166719436645508, -0.03169075772166252, 0.033264778554439545, 0.1062774807214737, -0.04715505987405777, -0.040747933089733124, 0.2418799102306366, -0.07382532209157944, -9.452834065737399e-33, -0.10587039589881897, 0.0696491003036499, 0.10218000411987305, -0.010379450395703316, -0.0010437648743391037, 0.12748298048973083, 0.11378061771392822, -0.08095728605985641, 0.13716919720172882, -0.12593816220760345, 0.15193957090377808, -0.03380010649561882, 0.005480660125613213, -0.07228422909975052, -0.04952484369277954, 0.15161249041557312, -0.15302765369415283, -0.12989984452724457, -0.11941809207201004, 0.12717515230178833, 0.09699029475450516, 0.11241891980171204, -0.09234381467103958, 0.10028117150068283, 0.12927985191345215, 0.12032851576805115, 0.06709188967943192, 0.07203610241413116, 0.048562463372945786, -0.09096156060695648, 0.015325856395065784, 0.017894230782985687, -0.27396079897880554, -0.05041756108403206, -0.017545800656080246, 0.052693285048007965, 0.08820130676031113, -0.071401447057724, -0.06706966459751129, -0.06780041754245758, 0.08518410474061966, 0.04799642413854599, -0.037852026522159576, 0.14348377287387848, -0.005088204052299261, 0.07472774386405945, 0.05277402698993683, 0.01650656946003437, -0.06433162093162537, -0.06257861107587814, -0.03047376498579979, 0.1872551143169403, 0.11124221980571747, 0.03375733643770218, -0.04101109132170677, -0.023539017885923386, 0.05713168904185295, 0.03586655110120773, -0.17018520832061768, 0.030257372185587883, -0.08073002099990845, -0.10810166597366333, -0.022220812737941742, 0.0640876293182373, 0.1510808765888214, 0.12663504481315613, 0.057318128645420074, -0.09855128079652786, 0.0016483739018440247, -0.01793115958571434, -0.023172704502940178, -0.0012688040733337402, -0.07066660374403, -0.09744256734848022, 0.02675265073776245, 0.07337085157632828, -0.10539019107818604, -0.22129404544830322, -0.20251472294330597, 0.04133506864309311, -0.027522876858711243, -0.04312049597501755, 0.01954960636794567, 0.012205099686980247, 0.0005245273932814598, 0.03564368933439255, 0.08681777119636536, -0.010650712996721268, -0.08800506591796875, -0.023810964077711105, -0.04020547866821289, -0.17742374539375305, -0.14429505169391632, 0.22992415726184845, 0.06661808490753174, -1.0036059450158064e-07, 0.13012602925300598, -0.07703150808811188, -0.08550615608692169, -0.18047258257865906, -0.05831853300333023, -0.043578971177339554, 0.09196516871452332, 0.07435601949691772, -0.048264890909194946, 0.12449727207422256, 0.046874161809682846, 0.1471201777458191, -0.07994775474071503, -0.11600840836763382, -0.07061286270618439, 0.005932885222136974, -0.01992669515311718, 0.1376459002494812, 0.010424239560961723, -0.00495480140671134, -0.0037616435438394547, -0.050366394221782684, 0.027923427522182465, -0.11591669917106628, 0.12559251487255096, -0.1336044818162918, 0.06521513313055038, 0.09198145568370819, 0.046106189489364624, -0.10248132050037384, -0.025177258998155594, -0.018789421766996384, 0.07431811094284058, 0.016377000138163567, -0.09047354757785797, -0.1509658545255661, 0.010804173536598682, 0.07625897228717804, -0.007886139675974846, 0.16176965832710266, 0.05399751290678978, 0.07453440129756927, -0.01845771074295044, 0.02017100527882576, 0.019461829215288162, -0.10625069588422775, 0.09679514914751053, 0.05816980078816414, 0.13790951669216156, -0.06435051560401917, -0.04379068687558174, 0.02310713566839695, 0.056239865720272064, -0.12077227234840393, -0.09721074998378754, 0.17155379056930542, -0.06802737712860107, 0.009470602497458458, -0.01688729040324688, -0.038025133311748505, 0.0448739230632782, -0.09748248755931854, 0.0994877964258194, 0.06847706437110901], "changes": {"1wk": -10.833069716040072, "1mo": -12.19512327743519}}, {"text": "PREMIUM Sector Update: Health Care MT Newswires Mon, Dec 16, 2024, 4:42 PM In This Article: EWTX +0.64% Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-16T13:42:17+00:00", "sentiment": {"score": 0.06289327330887318, "confidence": 0.0827612355351448, "probabilities": {"positive": 0.0827612355351448, "negative": 0.01986796222627163, "neutral": 0.8973708152770996}}, "embedding": [-0.08124351501464844, -0.06247010454535484, 0.0172676183283329, 0.04724268242716789, 0.2264440804719925, -0.06711256504058838, -0.12960676848888397, -0.029215490445494652, 0.04068924859166145, -0.05601748451590538, 0.07858999073505402, 0.08688930422067642, -0.03538753092288971, -0.12359808385372162, 0.08635146915912628, -0.03970851004123688, 0.017226658761501312, -0.08930250257253647, -0.10014607757329941, 0.22314685583114624, -0.19602161645889282, -0.03982467204332352, -0.00019668965251185, -0.03676576167345047, 0.21456491947174072, 0.057858485728502274, -0.0700392872095108, -0.01486295647919178, 0.04593954607844353, 0.006768571212887764, 0.17752708494663239, 0.04698287695646286, 0.10808532685041428, -0.012661098502576351, -0.20180343091487885, -0.07754075527191162, 0.021352618932724, -0.02465667761862278, -0.030760837718844414, 0.051741063594818115, 0.06316674500703812, -0.2276887595653534, -0.1817798614501953, -0.00038178847171366215, -0.024370044469833374, -0.014128915034234524, -0.05564984679222107, -0.034148234874010086, 0.08460821211338043, 0.059490758925676346, 0.03366918861865997, -0.17841844260692596, 0.014789897948503494, -0.014666341245174408, -0.06923308223485947, -0.09636148810386658, -0.1657354235649109, -0.169416606426239, 0.02419596165418625, -0.10185161232948303, -0.03103865683078766, -0.038586754351854324, 0.126781165599823, 0.14958027005195618, -0.12992528080940247, 0.11911217868328094, 0.11364386230707169, 0.08861644566059113, 0.029254304245114326, -0.22557377815246582, -0.07076234370470047, -0.016860270872712135, -0.0015589541289955378, 0.06723297387361526, 0.04369316250085831, 0.1773362159729004, 0.12497956305742264, -0.00735569279640913, 0.19369786977767944, -0.12898412346839905, -0.048836927860975266, 0.030513472855091095, 0.00691281259059906, 0.11126171052455902, 0.04557998850941658, -0.03532443568110466, -0.0017223467584699392, -0.04959684610366821, -0.0052872635424137115, -0.12334471940994263, 0.08490756899118423, -0.013115054927766323, -0.019562294706702232, 0.09119385480880737, 0.042722128331661224, -0.07870844751596451, -0.15527424216270447, -0.14429883658885956, -0.07967017590999603, -0.0137080829590559, 0.03259861096739769, -0.0022942875511944294, 0.004371138755232096, 0.07023470848798752, -0.15595999360084534, -0.28807225823402405, 0.0013625394785776734, 0.2690143287181854, 0.05680656433105469, 0.027171703055500984, 0.07052209228277206, 0.016562478616833687, 0.01023814082145691, -0.2010919451713562, -0.19919027388095856, 0.07955855131149292, -0.17614144086837769, -0.09671349078416824, 0.14887621998786926, 0.0065840198658406734, 0.0334235355257988, -0.002069316105917096, -0.18870553374290466, -0.04367411881685257, 0.06483696401119232, -0.024899421259760857, 0.02400314249098301, 1.1920688946372787e-32, -0.13456502556800842, 0.007060545962303877, 0.13960401713848114, -0.1415099799633026, -0.012027661316096783, 0.0845603495836258, 0.08103784173727036, -0.1536370813846588, -0.03397516906261444, -0.10732605308294296, -0.11600279062986374, 0.25019407272338867, -0.005851758178323507, 0.13856010138988495, -0.12268371880054474, -0.24132505059242249, -0.18772606551647186, 0.14165623486042023, 0.0754021555185318, 0.12581394612789154, 0.10034938156604767, -0.06342445313930511, -0.015287299640476704, -0.15544769167900085, -0.06197258457541466, 0.10668782144784927, 0.05571858212351799, -0.11771973967552185, 0.15321967005729675, 0.10912403464317322, -0.17856785655021667, 0.0038363297935575247, 0.04680561274290085, -0.030925266444683075, 0.010016430169343948, 0.18360354006290436, -0.0405445471405983, -0.0547037273645401, -0.0729537308216095, -0.12375176697969437, -0.04878860339522362, 0.0037022919859737158, -0.0619867779314518, -0.05668313056230545, -0.016269231215119362, 0.13193175196647644, -0.005833221133798361, -0.10334653407335281, -0.027486031875014305, -0.21445976197719574, -0.12614676356315613, 0.07252369076013565, -0.14933478832244873, -0.0367228165268898, 0.09155189990997314, 0.02312197908759117, -0.03858140483498573, 0.07606856524944305, -0.026943493634462357, -0.03864797577261925, 0.13989952206611633, 0.11192334443330765, 0.02576521970331669, -0.06127899885177612, -0.1219027191400528, 0.12979233264923096, 0.05937371030449867, -0.08526021987199783, -0.16338804364204407, 0.06503540277481079, 0.11898729205131531, 0.07627017796039581, 0.13537271320819855, 0.00027452962240204215, 0.0029000190552324057, 0.05037790164351463, -0.17318400740623474, 0.09795981645584106, 0.10537286847829819, 0.05984518304467201, 0.0033448480535298586, -0.014598604291677475, -0.018480809405446053, 0.10208138078451157, 0.035741206258535385, 0.07696826756000519, 0.01415521651506424, 0.13777895271778107, -0.10943546891212463, -0.060677748173475266, -0.12446996569633484, -0.05495620518922806, 0.06878192722797394, 0.16692966222763062, -0.01861824281513691, -1.6024125932058337e-32, -0.09111874550580978, 0.09170851111412048, 0.04041023552417755, 0.056646764278411865, -0.01743287965655327, 0.019431930035352707, 0.07899243384599686, 0.07245519012212753, 0.18404756486415863, 0.22060969471931458, 0.20197546482086182, 0.014632153324782848, -0.1425546407699585, 0.051032546907663345, 0.101582832634449, 0.045156724750995636, -0.02190442755818367, -0.009381680749356747, -0.14430969953536987, 0.053744103759527206, 0.09442388266324997, 0.02656932920217514, -0.04852913320064545, 0.3547467291355133, 0.12403098493814468, 0.03292916715145111, 0.05539197474718094, 0.12151506543159485, 0.04160511866211891, -0.19620688259601593, -0.15299144387245178, -0.06545022130012512, -0.09014485776424408, -0.0226266048848629, -0.04347237944602966, -0.1852385401725769, 0.032151300460100174, 0.030059179291129112, 0.02830425836145878, -0.09889151155948639, 0.1674446314573288, -0.22026586532592773, -0.056241508573293686, 0.12723954021930695, 0.10865745693445206, -0.029499022290110588, 0.08212745934724808, 0.07266752421855927, 0.21405741572380066, -0.00176618795376271, -0.13932757079601288, 0.1476823389530182, -0.004636330995708704, 0.26802781224250793, -0.09007725119590759, 0.10889368504285812, -0.029972754418849945, -0.025148723274469376, -0.05828942731022835, -0.1457342803478241, 0.05223649740219116, 0.15372353792190552, -0.11199267208576202, 0.0719175785779953, -0.03271406888961792, -0.10216754674911499, 0.07325036078691483, -0.20466597378253937, 0.03653549402952194, -0.06190044805407524, 0.059002529829740524, -0.09612954407930374, -0.16646899282932281, -0.26411741971969604, 0.08982490003108978, 0.11409731954336166, 0.033308904618024826, -0.16072627902030945, -0.1382703185081482, 0.0908534824848175, 0.05195293575525284, -0.15438221395015717, 0.05515230819582939, -0.0019093637820333242, -0.03502030670642853, 0.01883416809141636, 0.09962750226259232, -0.19453786313533783, -0.09596465528011322, 0.06469003856182098, -0.21491172909736633, -0.10685410350561142, -0.14438346028327942, 0.08239318430423737, -0.07324288040399551, -9.980956150457132e-08, 0.09087760746479034, -0.013688798062503338, 0.013843999244272709, -0.09439913183450699, 0.06095629185438156, -0.1263987272977829, -0.16440622508525848, -0.010813281871378422, 0.011822757311165333, 0.3878532648086548, 0.13729719817638397, -0.06353666633367538, -0.10241133719682693, -0.14768168330192566, 0.024435605853796005, -0.18353421986103058, -0.040997061878442764, 0.18055255711078644, -0.010351242497563362, -0.18470153212547302, 0.04129903391003609, 0.0010529736755415797, 0.24108298122882843, -0.13315731287002563, 0.04686560109257698, 0.059483032673597336, -0.02645406313240528, -0.03972049057483673, 0.14709722995758057, -0.026121053844690323, -0.08565083146095276, 0.1109960526227951, -0.03279026970267296, -0.020376799628138542, -0.060642059892416, 0.0429556705057621, 0.14170214533805847, 0.06155357509851456, 0.18364939093589783, 0.059370264410972595, -0.005759221967309713, -0.186654195189476, 0.08553425967693329, 0.01336575672030449, 0.021792547777295113, 0.14373286068439484, -0.10696062445640564, -0.15700381994247437, 0.14344416558742523, -0.13250498473644257, 0.06347630172967911, -0.10323552042245865, 0.11863699555397034, 0.024399153888225555, -0.12440010905265808, 0.09556358307600021, -0.15977104008197784, -0.046725768595933914, -0.11202547699213028, 0.15047378838062286, 0.14663296937942505, -0.2460525929927826, 0.04686610400676727, 0.12073177099227905], "changes": {"1wk": -5.842759315697661, "1mo": -15.815229079640355}}, {"text": "PREMIUM Top Premarket Gainers MT Newswires Mon, Dec 16, 2024, 3:53 PM Sidus Space (SIDU) shares soared 65% pre-bell Monday, adding to Friday's gains. U-BX Technology ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EWTX", "date": "2024-12-16T12:53:57+00:00", "sentiment": {"score": 0.15788891911506653, "confidence": 0.16751118004322052, "probabilities": {"positive": 0.16751118004322052, "negative": 0.009622260928153992, "neutral": 0.8228665590286255}}, "embedding": [-0.13831080496311188, -0.07436247169971466, -0.027054905891418457, 0.07114306092262268, -0.008799750357866287, 0.12746356427669525, -0.01050535123795271, 0.013811158947646618, 0.021122444421052933, 0.12875603139400482, -0.09932934492826462, 0.0886869728565216, 0.18029804527759552, -0.082976795732975, 0.15416210889816284, 0.09901683777570724, 0.060409240424633026, -0.22877313196659088, -0.025805272161960602, 0.05297832190990448, -0.272659569978714, -0.10425576567649841, -0.04129142314195633, -0.09330689162015915, 0.27106812596321106, -0.07572245597839355, -0.01927480660378933, -0.08619126677513123, 0.14993752539157867, -0.10503139346837997, -0.0953085720539093, -0.0329669825732708, 0.15313592553138733, -0.18293869495391846, -0.11210881173610687, -0.06274033337831497, -0.10363264381885529, -0.022776102647185326, 0.04652997478842735, 0.031028619036078453, 0.14484207332134247, -0.03146396204829216, -0.09965753555297852, -0.08656635135412216, -0.28363898396492004, -0.03340700641274452, 0.03406936302781105, 0.0861719623208046, 0.09858687222003937, 0.09576047211885452, -0.03735865652561188, 0.06253943592309952, -0.03314347192645073, 0.025044221431016922, -0.17081643640995026, 0.017059141770005226, -0.2735729217529297, 0.046340521425008774, 0.0867423564195633, -0.2398853302001953, -0.06048499420285225, -0.05615824833512306, 0.01784956268966198, 0.14373184740543365, 0.06392236799001694, 0.06610310822725296, -0.12675423920154572, 0.1999995857477188, -0.04685644060373306, -0.19566991925239563, 0.016778497025370598, 0.05433333292603493, 0.02843344211578369, 0.02037161774933338, 0.10879236459732056, 0.30110570788383484, 0.21755105257034302, 0.0031044220086187124, 0.029705220833420753, -0.1287623643875122, -0.15896254777908325, -0.00700466288253665, 0.015057175420224667, -0.05639122799038887, -0.04289894551038742, 0.26392537355422974, 0.07809668779373169, 0.019463295117020607, -0.13130298256874084, -0.16252703964710236, 0.14122962951660156, -0.12485460191965103, -0.04629404842853546, 0.04838734492659569, -0.14559932053089142, -0.031925100833177567, -0.27439337968826294, -0.13412675261497498, -0.15323881804943085, 0.13307231664657593, 0.07022694498300552, 0.1790526807308197, -0.07924346625804901, 0.010683226399123669, -0.06302084028720856, -0.16208778321743011, -0.05563778057694435, 0.18741075694561005, 0.09983468800783157, 0.11777221411466599, 0.03235238790512085, 0.1728355586528778, -0.012055736966431141, -0.28618496656417847, -0.12619642913341522, 0.1620892882347107, -0.13520845770835876, -0.028762342408299446, 0.1265062838792801, -0.1345815807580948, 0.1066567599773407, -0.1612773835659027, -0.14367873966693878, 0.0881270244717598, 0.020415136590600014, -0.06049846485257149, -0.009272230789065361, 1.0943788488650171e-32, -0.04593305289745331, -0.013170341029763222, 0.21560482680797577, -0.17869293689727783, -0.04101775586605072, 0.016069889068603516, -0.0024432223290205, -0.0933326780796051, -0.19049423933029175, -0.05519231781363487, -0.24056093394756317, 0.2747485935688019, -0.032880913466215134, -0.005336170084774494, 0.009636755101382732, -0.2970055341720581, -0.03592696040868759, 0.04207558184862137, 0.1502968817949295, -0.06547880917787552, 0.041623152792453766, 0.008938848040997982, -0.13476087152957916, 0.0369107611477375, 0.10117337852716446, 0.10760590434074402, 0.11385323852300644, -0.016352025792002678, -0.018996313214302063, 0.10137483477592468, -0.1593577265739441, -0.014060667715966702, -0.11746881157159805, -0.04083165526390076, -0.06535786390304565, 0.15466250479221344, -0.09264561533927917, -0.10251011699438095, -0.013814756646752357, -0.19771350920200348, 0.07972035557031631, -0.07206206023693085, -0.1796223521232605, -0.11796582490205765, -0.22727863490581512, -0.01455465517938137, -0.06816010177135468, -0.21089281141757965, 0.004827115684747696, -0.10143687576055527, -0.04992138221859932, 0.13629333674907684, -0.14283578097820282, 0.05451110005378723, -0.01932266540825367, -0.13468390703201294, 0.06663233786821365, -0.10913988202810287, 0.1808195263147354, 0.12320580333471298, 0.23804855346679688, -0.05127105116844177, 0.10837891697883606, -0.008679156191647053, -0.3433832824230194, 0.04576887562870979, 0.11992467939853668, -0.06703869998455048, 0.041305817663669586, 0.08614002168178558, 0.13383513689041138, 0.08695351332426071, 0.08918298035860062, -0.0875575989484787, 0.05757277086377144, 0.10463476926088333, -0.11684757471084595, -0.01736423932015896, 0.3309253752231598, 0.14832539856433868, 0.23248320817947388, -0.10243790596723557, -0.0247770007699728, -0.023486675694584846, 0.16877256333827972, -0.002479137619957328, 0.005446702241897583, -0.09864599257707596, -0.05682476609945297, 0.006397355813533068, -0.0013713358202949166, 0.10621564835309982, 0.029136480763554573, 0.27481135725975037, -0.2977439761161804, -1.2728324829732717e-32, -0.12696760892868042, -0.07995850592851639, 0.0009657189366407692, -0.11545322090387344, -0.058100320398807526, -0.03687701374292374, 0.03454042971134186, 0.21062225103378296, -0.041327133774757385, 0.05385669320821762, 0.08659973740577698, 0.07168322056531906, 0.043864380568265915, 0.06951942294836044, 0.04991661384701729, 0.022304680198431015, 0.31302809715270996, -0.12629354000091553, -0.08539911359548569, -0.011049866676330566, 0.07004471123218536, 0.07641996443271637, -0.2396036684513092, 0.1559252291917801, 0.05726594105362892, 0.01568613573908806, 0.11272478103637695, 0.2366744428873062, -0.015350929461419582, 0.1200481578707695, -0.20083384215831757, 0.013263407163321972, -0.181501567363739, 0.05812723934650421, -0.0854373350739479, 0.016874238848686218, 0.16225017607212067, 0.11512664705514908, -0.004405375570058823, -0.060423098504543304, 0.05083588510751724, -0.02019895240664482, 0.017779694870114326, 0.1680198609828949, 0.06253065913915634, -0.06847921013832092, 0.008806553669273853, 0.028506798669695854, -0.003698764368891716, 0.1682111918926239, -0.042396847158670425, 0.009333422407507896, 0.22130706906318665, 0.22210755944252014, -0.11297506093978882, 0.15141329169273376, -0.10433316975831985, 0.03558880835771561, 0.014893324114382267, -0.03642670810222626, 0.0020854193717241287, 0.06821374595165253, -0.14693976938724518, -0.006034963298588991, -0.009266587905585766, 0.05322724208235741, 0.19244417548179626, -0.10772249102592468, -0.18663249909877777, -0.10533788055181503, 0.1651265025138855, -0.08688978105783463, -0.11690793931484222, -0.2801738977432251, -0.03129548951983452, 0.258105605840683, 0.12310697883367538, -0.004670028109103441, -0.060628704726696014, 0.10767120122909546, -0.21654042601585388, 0.03867839649319649, 0.016751477494835854, 0.14366428554058075, -0.10009412467479706, 0.1499912589788437, 0.14661191403865814, -0.31728342175483704, -0.12842123210430145, -0.0033131891395896673, -0.18527691066265106, -0.0552104227244854, -0.04979566112160683, 0.11879482120275497, -0.023626217618584633, -9.948777801582764e-08, -0.11123806983232498, -0.18976610898971558, 0.013786791823804379, 0.10706576704978943, 0.17287573218345642, 0.005153706297278404, -0.024260900914669037, -0.003016095142811537, -0.0861320048570633, 0.2024238258600235, 0.08566966652870178, -0.05856931582093239, -0.09996186196804047, -0.13760440051555634, 0.12918926775455475, 0.012503929436206818, -0.10917148739099503, 0.08880854398012161, 0.0023087915033102036, -0.22791528701782227, 0.10883962363004684, 0.14576882123947144, 0.4886181354522705, -0.19880780577659607, 0.04312310740351677, 0.033837199211120605, 0.07250882685184479, -0.04719262197613716, 0.1336321383714676, 0.011838860809803009, -0.1170455664396286, 0.060394417494535446, -0.089323990046978, -0.18163485825061798, 0.065888911485672, 0.0638573169708252, 0.07135749608278275, 0.18464723229408264, 0.04777829349040985, 0.1575012356042862, 0.03015209175646305, -0.08675523847341537, 0.2026306390762329, 0.08141257613897324, -0.08285465836524963, 0.13184386491775513, -0.2257574200630188, -0.07574232667684555, 0.1636916995048523, -0.307526171207428, 0.13378004729747772, -0.09179796278476715, 0.02561936527490616, -0.08227239549160004, -0.053932975977659225, 0.05311625450849533, -0.1883787214756012, 0.015097630210220814, -0.05806135758757591, 0.1445484757423401, 0.023877788335084915, -0.06932909786701202, -0.07829966396093369, 0.08422061800956726], "changes": {"1wk": -5.842759315697661, "1mo": -15.815229079640355}}]